The impact of environmental metabolic disruptors on PPARgamma transcriptional regulation of adipocyte differentiation  and function by Kim, Stephanie
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
The impact of environmental
metabolic disruptors on
PPARgamma transcriptional
regulation of adipocyte
differentiation and function
https://hdl.handle.net/2144/36020
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF PUBLIC HEALTH 
 
 
 
 
 
Dissertation 
 
 
 
 
 
THE IMPACT OF ENVIRONMENTAL METABOLIC DISRUPTORS 
 
ON PPARgamma TRANSCRIPTIONAL REGULATION OF 
 
ADIPOCYTE DIFFERENTIATION AND FUNCTION 
 
 
 
by 
 
 
 
STEPHANIE KIM 
 
B.A., Johns Hopkins University, 2009 
Sc.M., Brown University, 2015 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2019 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ©  2019 by 
  Stephanie Kim 
  All rights reserved except for 
Chapter 2 ©  Springer-Verlag GmbH          
Germany, part of Springer Nature 2018 
Approved by 
 
 
 
 
 
First Reader   
 Jennifer J. Schlezinger, Ph.D. 
 Associate Professor of Environmental Health 
 
 
 
Second Reader   
 David H. Sherr, Ph.D. 
 Professor of Environmental Health 
 Boston University, School of Public Health 
 
 Professor of Pathology & Laboratory Medicine 
 Boston University, School of Medicine 
 
 
 
Third Reader   
 Stephen R. Farmer, Ph.D. 
 Professor of Biochemistry 
 Boston University, School of Medicine 
 
 
 
Fourth Reader   
 Stefano Monti, Ph.D. 
 Associate Professor of Medicine 
 Boston University, School of Medicine 
 
 Associate Professor of Biostatistics 
 Boston University, School of Public Health 
 
 
 
Outside Reader   
 Koren K. Mann, Ph.D. 
 Associate Professor of Oncology 
 McGill University
 iv 
 
DEDICATION 
 
 
 
 
 
 
 
 
This dissertation is dedicated to my husband, Hyun, my parents, Kyon and Hyon, and my 
sister, Tiffany, all who have always been there for me and provided me with love and 
support throughout any journey of mine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
ACKNOWLEDGEMENTS 
 
First, I would like to thank my advisor, Dr. Jennifer Schlezinger, for taking me on 
as an advisee and letting me be part of her exciting research projects with the Boston 
University Superfund Research Program (BUSRP). Your enthusiasm for science, 
teaching, and research has been inspirational and motivated me to be a better scientist. I 
am also grateful to you and your trust in me exploring various research ideas and 
developing collaborative projects.  
I am very grateful to my committee members: Dr. David Sherr, Dr. Stephen 
Farmer, and Dr. Stefano Monti. I would like to thank each of you for being involved with 
my research projects and for all the support, advice, and motivation throughout my 
dissertation. I would also like to thank the faculty and staff of the Department of 
Environmental Health at Boston University School of Public Health for their teachings 
and support, and thank Dr. Roberta White, Dr. Jon Levy, Dr. Madeleine Scammell, and 
Dr. Birgit Claus Henn, for their work and support as the former and current chairs and 
program directors for our doctoral program. 
I am also grateful to all BUSRP mentors and colleagues. A special thanks to Dr. 
David Sherr, Dr. David Ozonoff, Dr. Michael McClean, and Dr. Jean van Seventer for 
the support and training opportunities; Dr. Mark Hahn, Dr. Neel Aluru, and Dr. Wendy 
Heiger-Bernays, for their encouragement and science enthusiasm; Dr. Amy Li and Eric 
Reed, for being amazing research colleagues and letting me learn a lot from our 
collaborative work; and Dr. Jessica Ehinger, Ruthy Rickenbacker, Jessica Wilson, and 
Ashleane Alabre, for being friendly colleagues and all the support you have provided me 
 vi 
 
and for BUSRP. 
I have had the privilege to learn from and work with great people in all the labs. I 
would like to Dr. Karl Kelsey and Dr. Rondi Butler for their constant support and 
encouragement since my master’s studies. I would like to thank Dr. Zhongyan Wang, 
Cassie Huang, and Ale Ramirez-Cardenas for their expertise and support since I started in 
Dr. Schlezinger’s lab. I would like to thank former and current students in Dr. 
Schlezinger’s lab for being awesome colleagues to work with and receive support. I 
would also like to thank the amazing crew in Dr. Farmer’s lab: Dr. Nabil Rabhi for his 
expertise, support, and advice, and Dr. Tova Meshulam and Kathleen Desevin for all the 
support. 
I am also grateful to have had the privilege to learn and be part of many talented 
and encouraging students in the Environmental Health Doctoral program. Thank you all 
for being supportive, understanding, and motivational and appreciate the opportunity to 
be in this journey together. I look forward to continue being your colleague and friend. 
And most importantly, I thank my husband and my family for their endless love, 
support, and belief in me. Thank you for always being there in all my pursuits. 
 vii 
 
THE IMPACT OF ENVIRONMENTAL METABOLIC DISRUPTORS  
ON PPARgamma TRANSCRIPTIONAL REGULATION OF 
ADIPOCYTE DIFFERENTIATION AND FUNCTION 
STEPHANIE KIM 
 
Boston University School of Public Health, 2019 
 
Major Professor: Jennifer J. Schlezinger, Associate Professor of Environmental Health 
 
 
ABSTRACT 
 
Metabolic homeostasis is controlled, in part, by a family of proteins called nuclear 
receptors through which lipophilic hormones and hormone-like molecules regulate gene 
expression. One such nuclear receptor is peroxisome proliferator activated receptor γ 
(PPARγ). Its activation is essential for white, brite (brown-in-white) and brown 
adipogenesis, adipocyte function, mature adipocyte maintenance, and insulin sensitivity. 
PPARγ activation regulates energy homeostasis by both promoting storage of excess 
energy as lipids in white adipocytes and stimulating energy dissipation in brite and brown 
adipocytes. Accumulation of white adipocytes significantly increases the risk of obesity 
and metabolic syndrome. On the other hand, brown and brite adipocytes potentially 
counteract metabolic disease-related symptoms. The adipocyte differentiation and 
function as well as insulin sensitizing activities of PPARγ are regulated separately 
through differential post-translational modifications and/or co-regulator recruitment, with 
ligands having distinct abilities to activate each of PPARγ’s functions. These provide 
mechanisms by which a ligand could induce adipogenesis without stimulating PPARγ’s 
health promoting functions (i.e. insulin sensitivity, energy dissipation). The central 
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hypothesis of this dissertation is that compared to therapeutic PPARγ ligands (i.e. 
rosiglitazone), environmental PPARγ ligands will activate a distinct PPARγ 
transcriptional program that disrupts adipose and metabolic homeostasis. Two study aims 
were developed to test and refine this central hypothesis. The first aim identified genes 
and pathways that differentiate environmental PPARγ ligands from endogenous and 
therapeutic chemicals. In primary mouse bone marrow multipotent stromal cells and 3T3-
L1 cells, the environmental PPARγ ligands tributyltin (TBT, an antifouling agent and 
plasticizer) and triphenyl phosphate (TPhP, an organophosphate flame retardant) induced 
transcriptomic profiles that were distinct from rosiglitazone. All ligands induced 
adipogenesis; yet, only rosiglitazone strongly enriched pathways related to brown fat 
differentiation and mitochondrial processes and induced brite adipocyte gene markers 
(Cidea, Elovl3, Ucp1). Using the transcriptional profiles from 3T3-L1 adipocytes 
differentiated in the presence of 76 different chemicals, a taxonomy was built to identify 
environmental chemicals as PPARγ-modifying chemicals distinct from known PPARγ-
modifying therapeutics. The second aim investigated the role of phosphorylation of 
PPARγ in defining environmental ligand-induced changes in adipocyte differentiation 
and function. In differentiated 3T3-L1 cells, rosiglitazone and TPhP both induced 
adipogenesis through PPARγ, but only rosiglitazone enhanced mitochondrial biogenesis 
and mitochondrial respiration, which contribute to healthy energy expenditure. 
Rosiglitazone, but not TPhP, protected PPARγ from phosphorylation at Ser-273. 
However, in 3T3-L1 cells in which PPARγ cannot be phosphorylated, TPhP was able to 
induce mRNA expression of a suite of brite adipocyte genes. In male C57BL/6J mice fed 
 ix 
 
either a low or high fat diet, TPhP caused a significant decrease in brite adipocyte gene 
expression (Elovl3, Ucp1) in mature adipocytes from inguinal adipose tissue. Together, 
these studies support our hypothesis that environmental PPARγ ligands (i.e. TBT and 
TPhP) skew adipocyte differentiation toward white adipogenesis at the expense of brite 
adipogenesis, potentially because of differential post-translational modification of 
PPARγ. 
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CHAPTER 1: Introduction 
Obesity and Metabolic Syndrome 
 
The increase in obesity prevalence in the United States has been attributed to risk 
factors such as high caloric intake and lack of adequate physical activity (Holtcamp 
2012). While obesity itself is not necessarily an indication of disease, the white adipose 
tissue can develop pathological characteristics that link adiposity to metabolic 
dysfunctions such as hypoxia, fibrosis, inflammation, lipid spillover (accumulation of 
lipids in the liver and muscle), and insulin resistance (Mirhafez et al. 2015; Sam and 
Mazzone 2014). The odds of developing metabolic syndrome increase dramatically with 
body mass index, with the prevalence of metabolic syndrome being 5%, 22%, and 60% 
of normal-weight, overweight, and obese people in the general population (Park et al. 
2003). Metabolic syndrome is a constellation of conditions including high blood pressure, 
high blood sugar, excess body fat around the waist, and dyslipidemia (Grundy 2005). 
Metabolic syndrome increases risk of heart disease, stroke, and non-alcoholic fatty liver 
disease and diabetes (Grundy 2005). Importantly, newly recognized contributors to 
metabolic homeostasis are brite (brown-in-white) adipocytes, which develop in 
subcutaneous white adipose tissue, are mitochondria-rich, and contribute significantly to 
energy expenditure (Cohen and Spiegelman 2015; Hong Wang et al. 2016). It has been 
shown that rodents that lack brite adipocytes develop obesity with insulin resistance and 
hepatic steatosis (Cohen et al. 2014). Moreover, humans with a lower predisposition to 
develop brite adipocytes are more likely to be obese and diabetic (Claussnitzer et al. 
2015; Timmons and Pedersen 2009). 
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Environmental Metabolic Disruptors 
 
The term “obesogens” was first coined to explain the impact of environmental 
chemical exposures during development and critical periods around puberty and 
adulthood on increased fat deposition (A. Janesick and Blumberg 2012; Amanda S. 
Janesick and Blumberg 2016; La Merrill and Birnbaum 2011). Obesogens can contribute 
to obesity by increasing the number and size of fat cells, shifting energy balance to favor 
food storage, and altering hormonal control of food intake and energy expenditure 
(Amanda Janesick and Blumberg 2011; Newbold 2011). A recent consensus statement 
contended that the word, obesogen, has become “too restrictive” to describe 
environmental chemicals and their role in increased susceptibility to obesity and 
metabolism-related disorders such as diabetes (Heindel et al. 2015). Thus, the  “metabolic 
disruptor hypothesis” was proposed (Heindel et al. 2015). This hypothesis proposes that 
certain environmental chemicals can alter “programming or sensitivity for developing 
obesity/diabetes or aspects of metabolic syndrome later in life” as well as may require a 
second “hit” such as increased fat or sugar diet (Heindel et al. 2015). The final refinement 
to the “metabolism disrupting chemical (MDC) hypothesis” was made to distinguish the 
role of chemicals from other metabolic disruptors such as nutrition and stress (Heindel et 
al. 2017). 
 Adipose tissue is one of multiple organs that regulate metabolic homeostasis and 
could be targets of MDCs. In fact, the first “obesogen” described, tributyltin, significantly 
increases adipocyte differentiation in-vitro and adiposity in-vivo (Baker et al. 2015; 
Chamorro-García et al. 2013; Grün et al. 2006; Pereira-Fernandes et al. 2014; Watt and 
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Schlezinger 2015). Prenatal exposure to TBT results in increased lipid accumulation, 
increased adipose tissue mass, and reduced muscle mass that persists into adulthood in 
mouse models (Chamorro-García et al. 2013; Grün et al. 2006) and also increased 
adiposity in zebrafish (Yan et al. 2014). Since then, various chemicals have been shown 
to enhance adipocyte formation and disrupt not only adipose but also metabolic functions 
such as mitochondrial biogenesis and insulin sensitivity. Perturbed alterations in 
mitochondrial biogenesis and dynamics can negatively affect metabolic homeostasis, 
contributing to the establishment of insulin resistance and diabetes (Marroqui et al. 2018). 
For example, bisphenol A (BPA), an industrial chemical used in plastics, increased 
weight gain and body fat after developmental exposure in rats (Rubin et al. 2001; Wei et 
al. 2011) and mice (Anderson et al. 2013; Miyawaki et al. 2007; Ryan et al. 2010; Yang 
et al. 2016). Transcriptomic analysis of isolated pancreatic islets exposed to 1 nM BPA 
showed decreased the expression of 29 genes, a number of which were involved in 
oxidative phosphorylation and mitochondrial dysfunction such as Uqcrb, Atp1b1 and Iars 
(Carchia et al. 2015). Other MDCs disrupt glucose homeostasis in animal models. For 
example, exposure of rats to the flame retardant, polybrominated diphenyl ether (PBDE), 
increased lipolysis while reducing insulin-stimulated glucose uptake (Hoppe and Carey 
2007). Diethylhexyl phthalate (DEHP), a common plasticizer, reduced insulin levels and 
raised serum glucose levels in rats (Gayathri et al. 2004). 
Evidence of MDCs contributing to adipose and metabolic dysfunctions also have 
been noted in epidemiological studies. A recent study found that placental TBT was 
associated with a non-significant trend towards higher weight gain, but only in the first 
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three months of life (Rantakokko et al. 2014). Epidemiological studies have associated 
brominated flame retardants and urinary phthalates with impaired fasting glucose and/or 
glucose tolerance, metabolic syndrome, and insulin resistance (Lim, Lee, and Jacobs 
2008; Stahlhut et al. 2007). Epidemiological studies have associated exposures to 
organochlorine pollutants and heavy metals with impaired insulin secretion, which linked 
to diabetic outcomes (Jørgensen, Borch-Johnsen, and Bjerregaard 2008; Lai et al. 1994; 
Neel and Sargis 2011; Ukropec et al. 2010). Exposure to p,p’-diphenyldichloroethene 
(DDE), via consumption of sport fish from the Great Lakes in the U.S., was linked with 
diabetes incidence (Turyk et al. 2009). Overall, these observations support the relevance 
of the MDC hypothesis with respect to increased adiposity and metabolic perturbations in 
animal and human studies. 
 
PPARγ and its role in adipogenic and metabolic homeostasis 
 
MDCs can affect adipose and metabolic homeostasis via nuclear receptors, which 
integrate signals from metabolic and endocrine pathways to control target gene 
expression. One such family of nuclear receptors are peroxisome proliferator-activated 
receptors (PPARs), which heterodimerize with the retinoid X receptors (RXR) and bind 
to PPAR-responsive regulatory elements (PPRE, 5’-CAAAACAGGTCANAGGTCA-3’) 
(Corrales, Vidal-Puig, and Medina-Gómez 2018; Maradonna and Carnevali 2018). There 
are three different isoforms of PPARs in mammals: PPARα, PPARβ/δ, and PPARγ; and 
although these three PPARs isoforms have structural similarities, they exhibit differences 
in tissue distribution, ligand specificities, and functions (Corrales, Vidal-Puig, and 
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Medina-Gómez 2018; Zoete, Grosdidier, and Michielin 2007). PPARα is highly 
expressed in the liver and to a lesser extent in the muscle, heart, bone, and brown adipose 
tissue, all of which are pro-oxidative tissues rich in mitochondria content (Gross et al. 
2017; Kersten et al. 1999). PPARα plays a critical role in response to fasting and 
increases ATP production from β-oxidative phosphorylation (Gross et al. 2017; Kersten 
et al. 1999). PPARβ/δ is predominantly expressed and active in skeletal muscle, where it 
contributes to sustained energy expenditure and also upregulates fatty acid β-oxidation 
(Holst et al. 2003). 
There are two main isoforms of PPARγ, PPARγ1 and PPARγ2, which are 
differentiated by an extra exon of 30 amino acids in the end terminus of the latter isoform 
(Zhu et al. 1995). PPARγ1 is ubiquitously expressed, and PPARγ2 is highly expressed in 
adipose tissues (Lehrke and Lazar 2005). PPARγ is predominantly expressed in adipose 
tissues, both white and brown, where it plays an important anabolic role in facilitating fat 
storage, adipogenesis, and thermogenesis (Ferré 2004; Siersbaek, Nielsen, and Mandrup 
2010). Overall, PPARγ is a well-established regulator in coordinating molecular events 
during various stages of the adipocyte lifespan to ensure the normal physiological 
function of white, brown and brite adipocytes (Vegiopoulos, Rohm, and Herzig 2017). 
White adipocytes differentiate from a Myf5- osteogenic lineage, have large lipid droplet 
and store excess energy as triglycerides. Brown adipocytes differentiate from a Myf5+ 
myogenic lineage, are densely packed with mitochondria and contribute to energy 
expenditure and adaptive thermogenesis (Ma et al. 2018). Brite adipocytes differentiate 
from a Myf5- osteogenic lineage but share functional similarities with both white and 
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brown adipocytes. Upon cold or adrenogenic stimulation, brite adipocytes, within white 
adipose depots, are activated and emerge as cells with multiple small lipid droplets and 
increased mitochondria content (Stephen R. Farmer 2008; Ma et al. 2018). 
Adipogenic differentiation requires PPARγ but also involves a shared 
transcriptional cascade with CCAAT/enhancer-binding proteins (C/EBPs) (S. R. Farmer 
2005; Giralt and Villarroya 2013). C/EBPα functions to maintain PPARγ expression, and 
both cooperatively regulate gene transcription to promote and maintain adipocyte 
functions such as lipid metabolism, glucose metabolism, and insulin sensitivity (S. R. 
Farmer 2005). Interestingly, mice deficient in C/EBPα have defective adipose tissue 
development, yet fibroblasts from C/EBPα deficient mice do undergo adipocyte 
differentiation (Wu et al. 1999). C/EBPα deficient white adipocytes accumulate less lipid 
and show an absence of insulin-stimulated glucose transport (Wu et al. 1999), and 
C/EBPα deficient brown adipocytes do not express UCP1 have a reduced number and 
size of mitochondria (Carmona et al. 2002; Linhart et al. 2001).   
PPARγ directly controls the expression of genes involved in lipid transport and 
metabolism, insulin signaling, and adipokine production (Lehrke and Lazar 2005). For 
instance, PPARγ target genes include FABP4, which is a lipid transport protein, LPL and 
OLR1, which are involved in fatty acid uptake, and GPR81, which participates in 
lipolysis (Chui et al. 2005; Graves, Tontonoz, and Spiegelman 1992; Jeninga et al. 2009; 
Schoonjans et al. 1996). PPARγ regulates insulin sensitivity through the expression of 
adipokines. Adiponectin (ADIPOQ) expression is increased in adipocytes upon PPARγ 
activation, while expression of resistin (RETN) and TNFα is decreased (Rangwala and 
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Lazar 2004). Furthermore, PPARγ can exert anti-inflammatory effects by several 
molecular mechanisms (Varga, Czimmerer, and Nagy 2011).  
There are specific coregulatory networks that govern PPARγ’s transcriptional 
profile and influence the differentiation and function of adipocytes. An unliganded 
PPARγ/RXR heterodimer binds to the nuclear receptor corepressor (NCoR) and silencing 
mediator of retinoid and thyroid hormone receptor (SMRT), two well-characterized 
corepressors (Viswakarma et al. 2010). In the absence of ligand activation of 
PPARγ/RXR, the corepressor protein complex is known to suppress transcription of 
target genes by causing histone deacetylation (Karagianni and Wong 2007). Receptor 
interacting protein 140 (RIP140), a corepressor, directly recruits histone deacetylases and 
represses the activity of PPARγ by competing with their coactivators (Kiskinis et al. 
2014). Additionally, RIP140 is highly expressed in adipose tissues and is known to 
downregulate brown fat-associated genes in white adipocytes (Kiskinis et al. 2014). On 
the other hand, a coactivator, PR domain–containing protein-16 (PRDM16), coregulates 
C/EBPβ and PPARγ to induce brown fat–specific genes (Kajimura et al. 2008; Seale 
2015; Seale et al. 2007). Peroxisome proliferator–activated receptor γ-coactivator-1α 
(PGC-1α) also coactivates PPARγ and PPARα and is involved in regulating 
mitochondrial biogenesis, oxidative metabolism, and thermogenesis (Barbera et al. 2001; 
Puigserver et al. 1998; Uldry et al. 2006). Most factors that induce or repress the 
browning program act through modulation of PGC-1α activity (Giralt and Villarroya 
2013).  
PPARγ is also regulated by post-translational modifications, including 
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phosphorylation, acetylation, sumoylation and ubiquitination, each of which is a distinct 
PPARγ modulation that could be studied further for cell- or tissue-specific effects 
(Ahmadian et al. 2013; van Beekum, Fleskens, and Kalkhoven 2009). PPARγ is 
phosphorylated within the AF1 region by mitogen-activated protein kinases (MAPKs) 
(i.e. PPARγ2 at ser112), which represses its transcriptional activity by inhibiting ligand 
binding and impacting cofactor recruitment (Camp and Tafuri 1997; E. Hu et al. 1996). 
Interestingly, phosphorylation at ser112 by the cyclin-dependent kinases, Cdk7 and 
Cdk9, increases PPARγ activity (Compe et al. 2005; Iankova et al. 2006). Thus, the 
phosphorylation of PPARγ at ser112 can result in different transcriptional activity 
depending on the kinases involved. Recently, it has been determined that PPARγ2 can be 
phosphorylated within the ligand-binding domain at Ser273 by Cdk5, a protein kinase 
that can be activated by various proinflammatory cytokines that are known to be elevated 
in obesity (Ahmadian et al. 2013; Dhavan and Tsai 2001; Utreras et al. 2009). Cdk5-
mediated phosphorylation at serine-273 of PPARγ2 is known to dysregulate expression 
of metabolism related target genes, including adiponectin (ADIPOQ), in adipocytes 
(Banks et al. 2015; J. H. Choi et al. 2010). Phosphorylation of ser273 of PPARγ by 
CDK5 or ERK stimulates a diabetic repertoire of gene expressions in the white adipose 
tissue; and it has been recently found that roscovitine, a CDK5 inhibitor, prevents ser273 
phosphorylation and promotes formation of UCP1 brite adipocytes in the white adipose 
tissue (Hong Wang et al. 2016).  
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PPARγ as a target of environmental metabolic disruptors  
 
PPARγ has been studied extensively, in large part because it is a therapeutic target 
in the treatment of type 2 diabetes (Corrales, Vidal-Puig, and Medina-Gómez 2018; 
Olefsky 2000). The therapeutic ligands, thiazolidinediones (TZDs, including 
rosiglitazone and pioglitazone) improve insulin resistance and exert anti-inflammatory 
effects in the adipose tissue as well as on systemic level (Corrales, Vidal-Puig, and 
Medina-Gómez 2018; Kubota et al. 2006; Odegaard et al. 2007; Olefsky 2000). Yet, 
PPARγ is not only a target of action for therapeutic ligands but also for environmental 
ligands. 
One of the earliest discovered environmental PPARγ ligands were phthalates.   
Mono-ethylhexyl-phthalate (MEHP), a metabolite of the plasticizer di-ethylhexyl-
phthalate (DEHP), directly activates PPARγ and promotes adipogenesis, although to a 
lower extent compared to full PPARγ agonist, rosiglitazone (Desvergne, Feige, and 
Casals-Casas 2009; Feige et al. 2007; Maloney and Waxman 1999). MEHP also induces 
different PPARγ target genes such as adipocyte markers, Fapb4 and Cd36 (Feige et al. 
2007). Moreover, it was shown that MEHP selectively regulates PPARγ activity during 
adipogenesis as it promoted interactions with only a subset of PPARγ coregulators. For 
example, unlike rosiglitazone, MEHP did not promote recruitment of coregulators, p300 
or SRC-1, on target promoters but induced recruitment of Med1 and PGC-1α (Feige et al. 
2007). 
Organotins are organometallic compounds widely used for various industrial and 
agricultural applications including pesticides, fungicides, and anti-fouling agents and are 
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used in plastics manufacturing (Muncke 2011; Sundaya, Alafarab, and Oladelec 2012). 
Pre-natal exposure to TBT in mice resulted in enhanced liver lipid content at birth, 
increased adiposity in adult male mice, and reprograming of mesenchymal stromal cells 
to favor adipocyte differentiation at the expense of bone formation in subsequent 
generations (Chamorro-García et al. 2013; Grün et al. 2006). Adipose-derived stromal 
stem cells from mice exposed to TBT in-utero showed increased adipogenic capacity and 
lipid accumulation as well as increased expression of PPARγ (Kirchner et al. 2010). 
Adult exposure to TBT results in pathological effects on adipose and metabolic 
homeostasis such as increased adiposity, dyslipidemia, insulin resistance, and hepatic 
inflammation (Bertuloso et al. 2015; Ceotto Freitas-Lima et al. 2018; Penza et al. 2011; 
Sena et al. 2017; Zuo et al. 2011). TBT and dibutyltin (DBT), a major metabolite of TBT, 
enhances adipogenesis in human and mouse multipotent mesenchymal stromal cells 
(Chamorro-García et al. 2018; Hiromori et al. 2009; Yanik et al. 2011). Tributyltin (TBT) 
and triphenyltin were also the first organotins shown to induce differentiation of 3T3-L1 
pre-adipocytes and to activate PPARγ, as well as RXR (Grün et al. 2006; Kanayama et al. 
2005).   
 Recently, triphenyl phosphate (TPhP), an industrial chemical in the 
organophosphate esters (OPE) class of chemical, was identified as an environmental 
PPARγ ligand. OPEs have increased in used as replacements for the banned 
polybrominated flame retardants (Stapleton et al. 2012). TPhP is often used as a 
plasticizer and used in polyurethane foams for residential furniture (Stapleton et al. 2012; 
van der Veen and de Boer 2012). Pre-natal TPhP exposure in UCD-type 2 diabetes 
11 
 
 
mellitus rats results in increased leptin levels, increased plasma non-esterified-fasting 
fatty acids, and acceleration of type 2 diabetes onset in the males  (Green et al. 2016). 
Perinatal exposure to TPhP results in increased body and liver weights, hepatic steatosis, 
impaired glucose homeostasis, and insulin resistance in adult male mice (D. Wang et al. 
2018). In-vitro studies have shown that TPhP activates PPARγ signaling and enhances 
adipogenesis in mouse bone marrow stromal cells and in 3T3-L1 preadipocytes (Pillai et 
al. 2014; Tung, Ahmed, et al. 2017).  
  
Study Aims 
 
It is unknown how environmental PPARγ ligands may skew the balance of white 
and brown adipogenesis and how this may influence the development of obesity and 
metabolic disease. Thus, I hypothesize that environmental PPARγ ligands can be 
selective PPARγ ligands, which disrupt the balance of white and brite adipocyte 
differentiation and impair metabolic homeostasis. The following two study aims were 
designed to examine this hypothesis. My first aim was to identify genes and pathways 
that differentiate environmental PPARγ ligands from endogenous molecules and 
therapeutic chemicals. My second aim was to investigate the role of phosphorylation of 
PPARγ in defining environmental ligand-induced changes in adipocyte differentiation 
and function. Physiological in-vivo investigations coupled with in-vitro mechanistic 
studies in mouse and human adipocyte models were performed to understand how the 
biological actions of environmental PPARγ ligands might bridge enhanced adiposity with 
pathological metabolic outcomes. 
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Abstract 
 
Tributyltin (TBT), a peroxisome proliferator-activated receptor γ (PPARγ)/retinoid X 
receptor (RXR) ligand and founding member of the environmental obesogen chemical 
class, induces adipocyte differentiation and suppresses bone formation. A growing 
number of environmental PPARγ ligands are being identified. However, the potential for 
environmental PPARγ ligands to induce adverse metabolic effects has been questioned 
because PPARγ is a therapeutic target in treatment of type II diabetes. We evaluated the 
molecular consequences of TBT exposure during bone marrow multipotent mesenchymal 
stromal cell (BM-MSC) differentiation in comparison to rosiglitazone, a therapeutic 
PPARγ ligand, and LG100268, a synthetic RXR ligand. Mouse primary BM-MSCs 
(female, C57BL/6J) undergoing bone differentiation were exposed to maximally 
efficacious and human relevant concentrations of rosiglitazone (100 nM), LG100268 
(100 nM) or TBT (80 nM) for 4 days. Gene expression was assessed using microarrays, 
and in silico functional annotation was performed using pathway enrichment analysis 
approaches. Pathways related to osteogenesis were downregulated by all three ligands, 
while pathways related to adipogenesis were upregulated by rosiglitazone and TBT. 
However, pathways related to mitochondrial biogenesis and brown-in-white (brite) 
adipocyte differentiation were more significantly upregulated in rosiglitazone-treated 
than TBT-treated cells. The lack of induction of genes involved in adipocyte energy 
dissipation by TBT was confirmed by an independent gene expression analysis in BM-
MSCs undergoing adipocyte differentiation and by analysis of a publicly available 3T3 
L1 data set. Furthermore, rosiglitazone, but not TBT, induced mitochondrial biogenesis. 
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This study is the first to show that an environmental PPARγ ligand has a limited capacity 
to induce health promoting activities of PPARγ. 
15 
 
 
Introduction 
 
Metabolic disruptors are chemicals that play a role in altering susceptibility to 
obesity, metabolic syndrome and related metabolic disorders including type 2 diabetes 
(Heindel, et al., 2015). Identification of this new class of chemicals evolved from the 
initial recognition that environmental chemicals (originally termed environmental 
obesogens) play a role in the metabolic programming of obesity risk following in utero 
exposure (Grün and Blumberg 2006).  
The hunt for metabolism disrupting chemicals has focused on identifying ligands 
of peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor that is 
essential for white, brown-in-white (brite) and brown adipocyte differentiation and 
mature adipocyte, maintenance, function and survival (Anghel et al. 2007; Imai et al. 
2004; P. Tontonoz, Hu, and Spiegelman 1994). PPARγ is a ligand activated transcription 
factor, and its activation regulates energy homeostasis by both stimulating storage of 
excess energy as lipids in white adipocytes and stimulating energy utilization by 
triggering mitochondrial biogenesis, fatty acid oxidation and thermogenesis in brite 
adipocytes. PPARγ forms a heterodimeric complex with retinoid X receptors (RXR) and 
binds to the consensus response element (5’-CAAAACAGGTCANAGGTCA-3’) (Juge-
Aubry et al. 1997). Structurally diverse ligands can bind to PPARγ, because of its large 
binding pocket, including full agonist, partial agonist and antagonist ligand types (Garcia-
Vallvé et al. 2015; Nolte et al. 1998). However, not all ligands interact with the binding 
pocket of PPARγ in the same manner. For instance, greater stabilization of helix 12 by 
full agonists results in their efficacious transcriptional activation of PPARγ compared to 
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partial agonists (Pochetti et al. 2007). 
The organotin tributyltin (TBT), which inspired the coining of the term 
environmental obesogen, is an environmental PPARγ ligand (Grün et al. 2006; 
Kanayama et al. 2005). TBT is a highly potent PPARγ ligand, which induces 
differentiation of bone marrow and adipose-derived multipotent stromal cells (MSCs) 
into adipocytes and suppresses bone formation (Baker et al. 2015; Grün et al. 2006; X. 
Li, Ycaza, and Blumberg 2011; Watt and Schlezinger 2015; Yanik et al. 2011). Prenatal 
TBT exposure in mice leads to epigenetic changes in mesenchymal stem cells that favor 
adipogenesis at the expense of osteogenesis (Chamorro-García et al. 2013), reduced 
ossification of the skeleton (Tsukamoto et al. 2004), and increased adiposity in adulthood 
(Grün et al. 2006). In adults, TBT not only induces weight gain but also metabolic 
disruption (i.e. hepatic steatosis, hyperinsulinemia and hyperleptinemia) (Bertuloso et al. 
2015; Zuo et al. 2011) and adipocyte formation in bone (Baker et al. 2017). Since the 
discovery of TBT’s ability to activate PPARγ, a growing number of environmental 
PPARγ ligands that stimulate adipogenesis have been identified (e.g. organotins, 
phthalates, parabens, triflumizole, tetrabromobisphenol A, triphenyl phosphate) (P. Hu et 
al. 2013; Kanayama et al. 2005; X. Li et al. 2012; Pillai et al. 2014; Riu et al. 2011; Watt 
and Schlezinger 2015). 
Moreover, TBT is not only a PPARγ agonist, but also is an agonist for retinoid X 
receptors (RXR) α and β (le Maire et al. 2009; Shiizaki et al. 2014). The dual ligand 
nature of the organotins raises the possibility that RXR could contribute to TBT-induced 
effects on MSC differentiation, independently of PPARγ. RXRs heterodimerize with and 
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are essential for transcriptional activation of multiple nuclear receptors; further, they also 
act as homodimers (Kojetin et al. 2015). Permissive RXR heterodimer partners may be 
activated by ligand binding to either the partner or to RXR (Lammi, Perlmann, and 
Aarnisalo 2008; Schulman, Shao, and Heyman 1998). In reporter assays, TBT was shown 
to activate liver X receptor (LXR), nuclear receptor related 1 (NURR1), PPARγ and 
PPARδ, which are permissive RXR heterodimeric partners (Grün et al. 2006).We have 
previously shown that TBT can act through RXR homodimers and RXR/PPARγ 
heterodimers to induce adipogenesis and suppress osteogenesis in mouse bone marrow 
MSCs, as well as can induce LXR-dependent gene transcription (Baker et al. 2015).  
PPARγ is a therapeutic target in the treatment of type II diabetes. The PPARγ 
ligands Rosiglitazone (AvandiaTM) and pioglitazone (ActosTM) are prescribed to increase 
insulin sensitivity and reduce blood glucose (Nolte et al. 1998). This has raised the 
question as to whether environmental PPARγ ligands are simply adipogenic or will 
induce adverse metabolic effects. To begin to address this question, we compared the 
TBT-induced transcriptional response in bone marrow MSCs (BM-MSCs) to those 
induced by rosiglitazone and LG100268, a synthetic RXR agonist. Bioinformatics 
analyses of our BM-MSC-derived data and of a publicly available, independently 
generated 3T3 L1 dataset revealed that while TBT is potent and efficacious at stimulating 
white adipogenesis and lipid accumulation, it does not efficiently activate energy 
dissipating pathways (e.g. mitochondrial biogenesis, adipocyte browning). 
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Methods 
 
Chemicals. DMSO was purchased from American Bioanalytical (Natick, MA). 
Rosiglitazone (Rosi) was from Cayman Chemical (Ann Arbor, MI). Human insulin, 
dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), LG100268 (LG268), and 
tributyltin (TBT) chloride were from Sigma-Aldrich (St. Louis, MO). All other reagents 
were from Thermo Fisher Scientific (Suwanee, GA) unless noted.  
Cell culture. Primary bone marrow cultures were prepared from 8-weeks old, 
C57BL/6J female mice (RRID:IMSR_JAX:000664,Jackson Laboratories, Bar Harbor, 
ME). Mice were housed 4-5 per cage, with a 12 hour light cycle. Water and food (2018 
Teklad Global 18% Protein Rodent Diet, Irradiated, Harlan Laboratories, Indianapolis, 
IN) were provided ad libitum. The mice were euthanized for collection of bone marrow 
two days after arrival. After euthanasia (cervical dislocation under terminal euthanasia 
followed by pneumothorax), the limbs were aseptically dissected, and soft tissue was 
removed from the bone. The bone marrow was flushed from the femur, tibia and 
humerus, and then strained through a 70 μm cell strainer. The flushed cells were diluted 
in MSC media (α-MEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 0.25 μg/ml amphotericin B), and cells from 2–4 animals were pooled and 
plated so that each pool represented “n” experiment. Cells were seeded at 6×106/ml in 2 
ml per well in 6-well plates. Medium was replaced 5 days after plating, and 
differentiation was induced at day 7. Prior to the day 7 medium change, undifferentiated 
cells were harvested as a control for gene expression analysis. For microarray 
experiments, the medium was replaced with osteoinductive medium consisting of α-
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MEM, 12.5 µg/ml l-ascorbate, 8 mM β-glycerol phosphate, 0.5 µg/ml insulin, 10 nM 
dexamethasone, 100 U/ml penicillin, 100 μg/ml streptomycin. Upon addition of 
differentiation medium, cells received no treatment (naïve) or were dosed with vehicle 
(DMSO, 0.1% final concentration), rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 
100 nM) or TBT (80 nM). Following 4 days of incubation (medium was replaced and 
cultures were re-dosed once), cells were harvested for gene expression.  
For gene and phenotype validation experiments, BM-MSC and 3T3 L1 (ATCC 
Cat# CL-173, RRID:CVCL_0123, Lot # 63343749) cells were cultured with adipocyte 
differentiation medium consisting of DMEM, 10% FBS, 250 nM dexamethasone, 167 
nM of 1 µg/ml human insulin, 0.5 mM IBMX, 100 U/ml penicillin, 100 μg/ml 
streptomycin. Upon addition of differentiation medium, cells received no treatment 
(naïve) or were dosed as above. On day 3 of differentiation, medium was replaced 
adipocyte maintenance medium (DMEM, 10% FBS, 250 nM dexamethasone, 167 nM 
human insulin, 100 U/ml penicillin, 100 μg/ml streptomycin), and the cultures were re-
dosed. On days 5 and 7 of differentiation, the adipocyte maintenance medium was 
replaced and the cultures re-dosed. Following 5 or 10 days of differentiation, cells were 
harvested for analysis of mRNA expression, lipid accumulation, mitochondrial 
biogenesis and cellular respiration analyses.  
mRNA Expression. Total RNA was extracted and genomic DNA was removed 
using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). Microarray analyses were 
performed by the Boston University Microarray and Sequencing Resource using 
GeneChip®  Mouse Gene 2.0ST arrays (Affymetrix, Santa Clara, CA).  For RT-qPCR 
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analyses, cDNA was prepared from total RNA using the GoScript™ Reverse 
Transcription System (Promega), with a 1:1 mixture of random and Oligo (dT)15 
primers. All qPCR reactions were performed using the GoTaq®  qPCR Master Mix 
System (Promega). The qPCR reactions were performed using a 7500 Fast Real-Time 
PCR System (Applied Biosystems, Carlsbad, CA): hot-start activation at 95°C for 2 min, 
40 cycles of denaturation (95°C for 15 sec) and annealing/extension (55°C for 60 sec). 
The primer sequences are provided in Table S2.1. Relative gene expression was 
determined using the Pfaffl method to account for differential primer efficiencies (Pfaffl 
2001), using the geometric mean of the Cq values for beta-2-microglobulin (B2m) and 
18s ribosomal RNA (Rn18s) for normalization. The Cq value from naïve, 
undifferentiated cultures was used as the reference point. Data are reported as “Relative 
Expression”, unless log-transformed and reported as “Log Relative Expression.”  
Microarray data preprocessing and filtering. Microarray data processing and 
analyses were performed in R software (version 3.3.1). Affymetrix CEL files were 
processed using the Bioconductor package oligo, with the function read.celfiles. Gene 
expression was normalized using the package rma, which performs background 
correction and quantile normalization. Bioconductor annotation packages 
mogene20sttranscriptcluster.db and pd.mogene.2.0.st were used to annotate at the 
transcript (probeset) level. Data filtering consisted of removal of probesets without 
mapping to gene symbols, which ultimately led to 24,996 probesets retained for 
differential expression analysis. 
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Assessment of absolute expression of nuclear receptor genes. The absolute 
expression of nuclear receptors (e.g. PPARγ, RXR and its nuclear receptor binding 
partners) was estimated in (Day 0) naïve cells, using the method by Piccolo et al. (2013), 
which estimates the probability of absolute expression of the nuclear receptors at Day 0 
(Piccolo et al. 2013). The function UPC() from the SCAN.UPC R package was used to 
estimate absolute gene quantification and GC content bias was accounted for in the 
absolute gene expression estimation. 
Differential gene expression analyses. Differential analyses were performed on 
the normalized expression data using a two-group moderated t-test as implemented in the 
Bioconductor limma package (Ritchie et al. 2015). Heatmaps depicting significant 
differentially expressed genes were generated with rows and columns clustered based on 
Pearson correlation and Euclidean distance, respectively. The Ward agglomeration rule 
was used for both row and column clustering. Venn diagrams were created using the 
number of differentially expressed genes with false discovery rate (fdr) < 0.05 for each 
set of comparisons: each chemical (Rosi, LG268, and TBT) vs. the vehicle (Vh) in 
differentiated BM-MSCs. 
Pathway enrichment analyses. Pathway enrichment analyses were performed 
using a hypergeometric distribution-based test to determine the gene sets (Gene Ontology 
terms from GO database) over-represented in the lists of significant (fdr< 0.05) 
differentially expressed genes. Top enriched gene sets between each chemical vs. vehicle 
comparison included pathways related to brown adipocyte differentiation or 
mitochondrial biogenesis. We curated two separate lists of genes related to brite 
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adipocyte differentiation or mitochondrial biogenesis and related to osteogenesis to 
validate the upregulation and downregulation of these pathways with our lists of 
differentially expressed genes and associated t-test statistics (see Table S2.2).  
Validation of the enrichment of these curated gene sets was performed based on 
the Gene Set Enrichment Analysis (GSEA) software (Subramanian et al. 2005). Further, 
we validated the observations from our differential gene and pathway analyses in BM-
MSCs exposed to Rosi or TBT with publicly available data (GEO Accession: GSE53004) 
that examined Rosi or TBT exposures in 3T3-L1, another cell model commonly used in 
adipocyte biology (Pereira-Fernandes et al. 2014).  
Phenotype Analyses. Analyses were carried out following 10 days of 
differentiation and treatment of 3T3 L1 cells. To determine lipid accumulation, the cells 
were washed with PBS and incubated with Nile Red (1 µg/ml in PBS) for 15 minutes, in 
the dark, at room temperature. Fluorescence (excitation 485 nm, 20 nm bandwidth; 
emission 530 nm, 25 nm bandwidth) was measured using a BioTek Synergy2 plate reader 
(Biotek Inc., Winooski, VT). The fluorescence in experimental wells was normalized by 
subtracting the fluorescence measured in naïve (undifferentiated) cells and reported as 
“RFUs.” To measure mitochondrial biogenesis, the MitoBiogenesis In-Cell Elisa 
Colorimetric Kit (Abcam, Cambridge, UK, #110217) was used, following the 
manufacturer’s standard protocol. The levels of two mitochondrial proteins (COX1 and 
SDH) that are measured simultaneously in each well and normalized to the total protein 
content via JANUS staining. Absorbance (OD 600nm for COX1, OD 405nm for SDH, 
and OD 595nm for JANUS) was measured using a BioTek Synergy2 plate reader. The 
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absorbance ratios of COX/SDH in experimental wells were normalized to the naïve 
(undifferentiated) cells. To measure mitochondrial respiration, 3T3-L1 pre-adipocytes 
were seeded in Seahorse XF96 microplates (Agilent, Santa Clara, CA) at a density of 
50,000 cells per well, before being differentiated to adipocytes as outlined above. Prior to 
all assays, the medium was changed to Seahorse XF Assay Medium (0 mM glucose, 
1mM sodium pyruvate, 1mM GlutaMax, pH 7.4) and incubated at 37°C in a non-CO2 
incubator for 30 min. Oxygen concentration in the medium was measured using an 
Seahorse XF96 Analyzer (Agilent), following the manufacturer’s standard protocol. The 
concentration of test compounds used to determine oxygen consumption rate (OCR) 
included 0.5 μM oligomycin, 1.0 μM carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), and 2 μM rotenone. 
Statistics. All statistical analyses were performed with Prism 5 (GraphPad 
Software, Inc., La Jolla, CA). Data are presented as means ± standard error (SE). Four 
biological replicates of naïve, vehicle, or each chemical-treated cells were processed for 
the microarray. The n value indicates the number of independent samples that were 
evaluated. The qPCR data were log-transformed before statistical analyses. One-factor 
ANOVAs (Dunnett’s) were performed to analyze the qPCR and phenotypic data. 
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Results 
 
Nuclear receptor expression in undifferentiated BM-MSCs 
BM-MSCs are multipotent cells that can differentiate into adipocytes, 
chondrocytes, and osteocytes (Pittenger et al. 1999). We began by determining the 
probability of absolute expression of nuclear receptors in undifferentiated BM-MSCs. 
Bone marrow cells isolated from female C57BL/6J mice were cultured in basal medium 
for 7 days. RNA was isolated and analyzed for mRNA expression by microarray. Using 
the absolute gene quantification in microarrays method by Piccolo et al. (2013), we 
determined that 8 RXR-related nuclear receptors had greater than a 50% probability of 
expression in undifferentiated cells: Lxrb, Nur77, Pparg, Ppard, Rara, Rxra, Rxrb, and 
Vdr (Figure 2.1). Thus, at the onset of exposure, TBT activate could PPARγ and RXRs 
directly (le Maire et al. 2009; Grün et al. 2006), as well as LXRβ, Nur77 and PPARδ 
through permissive activation via RXR (Giner et al. 2015). 
 
Chemical treatment modifies nuclear receptor and coregulator expression 
Our previous work showed that TBT is able not only to stimulate adipocyte 
differentiation in BM-MSCs, but also to divert osteogenic differentiation toward 
adipocyte differentiation (Baker et al. 2015). To determine the potential nuclear receptor 
pathways involved, BM-MSC cultures were stimulated to undergo osteogenic 
differentiation and treated with Vh or TBT (80 nM). This concentration falls between the 
ED50 and the maximally efficacious concentration determined in multiple human and 
mouse cell culture models (Biemann et al. 2012; Carfi et al. 2008; Hiromori et al. 2009; 
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Kirchner et al. 2010; Pereira-Fernandes et al. 2013; Yanik et al. 2011), and is a 
maximally efficacious concentration in mouse-derived BM-MSCs (Yanik et al. 2011). 
Furthermore, this concentration of TBT is in line with butyltin concentrations measured 
in human serum (Kannan et al. 1999). We compared the TBT-induced transcriptional 
response to those induced by agonists specific for either PPARγ (rosiglitazone (Rosi), 
100 nM) or RXR (LG100268 (LG268), 100 nM) at the lowest concentrations shown to be 
maximally efficacious (Lala et al. 1996; Lehmann et al. 1995). After 4 days of 
differentiation, RNA was isolated and analyzed for mRNA expression by microarray. 
Chemical treatment modified the expression of nuclear receptors that 
heterodimerize with RXR. In BM-MSCs exposed to Rosi or TBT, expression of nuclear 
receptors Pparg, Thrb, Rarb, Rxrg, Ppara, and Rxra was greater than in undifferentiated 
and Vh-treated BM-MSCs (Figure 2.2.a). Rosi and TBT also decreased the expression of 
Nr4a1 (Nur77) and Vdr (Figure 2.2.a). In LG268-treated cells, Thrb, Rarb, and Rarg 
were significantly induced and Nr1i3 (Car) was differentially downregulated, compared 
to undifferentiated BM-MSCs (Figure 2.2.a). To examine a broader spectrum of nuclear 
receptors, including steroid receptors (Robinson-Rechavi 2003), we queried the data for 
47 mouse nuclear receptors identified from the Nuclear Receptor Signaling Atlas 
(NURSA) (Becnel et al. 2015). Overall, TBT induced a nuclear receptor expression 
profile similar to both Rosi (PPARγ) and LG268 (RXR) (Figure S2.1). 
Nuclear receptor coregulators play an important role in regulating nuclear 
receptor transcriptional activities (Feige and Auwerx 2007). Therefore, we examined the 
expression of nuclear receptor coregulators in the cultures. Using a list of 280 identified 
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mouse nuclear receptor coregulators from NURSA, we determined that there were 181 
nuclear receptor coregulators that were significantly differentially expressed between the 
undifferentiated and chemically-treated BM-MSCs (Figure 2.2.b). TBT has similar 
coregulator expression profile with Rosi; yet, Rosi induced more strongly some of the 
coregulator genes’ expressions as indicated by the color intensity of the induced 
expression (Figure 2.2.b). Thus, we examined more closely the expression profiles of 
nuclear receptor coregulators by directly comparing Rosi and TBT (Figure S2.2). The 
expression pattern of the nuclear receptor coregulators differed significantly (fdr< 0.05) 
between the two chemicals. Rosi significantly upregulated the expression of coregulators 
involved in brite/brown adipocyte differentiation (Ppargc1a, also known as Pgc1a) and 
mitochondrial function (e.g. Phb2). Thus, TBT did not appear to efficiently induce the 
expression of coregulators involved in brite adipocyte differentiation compared to a 
therapeutic chemical, rosiglitazone. 
 
TBT induces a distinct transcriptional response  
Comparisons of the overall differentially expressed genes between vehicle (Vh) 
and chemical (Rosi, TBT, LG268) treatments in differentiated BM-MSCs reveal both 
overlapping and unique genes across all treatments (Figure 2.3.a). Principal component 
analyses (PCA) revealed that the Rosi-induced gene expression patterns cluster separately 
from those induced by TBT and LG268 (Figure 2.3.b). The variability in the replicates in 
a given cluster likely reflects the fact that primary cultures generated from distinct sets of 
mice were used. TBT has gene expression profiles in common with both the PPARγ 
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ligand (Rosi) and the RXR ligand (LG268). Using fdr<0.05, there were a total of 4318 
genes uniquely up- and down-regulated by Rosi, 274 genes uniquely regulated by TBT, 
and 18 genes uniquely regulated by LG268 (Figure 2.3.c). There were a total of 164 
significantly induced genes in common between all three chemicals. As expected, a set of 
genes commonly downregulated by all three chemicals were those related to osteogenesis 
(Figure S2.3). However, the enrichment of this set had much higher significance for Rosi 
and TBT (q<0.001) than for LG268 (q=0.05).  
 The significant differential genes for each chemical (compared to Vh-treated 
cells) were used for pathway enrichment analyses using GO (Biological Processes) terms. 
The most significantly enriched biological processes in Rosi-treated cells were pathways 
related to brown adipocyte differentiation or mitochondrial biogenesis (Figure 2.4). The 
most significantly enriched pathways in TBT-treated BM-MSCs were pathways related to 
lipid metabolic processes as well as to metabolic processes (Figure 2.4). Biological 
processes such as cell cycle regulation were significantly enriched in cells treated with 
LG268 (Figure 2.4). The overall pathways common and different between all chemicals 
are shown in Figure S2.4. Ultimately, the environmental chemical, TBT, does not induce 
a gene expression pattern specifically like the PPARγ ligand or the RXR ligand. 
 
TBT does not efficaciously induce health-promoting genes  
We directly compared the enriched pathways between Rosi and TBT and found 
that mitochondrial biogenesis was significantly upregulated by Rosi compared to TBT 
(Figure 2.5.a). To investigate the difference between the transcriptional responses more 
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thoroughly, we curated gene sets, from the literature, related to brite/brown adipocyte 
differentiation and mitochondrial biogenesis (Table S2.2). Using GSEA software, we 
determined which curated pathways were enriched in Rosi- versus TBT-treated cultures. 
Rosi effectively upregulated metabolism- and mitochondria-related pathways in 
differentiated BM-MSCs, with enrichment score (ES) of 0.82 (q<0.001) and 0.80 
(q<0.001), respectively (Figure 2.5.b; Figure S2.5.a). Other significant pathways induced 
by Rosi were transcriptional factors/coregulators and brite/brown adipocyte 
differentiation (Figure 2.5.b). To validate whether the genes in the curated genesets 
related to brite adipocyte differentiation and mitochondrial biogenesis were uniquely 
upregulated by Rosi, we compared the differential expression of these genes across the 
three chemicals. Rosi significantly induced most of the genes (e.g. Coq3, Coq9, Acaa2, 
Pck1) related to mitochondria and metabolism as highlighted in boxed area “a”, and 
TBT-treated cells induced some genes in common with LG268 that were immune- or 
inflammatory-related (e.g. Ifnar2, IL10, Kng1) and hormone/vitamin (e.g. Irs1, Cnp) as 
shown in boxed area “b” (Figure 2.5.c). 
We used two approaches to validate the finding that TBT induces a transcriptional 
response distinct from Rosi. First, BM-MSCs were cultured for 5 and 10 days in 
adipogenic medium to evaluate effects on adipocyte differentiation by the three 
chemicals. We analyzed by RT-qPCR expression of genes common to all classes of 
adipocytes (Figure 2.6.a), as well as those involved in brite/brown adipogenesis (Figure 
2.6.b). Rosi and TBT both induced Pparg expression, with Rosi more robustly inducing 
expression than TBT (Figure 2.6.a). The expression levels of adipogenic target genes of 
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PPARγ, such as Fabp4 (Fatty Acid Binding Protein 4), Plin1 (Perilipin 1), and Scd1 
(Stearoyl-Coa Desaturase 1), were all significantly induced by TBT and Rosi by day 10 
of differentiation (Figure 2.6.a). Compared to TBT and LG268, Rosi more strongly 
induced the nuclear receptor, Ppara, and coregulator, Pgc1a (peroxisome proliferator-
activated receptor gamma coactivator 1-alpha), which play roles in regulating 
mitochondrial biogenesis and brite/brown adipocyte differentiation, respectively (Figure 
2.6.b). Additionally, brite adipocyte-related genes Cidea (Cell Death-Inducing DFFA-like 
Effector A) and Elovl3 (Elongation of Very Long Chain Fatty Acid 3) were uniquely and 
significantly induced by Rosi (Figure 2.6.b). The classic marker of brite/brown 
adipocytes, Ucp1 (Uncoupling protein 1), showed a trend toward upregulation by Rosi, 
but the expression level did not reach statistical significance because of high variability 
(Figure 2.6.b).  
Second, we validated the unique upregulation of brite adipogenesis and 
mitochondrial biogenesis by Rosi (and not by TBT) with a publicly available 
transcriptomic dataset (GSE53004) generated in 3T3 L1 cells and with phenotypic 
analyses of 3T3 L1 cells, a preadipocytes model commonly used in adipocyte biology 
(Pereira-Fernandes et al. 2014). Consistent with our observations in Rosi- and TBT-
treated BM-MSCs, Rosi upregulated the mitochondrial and metabolism pathways in 3T3 
L1 cells (both ES=0.68) more so than TBT (ES=0.87) (Figure 2.7.a, Figure S2.5). Rosi 
also significantly induced more genes in the curated pathways related to adipocyte 
browning and mitochondria than TBT (Figure 2.7.b). Both Rosi and TBT significantly 
induced lipid accumulation in differentiating 3T3 L1 cells (Figure 2.8.a). However, only 
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Rosi significantly upregulated mitochondrial biogenesis (Figure 2.8.b). Mitochondrial 
function was evaluated by measuring the oxygen consumption rate (OCR). Rosi-treated 
3T3 L1 cells increased OCR, while TBT-treated cells decreased OCR compared to both 
control- and Rosi-treated cells (Figure 2.8.c). The spare respiratory capacity (difference 
between maximal respiration and basal respiration) was marginally increased in Rosi-
treated cells; however, TBT-treated cells had significantly the spare capacity, which 
indicates inhibited response of energy expenditure (Figure 2.8.c). The difference in the 
energy usage of the cells treated with Rosi versus TBT was evident even by observing the 
color of the media (Figure S2.6). Thus, the distinct upregulation of adipocyte browning 
and mitochondrial biogenesis and function by Rosi is not unique to BM-MSCs. 
31 
 
 
Discussion 
 
TBT, the original “environmental obesogen,” binds and activates both PPARγ and 
RXRs, and its engagement of several nuclear receptor pathways contributes to the effects 
of this environmental toxicant on adipose and bone homeostasis (Grün et al. 2006; le 
Maire et al. 2009; Yanik et al. 2011; Baker et al. 2015; Watt and Schlezinger 2015). We 
used primary BM-MSCs to investigate the molecular pathways that are activated and/or 
disrupted by TBT during osteoblast and adipocyte differentiation. Because of TBT’s 
ability to interact directly with both PPARγ and RXR, we included specific ligands for 
these receptors: rosiglitazone (PPARγ ligand) and LG100268 (RXR ligand) for 
comparison. Here, we show that, as expected, rosiglitazone, TBT and LG100268 all 
suppress osteogenesis; but that unexpectedly, TBT has a limited capacity to fully activate 
PPARγ’s transcriptional programs that regulate energy homeostasis. 
There has been a challenge in understanding the potential for obesogenic effects 
of environmental PPARγ ligands (e.g. TBT) to lead to adverse effects on metabolic 
health, as people treated with therapeutic PPARγ ligands (e.g. rosiglitazone) gain weight 
but improve their metabolic health (Soccio, Chen, and Lazar 2014). Recent studies 
support the idea that, “PPARγ agonism is not correlated directly with anti-diabetic 
action” (S.-S. Choi et al. 2014). The biological pathways regulated by PPARγ (e.g. white 
adipogenesis, brite/brown adipogenesis, insulin sensitivity suppression of osteogenesis) 
are regulated separately through differential coregulator recruitment and post-
translational modifications (J. H. Choi et al. 2010, 2011; Claussnitzer et al. 2015; Cohen 
et al. 2014; Cohen and Spiegelman 2015; Feige and Auwerx 2007; Timmons and 
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Pedersen 2009; Hong Wang et al. 2016). The unliganded PPARγ/RXR receptors are 
engaged in large complexes of corepressors and coactivators that can promote repression 
or activation of PPARγ target genes (Tudor et al. 2007; Guan 2005; Michalik et al. 2007). 
In order to induce PPARγ transcriptional activation, ligand binding initiates corepressor 
release and coactivator recruitment through protein structure remodeling and epigenetic 
changes of the chromatin (Feige and Auwerx 2007). Furthermore, acetylation and 
dephosphorylation of PPARγ are crucial to the release and recruitment of its coregulators. 
For example, phosphorylation of S273 of PPARγ by CDK5 or ERK not only induces a 
“diabetogenic” program of gene expression by attenuating expression of insulin 
sensitizing genes but also reduces brite/brown gene expression (Banks et al. 2015).  
Rosiglitazone induced a distinct spectrum of transcriptional coregulators, relative 
to TBT. In particular, TBT does not efficaciously induce expression of coregulators 
related to mitochondrial biogenesis such as Phb2 (see Figure S2.2). Phb2 is required for 
modulation of mitochondrial assembly and respiration (Pbm, A, and Mic 2016). 
Rosiglitazone also uniquely induced expression of Pgc1a, which is a crucial 
transcriptional coregulator of brite/brown fat differentiation (Feige and Auwerx 2007; 
Koppen and Kalkhoven 2010; Seale 2015). PGC1α is also an important transcriptional 
inducer of mitochondrial biogenesis as it plays a role in regulating transcription of 
nucleus encoded mitochondrial genes and activates other transcription factors (e.g. NRF-
1 and NRF-2) that influence expression of key mitochondrial enzymes such as ATP 
synthetase and cytochrome c oxidase (Aquilano et al. 2010; Jornayvaz and Shulman 
2010). Another environmental PPARγ ligand, MEHP, modifies PPARγ coregulator 
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recruitment distinctly from rosiglitazone (Feige et al. 2007). While MEHP binds to 
PPARγ in a configuration similar to rosiglitazone, MEHP is unable to stabilize helix 12 
of PPARγ thus limiting its ability to release the corepressor NCOR, and MEHP 
stimulates the recruitment of the coactivators MED1 and PGC1α but not of p300 and 
SRC1 (Feige et al. 2007). Therefore, TBT may not only differentially induce coregulator 
expression, but we also hypothesize that TBT, like MEHP, is a selective PPARγ ligand, 
with a limited capacity to release and recruit coregulators. 
Moreover, TZDs such as pioglitazone and rosiglitazone can induce mitochondrial 
biogenesis and fatty acid oxidation in human adipose tissue (Harms and Seale 2013). We 
observed upregulation of genes related to mitochondrial biogenesis (Ppara and Cidea); 
browning of fat (Elovl3 and Pgc1a) only by rosiglitazone both in the osteogenic BM-
MSC cultures as well as in the adipogenic BM-MSC cultures. Importantly, only 
rosiglitazone upregulated mitochondrial protein expression and increased respiration in 
3T3 L1 cells, as well. 
TBT is a dual ligand of PPARγ and its heterodimerization partner, RXR and its 
dual nature raises the possibility that RXR or other partners could contribute to TBT-
induced effects on BM-MSC adipocyte differentiation. TBT is known to activate 
permissive RXR heterodimeric partners: PPARδ, LXR, and NURR1 (Grün et al. 2006). 
For example, the LXRα and β have influence on a number of genes involved in reverse 
cholesterol transport such as Abca1, Apoe, and Lpl (Peter Tontonoz and Mangelsdorf 
2003). We have shown previously in BM-MSC cell line (BMS2 cells) that TBT induced 
mRNA expression of LXR target gene, Abca1 (Yanik et al. 2011).  
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TBT’s limited ability to activate the PPARγ-driven transcriptional repertoire does 
not only occur in BM-MSCs, but also in the classic adipogenic model, 3T3 L1 cells. Our 
analysis of the publicly available transcriptional data set derived from 3T3-L1 cells 
showed that rosiglitazone, but not TBT, was able to efficaciously upregulate expression 
of genes and pathways related to brite fat differentiation and mitochondrial function. TBT 
did not induce mitochondrial biogenesis in our study, which is in line with a previous 
study showing that TBT induces a phenotypically distinct adipocyte in 3T3 L1 cells 
(Regnier et al. 2015). Furthermore, unlike rosiglitazone, TBT not only induces weight 
gain in vivo but also metabolic disruption (i.e. hepatic steatosis, hyperinsulinemia and 
hyperleptinemia) following adult exposure (Zuo et al. 2011; Bertuloso et al. 2015; Oakes 
et al. 1994).  
 Here, we provide support for the novel hypothesis that environmental PPARγ 
ligands, such as but not limited to TBT, act as selective PPARγ ligands that favor white 
over brite adipogenesis. While these studies investigated this hypothesis using in vitro 
mouse models, they are an important step in understanding how white adipocyte- (vs. 
brite adipocyte-) skewed differentiation may impact human health. First, TBT is well 
known to induce adipogenesis and metabolic disruption in vivo (Bertuloso et al. 2015; 
Grun et al. 2006; Zuo et al. 2011). Second, there is a high degree of structural and 
functional similarity between the mouse and human PPARγ’s (Lambe and Tugwood 
1996). Last, TBT has been shown to be highly potent and efficacious as stimulating 
adipocyte differentiation in human adipose- and bone marrow-derived MSCs (Carfi et al. 
2008; Kirchner et al. 2010). Therefore, it is highly likely that TBT also is able to skew 
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adipocyte differentiation in human cells, and as human pre-adipocytes become more 
readily available, we will test our hypothesis in a human system. 
 Critically, when homeostasis is out of balance, white adipocytes become 
dysfunctional, this results in adipose stress that leads to lipid overflow, systemic 
inflammation and insulin resistance (Stinkens et al. 2015; Wensveen et al. 2015). 
Humans with minimal brite adipocyte populations are at higher risk for obesity and type 
2 diabetes (Claussnitzer et al. 2015; Sidossis and Kajimura 2015; Timmons and Pedersen 
2009).Thus, it is essential to understand how environmental PPARγ ligands modify not 
only adipocyte differentiation but also adipocyte function (energy storage vs. insulin 
sensitization and energy dissipation) in order to assess the risk to metabolic health. 
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Conclusions 
 
PPARγ can regulate white and brite/brown adipogenesis independently, with 
distinct transcriptional profiles controlled through specific ligand binding. Compared to a 
therapeutic PPARγ ligand, rosiglitazone, the environmental metabolic disruptor, TBT, is 
a PPARγ ligand that selectively activates PPARγ transcriptional activities that favor 
white adipogenesis at the expense of promoting the browning and healthy metabolic 
activities of PPARγ. 
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Figures 
 
Figure 2.1. Expression of retinoid X receptors (RXR) and their nuclear receptor 
partners in  BM-MSCs. RNA was isolated from bone marrow cells isolated from 
female, 8 week old, C57BL/6J mice and cultured in basal medium for 7 days. mRNA 
expression was analyzed by microarray. The probability of expression was determined 
using the method of Piccolo et al. (2013). 
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Figure 2.2. Differential expression of RXR heterodimer partners (a) and nuclear 
receptor coregulators (b) in BM-MSCs undergoing osteogenic differentiation and 
treated with PPAR/RXR ligands. Primary bone marrow cells were isolated from 
female, 8 week old, C57BL/6J mice, plated, and allowed to adhere for 7 days, and 
undifferentiated cultures were harvested at this time. In experimental cultures, the 
medium was replaced with basal medium supplemented with osteogenic additives, -
glycerol phosphate, ascorbate, insulin and dexamethasone. Cultures were treated with Vh 
(DMSO, 0.1%), Rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 100 nM) or TBT (80 
nM). After 4 days of culture, cells were harvested and analyzed for gene expression using 
microarray. The heatmaps display the significant differentially expressed (a) nuclear 
receptors and (b) coregulators (fdr<0.05). 
(a) 
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(b) 
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Figure 2.3. Significant differentially expressed genes induced by rosiglitazone, 
LG100268 and TBT. Transcriptomic profiles from each chemical (TBT, Rosi, and 
LG268) were compared to vehicle (DMSO). (a) The heatmap depicts 7044 significant 
differentially expressed genes with false discovery rate (fdr) < 0.05 between the 
chemicals and Vh, with rows and columns sorted according to hierarchical clustering (as 
described in the Methods). (b) Principal component analyses (PCA) were performed in R, 
and the plots show the clustering of the undifferentiated and chemically treated cells by 
the first two principal components. (c) The Venn diagram depicts the number of 
significant differentially expressed genes with fdr<0.05 for each set of chemical 
comparisons. 
(a)      (b) 
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(c) 
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Figure 2.4. Top enriched pathways (GO Terms) induced by rosiglitazone (Rosi), 
tributyltin (TBT), and LG100268 (LG268). Pathway enrichment analyses were 
performed using a hypergeometric distribution-based test to determine the gene sets 
(Gene Ontology terms from GO database) over-represented in the lists of significant 
(fdr< 0.05) differentially expressed genes. 
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Figure 2.5. Pathway enrichment analyses related to brite/brown adipogenesis and 
mitochondrial biogenesis. (a) Most significant differentially enriched pathways between 
the Rosi- and TBT-treated cells. (b) GSEA analysis of curated genesets related to brown 
adipocyte differentiation and mitochondrial biogenesis. (c) The heatmap displays the 
significant differentially expressed genes (fdr<0.05) related to mitochondrial biogenesis 
and adipocyte browning between Rosi, LG200268 and TBT. 
(a)               
 
 
(b) 
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(c) 
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Figure 2.6. Differential adipogenic gene expression induced by rosiglitazone versus 
TBT in BM-MSCs. Primary bone marrow cells were isolated from female, 8 week old, 
C57BL/6J mice, plated, and allowed to adhere for 7 days. The medium was replaced with 
DMEM supplemented with adipogenic additives: 10% FBS, 250 nM dexamethasone, 167 
nM of 1 µg/ml human insulin, 0.5 mM IBMX. Cultures were treated with Vh (DMSO, 
0.1%), Rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 100 nM) or TBT (80 nM). On 
days 3, 5 and 7 days of differentiation, medium was replaced with adipocyte maintenance 
medium (DMEM, 10% FBS, 250 nM dexamethasone, 167 nM of 1 µg/ml human 
insulin), and the cultures were re-dosed. Following 5 or 10 days of differentiation, cells 
were harvested and analyzed for gene expression by RT-qPCR. (a) Common PPARγ-
related genes. (b) Genes related to brite/brown adipogenesis and mitochondrial 
biogenesis. Statistically different from Vh-treated on the same day (*p<0.05, **p<0.01, 
***p<0.001; ****p<0.0001, ANOVA, Dunnett’s).  
(a) 
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(b) 
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Figure 2.7. Differential adipogenic gene expression induced by rosiglitazone versus 
TBT in 3T3 L1 cells. The publicly available dataset (GSE53004) was generated from 
3T3-L1 cells treated with Rosiglitazone (500 nM) or TBT (50 nM) for 10 days in DMEM 
with 10% FBS (Pereira-Fernandes et al. 2014). (a) GSEA analysis of curated genesets 
related to brown adipocyte differentiation and mitochondrial biogenesis. (b) The heatmap 
displays the significant differentially expressed genes (fdr<0.05) related to mitochondrial 
biogenesis and adipocyte browning between Rosi and TBT.  
(a) 
 
(b) 
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Figure 2.8. Lipid accumulation and mitochondrial biogenesis induced by 
rosiglitazone versus TBT in 3T3 L1 cells. Cells were plated and then incubated for 4 
days. Differentiation and dosing were carried out as described in Figure 6. Following 10 
days of differentiation, cells were washed and analyzed for (a) lipid accumulation (Nile 
Red staining); (b) mitochondrial biogenesis (ELISA); and (c) mitochondrial respiration 
(Seahorse XF Cell Mito Stress Test). No toxicities of cells were observed in any of the 
assays. Statistically different from Vh-treated on the same day (*p<0.05, ***p<0.001; 
****p<0.0001, ANOVA, Dunnett’s). 
(a) (b) 
         
(c) 
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Supplement material 
 
Table S2.1. Mouse primer sequences for reverse transcriptase qPCR. 
 
 
 
 
 
 
 
 
 
 
 
GENE SYMBOL FORWARD REVERSE 
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
B2m 
CTGCTACGTAACACAGTTCCACC
C 
CATGATGCTTGATCACATGTCTCG 
Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 
Elvol3 TCCGCGTTCTCATGTAGGTCT GGACCTGATGCAACCCTATGA 
Fabp4 AGCCCAACATGATCATCAGC  TTTCCATCCCACTTCTGCAC  
Plin1 GGGACCTGTGAGTGCTTCC GTATTGAAGAGCCGGGATCTTTT 
Ppara GCGTACGGCAATGGCTTTAT GAACGGCTTCCTCAGGTTCTT 
Pparg TGGGTGAAACTCTGGGAGATTC AATTTCTTGTGAAGTGCTCATAGGC 
Ucp1 CTCAGTGGGAGCGACTCTTCA GGCCTCTGTGGTACACGACAA 
Scd1 CCTCCTGCAAGCTCTACACC CAGCCGAGCCTTGTAAGTTC 
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Table S2.2. Curated genesets related to brite adipogenesis and mitochondrial 
biogenesis (a) and osteogenesis (b). The table displays the genes used for each curated 
pathway related to mitochondrial biogenesis or brite fat differentiation and osteogenesis 
(Accomando et al. 2014; Calderon-Dominguez et al. 2016; Gburcik et al. 2012; Harms 
and Seale 2013; Hilton, Karpe, and Pinnick 2015; Kajimura et al. 2008; Krings et al. 
2012; Lo and Sun 2013; Murholm et al. 2009; Rosell et al. 2014; Spoto et al. 2014; P. 
Wang et al. 2007) and osteogenesis (Cappellen et al. 2002; Ji et al. 2000; Saeed and 
Iqtedar 2015; Schilling et al. 2005; Xiao et al. 2010, 2011; Yao et al. 2008)based on 
literature review. 
 
 
Curated Gene Sets 
(a) Brite Adipogenesis and 
Mitochondrial Biogenesis 
Genes 
Mitochondria Bckdha, Cabc1, Chchdh10, Coq3, Coq5, Coq9, Cox7a1, 
Cox8b, Crat, Cyc1, Decr1, Etfdh, Hsha, Idh3a, Letm1, 
Letmd1, Me3, Plat, Rilp, Sirt3, Ucp1, Uqcr10, Uqcrfs1, 
Adck3, Cs, Ndufa5, Sdhd, Atp5h, Uqcrc1 
Metabolism 
 
Acaa2, Acads, Acadvl, Acc, Acot11, Acot4, Acsf2, Cacb, 
Coasy, Cyp2b10, Fbp2, Fn3k, Gk, Ldhb, Pank1, Pck1, Pdhb, 
Pdhx, Pdk2, Pdk4, Pfkb3, Sod2, Acadl, Acox1, Cd36, Acs11, 
Crat, Slc25a20, Acaa1, Gk, Gpd1, Pnpla2, Mgst3, Gsta4, 
Cbr3, Ptges2, Nsdhl, Pdha1 
Hormone or Vitamin Cyp2b10, Dio2, Retsat, Rdn16, Irs1, Fgf21, Nrg4, Cnp 
Immune or Inflammatory-
Related 
 
C8g, Ifnar2, Igsf21, Il15ra, Kng1, Serpina12, Lgals3, Il2, Il4, 
Il10, Il13, Socs3, Cd163, Adipoq 
Transcription Factors and 
Coregulators 
Cebpa, Ebf2, Foxc2, Pparg, Prdm16, Tbx15, Ppargc1a, 
Sirt1, Ppara, Ppard, Ppargc1b, Sirt3, Ncoa1 
Pro-Browning 
 
Cpt1a, Cpt1b, Gata2, Gata3, Klf2, Klf3, Bmp7, Creb1, Dio2, 
Insr, Mapk14, Nrf1, Wnt5a, Bmp8b, Ptgs2, Elovl3, Slc27a2, 
Slc27a1, Hoxc9, Shox2, Hoxc8, Hoxc4, Hoxa5, Tfb2m, 
Ctbp1, Ctbp2, Cidec, Cidea, Tmem26 
(b) Osteogenesis 
 
Alpl, Col1a1, Fgf23, Bglap2, Spp1, Postn, Sparc, Bglap, 
Nfatc1, Ctsk , Tnfsf11, Cybb, Pdgfb, Itgb3, Calcr, Tnfrsf11a, 
Acp5, Calcr, Mitf, Car2, Mmp9, Sp7, Bmp4 , Fos, Ubd, 
Mmp13, Runx2, Col1a2, Col2a1, Col11a1, Ibsp, Pdgfa, 
Itgb1, Smad3, Dmp1, Fgfr2, Tgfb1, Smad1, Mafb, Apoe 
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Figure S2.1. Differential expression of nuclear receptors by Day 4 of differentiation 
of BM-MSCs. Primary bone marrow cells were isolated from female, 8 week old, 
C57BL/6J mice, plated, and allowed to adhere for 7 days.  The medium was replaced 
with basal medium supplemented with osteogenic additives, -glycerol phosphate, 
ascorbate, insulin and dexamethasone. Cultures were treated with Vh (DMSO, 0.1%), 
rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 100 nM) or TBT (80 nM), cultured for 
4 days and analyzed for mRNA expression using microarray. The heatmap displays the 
significant differentially expressed nuclear receptors (fdr<0.05) of 47 identified mouse 
nuclear receptors from NURSA between the vehicle and chemical-treated BM-MSCs 
compared to naïve BM-MSCs. 
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Figure S2.2. Differential expression of nuclear receptor coregulators by Day 4 of 
differentiation between Rosi- and TBT-treated BM-MSCs. Primary bone marrow 
cells were isolated from female, 8 week old, C57BL/6J mice, plated, and allowed to 
adhere for 7 days. The medium was replaced with basal medium supplemented with 
osteogenic additives, -glycerol phosphate, ascorbate, insulin and dexamethasone. 
Cultures were treated with Vh (DMSO, 0.1%), rosiglitazone (Rosi, 100 nM) or TBT (80 
nM), cultured for 4 days and analyzed for mRNA expression using microarray. The 
heatmap displays the significant differentially expressed nuclear receptor coregulators 
(fdr<0.05) of 280 identified mouse nuclear receptors from NURSA between the Rosi- 
and TBT-treated BM-MSCs. 
 
Rosi	 TBT	
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Figure S2.3. GSEA plots of enriched osteogenic genes in TBT-, LG100268-, and 
rosiglitazone-treated BM-MSCs. Primary bone marrow cells were isolated from female, 
8 week old, C57BL/6J mice, plated, and allowed to adhere for 7 days.  The medium was 
replaced with basal medium supplemented with osteogenic additives, -glycerol 
phosphate, ascorbate, insulin and dexamethasone. Cultures were treated with Vh (DMSO, 
0.1%), rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 100 nM) or TBT (80 nM), 
cultured for 4 days and analyzed for mRNA expression using microarray. Enrichment 
analyses were performed for the curated osteogenesis pathway geneset (See Table S2.2).  
 
 
 
 
 
 
 
54 
 
 
(Attached Separately as Excel File) 
 
Figure S2.4. Top Gene Ontology (GO) terms enriched for each chemical. Primary 
bone marrow cells were isolated from female, 8 week old, C57BL/6J mice, plated, and 
allowed to adhere for 7 days.  The medium was replaced with basal medium 
supplemented with osteogenic additives, -glycerol phosphate, ascorbate, insulin and 
dexamethasone. Cultures were treated with Vh (DMSO, 0.1%), rosiglitazone (Rosi, 100 
nM), LG100268 (LG268, 100 nM) or TBT (80 nM), cultured for 4 days and analyzed for 
mRNA expression using microarray. The heatmap highlights all the different GO Terms 
enriched by each chemical exposure on differentiated BM-MSCs (red = upregulation; 
blue = downregulation; significance = q-value<0.1 and q-value<0.05). 
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Figure S2.5. GSEA plots of rosiglitazone- versus TBT- enriched metabolism- and 
mitochondria-related gene sets (a) in BM-MSCs and (b) in 3T3 L1 cells. Primary 
bone marrow cells were isolated, differentiated and treated as described in Figure 2.2. 
Data for 3T3 L1 cells are from a publicly-available data set (GSE53004). Enrichment 
analyses were performed for the curated metabolism and mitochondria pathway genesets 
(see Table S2.2). 
a) Rosiglitazone vs TBT – BM-MSCs 
b) Rosiglitazone vs TBT – 3T3 L1 cells 
 
ES	=	0.82	
FDR	<	0.001	
ES	=	0.80	
FDR	<	0.001	
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Figure S2.6. 3T3 L1 cells cultured with LG268, Rosi and TBT during 
differentiation. Cells were plated and then incubated for 4 days. Differentiation and 
dosing were carried out as described in Figure 2.6. Pictures were taken prior to 
mitochondrial biogenesis/activity analyses. Representative image. 
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Abstract 
 
Growing evidence suggests that chemicals in disparate structural classes activate specific 
subsets of PPARγ’s transcriptional programs to generate adipocytes with distinct 
phenotypes. Our objectives were to 1) establish a novel classification method to predict 
PPARγ-interacting and modifying chemicals, and 2) create a taxonomy to group 
chemicals based on their effects on PPARγ’s transcriptome and downstream metabolic 
functions. We tested the hypothesis that environmental ligands highly ranked by the 
taxonomy, but that segregated from the therapeutic ligands, would induce white but not 
brite adipogenesis. 3T3-L1 cells were differentiated in the presence of 76 chemicals 
(negative controls, synthetic nuclear receptor ligands known to influence adipocyte 
biology, suspected environmental PPARγ ligands). Differentiation was assessed by 
measuring lipid accumulation. mRNA expression was determined by highly multiplexed 
RNA-Seq and validated by RT-qPCR.  A novel classification model was developed using 
an amended random forest procedure tailored to the experimental design. A subset of 
environmental contaminants identified as strong PPARγ agonists were characterized 
further for lipid handling, mitochondrial biogenesis and cellular respiration in 3T3-L1 
cells and primary human preadipocytes. The 76 chemicals generated a spectrum of 
adipogenic differentiation. We used lipid accumulation and RNA sequencing data to 
develop a classification system that 1) identified PPARγ agonists, and 2) sorted agonists 
into likely white or brite adipogens. Expression of Cidec was the most efficacious 
indicator of strong PPARγ activation. Two known environmental PPARγ ligands, 
tetrabromobisphenol A and triphenyl phosphate, which sorted distinctly from therapeutic 
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ligands, induced white but not brite adipocyte genes and induced fatty acid uptake but not 
mitochondrial biogenesis in 3T3-L1 cells. Moreover, two chemicals were identified as 
highly ranked PPARγ agonists, tonalide and quinoxyfen, induced white adipogenesis 
without the concomitant health-promoting effects in 3T3-L1 cells and primary human 
preadipocytes. A novel classification procedure accurately identified environmental 
chemicals as PPARγ-modifying chemicals distinct from known PPARγ-modifying 
therapeutics. The developed computational and experimental framework has general 
applicability to the classification of as-yet uncharacterized chemicals. 
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Introduction 
 
Since 1980, the prevalence of obesity has been increasing globally and has 
doubled in more than 70 countries. In 2015, it was estimated that a total of 108 million 
children and 604 million adults were obese worldwide (Collaborators et al. 2017). This 
poses a major public health threat since overweight and obesity increase the risk of 
metabolic syndrome, which, in turn, sets the stage for metabolic diseases, such as type 2 
diabetes, cardiovascular disease, nonalcoholic fatty liver disease and stroke (Park et al. 
2003). The Endocrine Society’s latest scientific statement on the obesity pathogenesis 
states that obesity is a disorder of the energy homeostasis system, rather than just a 
passive accumulation of adipose, and that environmental factors, including chemicals, 
confer obesity risk (Schwartz et al. 2017). The rapid increases in obesity and metabolic 
diseases correlate with substantial increases in environmental chemical production and 
exposures over the last few decades, and experimental evidence in animal models 
demonstrates the ability of a broad spectrum of chemicals to induce adiposity and 
metabolic disruption (Heindel et al. 2017).  
Adipocytes are crucial for maintaining metabolic homeostasis as they are 
repositories of free fatty acids and release hormones that can modulate body fat mass 
(Rosen and Spiegelman 2006). Adipogenesis is a highly regulated process that involves a 
network of transcription factors acting at different time points during differentiation 
(Farmer 2006)  Peroxisome proliferator activated receptor γ (PPARγ) is a ligand 
activated, nuclear receptor and essential regulator of adipocyte formation and function 
(Tontonoz et al. 1994), as well as metabolic homeostasis, as all PPARγ haploinsufficient 
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and KO models present with lack of adipocyte formation and metabolic disruption 
(Gumbilai et al. 2016; He et al. 2003; Jiang et al. 2014; O'Donnell et al. 2016; Zhang et 
al. 2004).  
PPARγ activation regulates energy homeostasis by both stimulating storage of 
excess energy as lipids in white adipocytes and stimulating energy utilization by 
triggering mitochondrial biogenesis, fatty acid oxidation and thermogenesis in brite and 
brown adipocytes. The white adipogenic, brite/brown adipogenic and insulin sensitizing 
activities of PPARγ are regulated separately through post-translational modifications 
(Banks et al. 2015; Choi et al. 2010; Choi et al. 2011; Qiang et al. 2012) and differential 
co-regulator recruitment, (Burgermeister et al. 2006; Feige et al. 2007; Ohno et al. 2012; 
Villanueva et al. 2013). Rapid expansion of white adipose depots and adipocyte 
hypertrophy that outpace vascularization generates hypoxic conditions that trigger the 
inflammation, fibrosis and lipotoxicity that contribute to the development of metabolic 
syndrome (Kusminski et al. 2016). Importantly, humans with minimal brite adipocyte 
populations are at higher risk for obesity and type 2 diabetes. (Claussnitzer et al. 2015; 
Sidossis and Kajimura 2015; Timmons and Pedersen 2009). 
Growing evidence supports the hypothesis that environmental PPARγ ligands 
induce phenotypically distinct adipocytes. Tributyltin (TBT) induces the formation of an 
adipocyte with reduced adiponectin expression and altered glucose homeostasis (Regnier 
et al. 2015). Furthermore, TBT fails to induce expression of genes associated with 
browning of adipocytes (e.g. Ppara, Pgc1a, Cidea, Elovl3, Ucp1) in differentiating 3T3-
L1 adipocytes (Kim et al. 2018; Shoucri et al. 2018). As a result, TBT-induced 
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adipocytes fail to upregulate mitochondrial biogenesis and have low levels of cellular 
respiration (Kim et al. 2018; Shoucri et al. 2018). The structurally similar environmental 
PPARγ ligand, triphenyl phosphate, also fails to induce brite adipogenesis, and this 
correlates with an inability to prevent PPARγ from being phosphorylated at S273 
(Schlezinger 2018). 
The EPA developed the Toxicity Forecaster (ToxCast™) program to use high-
throughput screening assays to prioritize chemicals and inform regulatory decisions 
regarding thousands of environmental chemicals (Kavlock et al. 2012). Several 
ToxCast™ assays can measure the ability of chemicals to bind to or activate PPARγ, and 
these assays have been used to generate a toxicological priority index (ToxPi) that were 
expected to predict the adipogenic potential of chemicals in cell culture models 
(Auerbach et al. 2016). Yet, it has been shown that the results of ToxCast™ PPARγ  
assays do not always correlate well with activity measured in a laboratory setting and that 
the ToxPi designed for adipogenesis was prone to predicting false positives (Janesick et 
al. 2016). Furthermore, the ToxCast/ToxPi approach cannot distinguish between white 
and brite adipogens.   
Here, we generate phenotypic and transcriptomic data from adipocytes 
differentiated in the presence of 76 different chemicals. We combined the cost-effective 
generation of agonistic transcriptomic data by the novel highly multiplexed RNA-seq 
technology 3’Digital Gene Expression with a new classification method to predict 
PPARγ-interacting and modifying chemicals. Further, we investigated metabolic-related 
outcome pathways as effects of the chemical exposures. We created a data-driven 
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taxonomy to specifically classify chemicals into distinct categories based on their various 
interactions with and effects on PPARγ. Based on the taxonomy-based predictions, we 
tested the phenotype (white vs. brite adipocyte functions) of environmental adipogens 
predicted to fail to induce brite adipogenesis in 3T3 L1 cells and primary human 
adipocytes. 
64 
 
 
Methods 
 
Chemicals. DMSO was purchased from American Bioanalytical (Natick, MA). 
CAS numbers, sources and catalog numbers of experimental chemicals are provided in 
Table S3.1. Human insulin, dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), and 
all other chemicals were from Sigma-Aldrich (St. Louis, MO) unless noted.  
Cell Culture. NIH 3T3-L1 (ATCC: CL-173, RRID:CVCL_0123) pre-adipocytes 
were maintained in high-glucose DMEM with 10% calf serum, 100 U/ml penicillin, 100 
μg/ml streptomycin, 0.25 μg/ml amphotericin B. Cells were plated in maintenance for 
experiments and incubated for 4 days. “Naïve” cells were cultured in maintenance 
medium for the duration of an experiment. To induce adipogenesis, the medium was 
replaced with DMEM containing 10%  fetal bovine serum (FBS, Sigma-Aldrich), 250 
nM dexamethasone, 167 nM human insulin, 0.5 mM IBMX, 100 U/ml penicillin, and 100 
μg/ml streptomycin. Experimental wells received induction medium and were treated 
with Vh (DMSO, 0.2% final concentration) or test chemicals at concentrations indicated 
in Table S3.1. On days 3 and 5 of differentiation, medium was replaced with adipocyte 
maintenance medium (DMEM, 10% FBS, 167 nM human insulin, 100 U/ml penicillin, 
100 μg/ml streptomycin), and the cultures were re-dosed. On Day 7 of differentiation, 
medium was replaced with adipocyte medium (DMEM, 10% FBS, 100 U/ml penicillin, 
100 μg/ml streptomycin), and the cultures were re-dosed. On day 10, cytotoxicity was 
assessed by microscopic inspection, with cultures containing more than 10% rounded 
cells excluded from consideration. Healthy cells were harvested for analysis of gene 
expression, lipid accumulation, fatty acid uptake, mitochondrial biogenesis, 
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mitochondrial membrane potential, and cellular respiration.  
Primary human subcutaneous pre-adipocytes were obtained from the Boston 
Nutrition Obesity Research Center (Boston, MA). The pre-adipocytes were maintained in 
αMEM with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml 
amphotericin B. Pre-adipocytes were plated in maintenance medium for experiments and 
incubated for 3 days. “Naïve” cells were cultured in maintenance medium for the 
duration of an experiment. To induce adipogenesis, the medium was replaced with 
DMEM/F12, 25 mM NaHCO3, 100 U/ml penicillin, 100 μg/ml streptomycin, 33 μM d-
Biotin, 17 μM pantothenate, 100 nM dexamethasone, 100 nM human insulin, 0.5 mM 
IBMX, 2 nM T3, and 10 μg/ml transferrin. Experimental wells received induction 
medium and were treated with vehicle (0.1% DMSO), tonalide, or quinoxyfen (4 μM)). 
On day 3 of differentiation, medium was replaced with induction medium, and the 
cultures were re-dosed. On days 5, 7, 10, and 12 of differentiation, the medium was 
replaced with adipocyte medium (DMEM/F12, 25 mM NaHCO3, 100 U/ml penicillin, 
100 μg/ml streptomycin, 33 μM d-Biotin, 17 μM pantothenate, 10 nM dexamethasone, 
and 10 nM insulin), and the cultures were re-dosed. Following 14 days of differentiation 
and dosing, cells were harvested for analysis of gene expression, lipid accumulation, fatty 
acid uptake, mitochondrial biogenesis, and cellular respiration. 
Transcriptome Analysis. 3T3-L1 cells were plated in 24 well plates at 50,000 
cells per well in 0.5 ml maintenance medium at initiation of the experiment. Total RNA 
was extracted and genomic DNA was removed using the Direct-zol MagBead RNA Kit 
(Zymo Research, Orange, CA). A final concentration of 5 ng RNA/ul was used for each 
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sample (n = 6 for naïve, n = 3-4 per vh or chemical) across six 96 well plates. Sequencing 
and gene expression quantification was carried out by the Broad Institute (Cambridge, 
MA). RNA was sequenced using highly multiplexed 3’ Digital Gene Expression (3’ 
DGE, (Xiong et al. 2017)).  Only instances of uniquely aligned reads were quantified, 
i.e., reads that aligned to only one transcript.  Furthermore, multiple reads with the same 
UMI, aligning to the same gene were quantified as a single count.  
Gene Expression Data Preprocessing. All analyses of gene expression data was 
carried out in R v3.4.3 (Team 2013).  The number of counted reads per samples varied 
widely with a range of 7.9E1 to 2.27E6 (Mean = 2.25E5, SD = 2.94E5).  To determine 
threshold of acceptable sample level quantification, we performed an iterative clustering-
based approach to determine sets of low expression outlier samples.  Each iteration 
included four steps: removal of low count genes, normalization, plate-level batch 
correction, and hierarchical clustering. Low count genes were defined as genes with mean 
counts < 1 across all samples.  Normalization was performed using Trimmed mean of M-
values, the default method employed by limma v3.34.9 (Ritchie et al. 2015). Batch 
correction was performed by ComBat v3.26.0 (Leek et al. 2012). Hierarchical clustering 
was performed on the 3000 genes with the largest median absolute deviation (MAD) 
score, using Euclidean distance and 1-Pearson correlation as the distance metric for 
samples and genes, respectively, as well as Ward’s agglomerative method. Clusters of 
samples clearly representative of low expression quantification were removed.  This 
process was repeated until no low expression outlier sample was present (four iterations). 
For the remaining samples, once again low count genes were removed and samples were 
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normalized and batch corrected by the same procedure. The final data set includes 9,616 
genes across 234 samples.  
PPARγ Modifier Classification. A classification model was inferred from the 
training set consisting of 38 known PPARγ-modifying compounds and 22 known non-
PPARγ modifying compounds, including vehicle, to predict the label of the test set of 17 
suspected PPARγ-modifying compounds. The model inference was based on an amended 
random forest procedure developed to better account for the presence of biological 
replicates in the data (manuscript in preparation).  Specifically, for each classification 
tree, samples and genes were bagged, such that samples were sampled with replacement 
and the square root of the total number of genes were randomly selected.  Within these 
“bags”, replicates of the same chemical exposure were then collapsed to their mean 
expression. The random forest classification vote, a number between 0 and 1, was then 
computed as the proportion of trees in the forest that assign the sample to the positive 
class. Prior to running the random forest procedure, genes were filtered based on within 
versus between exposure variance, using ANOVA.  Genes with an F-statistics associated 
with an FDR corrected p-value < 0.05, were used in the classification procedure. The 
predictive performance of the classification approach was estimated using 10-fold cross 
validation over the training set. For each fold, samples were stratified at the chemical 
exposure level, such that each fold included 6 distinct compounds and a different number 
of samples, and all replicates of the same compound were only included in either the 
training or the test folds.  Thresholds for determining class membership based on voting 
was determined by running the training folds through the random forest and selecting the 
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threshold producing the highest F1-score, i.e., the harmonic mean of precision and 
sensitivity.  Performance was assessed in terms of area under the ROC curve (AUC), as 
well as precision, sensitivity, specificity, F1-score, and balanced accuracy, i.e., the mean 
of specificity and sensitivity. All random forests were generated using 2000 decision 
trees. The final classification model used to predict the unlabeled chemicals was built 
using the full training set of 60 labelled chemicals and 1,199 genes after filtering. The 
performance of this procedure was compared to three alternative random forest strategies.  
In the first, denoted as pre-merge, the mean gene expression across replicates is 
computed, and a classic random forest is applied to the classification of each merged 
chemical profile.  In the second, denoted as classic, replicate samples are treated as 
independent perturbations and classified based on a classic random forest. Finally, in the 
third, denoted as pooled, the mean of votes across replicates from the previous strategy 
are used to estimate class membership per compound. To compare the performance of 
each strategy, the 10-fold CV procedure applied to the training set was repeated 10-times 
to generate a distribution of performance statistics. The importance of each gene in each 
random forest model was measured using the gini importance measure (Breiman 2001). 
PPARγ Activity Modifier Clustering. Known and suspected PPARγ modifiers 
were clustered based on their test statistics from univariate analysis comparing each 
chemical or naive exposure to vehicle using limma v3.34.9. In order to assess taxonomic 
differences between different exposure outcomes, a recursive clustering procedure, which 
we refer to as “K2 clustering”, was developed, whereby a set of chemicals is iteratively 
split into two subgroups. At each iteration of the procedure, the genes with the top 10% 
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of the sum of squared test statistics across all samples within the current set are selected. 
Samples are then clustered using Euclidean distance and Ward’s agglomerative method, 
and are split into two clusters using the cutree R function. The procedure is then 
recursively applied to each of the two clusters, until the two-cluster split would result in a 
single chemical in the terminal subgroup.  To obtain and measure the most stable clusters, 
each iteration was bootstrapped 200 times by resampling gene-level statistics with 
replacement.  The most common clusters were used, and the proportion of total 
bootstrapping iterations that included these identical clustering assignments was reported.  
At each step, all clusters must include at least non-vehicle exposures. In order to derive 
gene-signatures of each split, differential analysis was performed between samples from 
compounds of either cluster at a split.  In these models, biological replicate status was 
accounted for using the duplicate correlation procedure in the limma package. From these 
models, signatures of genes assigned to either the two subgroups were generated based on 
two criteria. First, for a particular gene, the difference between mean expression between 
the two groups must have |log2(Fold-Change)|> 1 and an FDR Q-value < 0.1. Each gene 
is then assigned to either of the two subgroups based on the mean of their test statistics 
from the comparison of each chemical to vehicle, i.e., a gene is assigned to a subgroup 
with maximum absolute value of the mean of these test statistics. This yielded four gene 
sets per split, pertaining to both subgroup assignment and direction.  Functional 
enrichment, comparing these gene sets to independently annotated gene sets was carried 
out via Fisher’s Exact Test.  These gene sets include those of the Gene Ontology 
Biological Processes gene set compendia downloaded from MSigDB 
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(c5.bp.v6.2.symbols.gmt), as well two gene sets derived from publicly available 
microarray expression data from an experiment using mouse embryonic fibroblasts to 
compare wild-type samples with mutant samples that do not undergo phosphorylation of 
PPARγ at Ser273, GEO accession number GSE22033 (Choi et al. 2010). These 
additional gene sets were comprised of genes, measured to be significantly up- or down-
regulated (FDR Q-Value < 0.05) in mutant samples, based on differential analysis of 
RMA normalized expression with limma.  
Reverse Transcriptase (RT)-qPCR. Cells were plated in 24 well plates at 
50,000 cells per well in 0.5 ml maintenance medium at initiation of the experiment. Total 
RNA was extracted and genomic DNA was removed using the 96-well Direct-zol 
MagBead RNA Kit (Zymo Research). cDNA was synthesized from total RNA using the 
iScript™ Reverse Transcription System (BioRad, Hercules, CA). All qPCR reactions 
were performed using the PowerUp™ SYBR Green Master Mix (Thermo Fisher 
Scientific, Waltham, MA). The qPCR reactions were performed using a 7500 Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA): UDG activation (50°C for 2 
min), polymerase activation (95°C for 2 min), 40 cycles of denaturation (95°C for 15 sec) 
and annealing (various temperatures for 15 sec), extension (72°C for 60 sec). The primer 
sequences and annealing temperatures are provided in Table S3.2. Relative gene 
expression was determined using the Pfaffl method to account for differential primer 
efficiencies (Pfaffl 2001), using the geometric mean of the Cq values for beta-2-
microglobulin (B2m) and 18s ribosomal RNA (Rn18s) for mouse gene normalization and 
of ribosomal protein L27 (RPL27) and B2M for human gene normalization. The Cq value 
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from naïve, undifferentiated cultures was used as the reference point. Data are reported as 
“Relative Expression.” 
Lipid Accumulation. Cells were plated in 24 well plates at 50,000 cells per well 
in 0.5 ml maintenance medium at initiation of the experiment. Medium was removed 
from the differentiated cells, and they were rinsed with PBS. The cells were then 
incubated with Nile Red (1 µg/ml in PBS) for 15 min in the dark. Fluorescence (λex= 485 
nm, λem= 530 nm) was measured using a Synergy2 plate reader (BioTek Inc., Winooski, 
VT). The fluorescence in experimental wells was normalized by subtracting the 
fluorescence measured in naïve (undifferentiated) cells and reported as relative 
fluorescence units (“RFUs”). 
Mitochondrial Membrane Potential. Cells were plated in 96 well, black-sided 
plates at 10,000 cells per well in 0.2 ml maintenance medium at initiation of the 
experiment. Mitochondrial membrane potential was measured by treating differentiated 
cells will MitoOrange Dye according to manufacturer’s protocol (Abcam, Cambridge, 
MA). Measurement of fluorescence intensity (λex= 485 nm, λem= 530 nm) was 
performed using a Synergy2 plate reader.  The fluorescence in experimental wells was 
normalized by subtracting the fluorescence measured in naïve (undifferentiated) cells and 
reported as “RFUs.” 
Fatty Acid Uptake. Cells were plated in 96 well, black-sided plates at 10,000 
cells per well in 0.2 ml maintenance medium at initiation of the experiment. Fatty acid 
uptake was measured by treating differentiated cells with 100 μL of Fatty Acid Dye 
Loading Solution (Sigma-Aldrich, MAK156).  Following a 1 hr incubation, measurement 
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of fluorescence intensity (λex= 485nm, λem= 530nm) was performed using a Synergy2 
plate reader.  The fluorescence in experimental wells was normalized by subtracting the 
fluorescence measured in naïve (undifferentiated) cells and reported as fold difference 
from vehicle “RFUs.”  
Mitochondrial Biogenesis. Cells were plated in 24 well plates at 50,000 cells per 
well in 0.5 ml maintenance medium at initiation of the experiment. Mitochondrial 
biogenesis was measured in differentiated cells using the MitoBiogenesis In-Cell Elisa 
Colorimetric Kit, following the manufacturer’s protocol (Abcam). The expression of two 
mitochondrial proteins (COX1 and SDH) were measured simultaneously and normalized 
to the total protein content via JANUS staining. Absorbance (OD 600nm for COX1, OD 
405nm for SDH, and OD 595nm for JANUS) was measured using a BioTek Synergy2 
plate reader. The absorbance ratios of COX/SDH in experimental wells were normalized 
to the naïve (undifferentiated) cells.  
Oxygen Consumption. Cells were plated in Agilent Seahorse plates at a density 
of 50,000 cells per well in 0.5 ml maintenance medium at initiation of the experiment. 
Prior to all assays, cell media was changed to Seahorse XF Assay Medium without 
glucose (1mM sodium pyruvate, 1mM GlutaMax, pH 7.4) and incubated at 37°C in a 
non-CO2 incubator for 30 min. To measure mitochondrial respiration, the Agilent 
Seahorse XF96 Cell Mito Stress Test Analyzer (available at BUMC Analytical 
Instrumentation Core) was used, following the manufacturer’s standard protocol. The 
compounds and their concentrations used to determine oxygen consumption rate (OCR) 
included 1) 0.5 μM oligomycin, 1.0 μM carbonyl cyanide-p-
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trifluoromethoxyphenylhydrazone (FCCP) and 2 μM rotenone for 3T3-L1s; and 2) 5 μM 
oligomycin, 2.5 μM FCCP, and 10 μM rotenone for the primary human adipocytes. 
Statistical Analyses. All statistical analyses were performed in R (v 3.4.3) and 
Prism 7 (GraphPad Software, Inc., La Jolla, CA). Data are presented as means ± standard 
error (SE). For 3T3-L1 experiments the biological replicates correspond to independently 
plated experiments. For human primary preadipocyte experiments the biological 
replicates correspond to distinct individuals’ preadipocytes (3 individuals in all). The 
qPCR data were log-transformed before statistical analyses. One-factor ANOVAs 
(Dunnett’s) were performed to analyze the qPCR and phenotypic data. Sequencing data 
from 3’DGE have been deposited into GEO (Accession: GSE124564).  
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Results 
 
Development of novel taxonomic subgroups of PPARγ modifiers 
Potential adipogens (chemicals that change the differentiation and/or function of 
adipocytes including endogenous, natural, therapeutic, synthetic and environmental 
chemicals) were identified by review of the literature and based on reports of PPARγ 
agonism or modulation of adipocyte differentiation. We also identified chemicals to act 
as negative controls. Our classification groups were based on “yes”, “no”, or “-” of the 
chemical’s potential ability to interact or modify PPARγ (i.e., to alter its post translational 
modifications) as noted in the “PPARγ Modifier” column in Table S3.1. 
The classic mouse pre-adipocyte model, 3T3-L1 cells, was either maintained in an 
undifferentiated state (naive), or differentiated and treated with Vh (0.1% DMSO, final 
concentration) or with each of the chemicals (concentrations are reported in Table S3.1). 
Lipid accumulation, indicative of adipocyte differentiation, was determined after 10 days. 
A spectrum of adipocyte differentiation was induced (Figure 3.1). Of the 27 chemicals 
that significantly increased adipocyte differentiation, 18 were known PPARγ modifiers 
and 9 were suspected PPARγ modifiers. Mono(2-ethylhexyl) phthalate (MEHP), SR1664, 
and 15-deoxy-Δ12,14-prostaglandin J2 (15dPGJ2) are PPARγ agonists that were expected 
to increase adipocyte differentiation, but did not. LG268 and TBT are RXR agonists that 
were also expected to significantly increase adipocyte differentiation, but did not. The 3 
chemicals that significantly downregulated adipocyte differentiation are all known to 
interact with the retinoic acid receptor. T007 is a PPARγ antagonist that was expected to 
decrease adipocyte differentiation, but did not. The negative controls did not significantly 
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influence adipocyte differentiation. Many of the suspected PPARγ modifiers did not 
significantly increase adipocyte differentiation. We hypothesize that this likely resulted 
from the fact that we did not apply any chemical above 20 μM (with the exception of 
fenthion), while higher concentrations were used in previous studies. 
When predicting PPARγ modifying status (“yes” vs. “no”), the mean AUC, 
precision, sensitivity, specificity, F1-score, and balanced accuracy from repeated 10-fold 
cross validation (over the training set) of the random forest with bag merging procedure 
was 0.89, 0.90, 0.80, 0.85, 0.85, and 0.82, respectively (Figure 3.2.a). We observed the 
most drastic improvement of measured balanced accuracy, precision, and specificity by 
the bag merging procedure compared to other assessed strategies (Figure S3.1). The first 
two metrics in particular reflect expectation of relatively few false positive results 
compared to the other strategies. In the final model, the voting threshold that produced 
the highest F1-score was 0.53. Of the 17 chemicals of unknown interaction with PPARγ, 
13 had random forest vote greater than this value (Table 3.1).  Of these 13 compounds, 
four had vote > 0.88. These chemicals included quinoxyfen, tonalide, allethrin, and 
fenthion.  These compounds were predicted as PPARγ modifiers with high confidence, 
and were selected for further functional analyses. Of the 1,199 genes used to train the 
final classification model, ribosomal protein L13 (Rpl13) and cell death Inducing DFFA 
Like Effector C (Cidec) had the highest measured Gini Importance (Figure 3.2.b) with 
Rpl13 mostly down-regulated and Cidec mostly up-regulated by known PPARγ-
modifying compounds (Figure S3.2). This is consistent with known relationships between 
cellular processes and adipogenesis. Specifically, ribosomal machinery is down-regulated 
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during human adipogenesis (Marcon et al. 2017). Cidec is a lipid droplet structural gene, 
the expression of which is positively correlated with adipocyte lipid droplet size, insulin 
levels, and glycerol release (Ito et al. 2010).  
The taxonomy derived by the K2 clustering procedure recapitulates many known 
characteristics shared by PPARγ-modifying compounds included in this study (Figure 
3.3).  For example, three terminal subgroups are labelled in figure 3.3 based on their 
shared characteristics.  These include: flame retardants (tetrabromobisphenol A (TBBPA) 
and triphenyl phosphate (TPHP)), phthalates (MBUP, MEHP, MBZP, and BBZP), and 
RXR agonists (TBT and LG268). Interestingly, we observe two subgroups containing all 
of the four thiazolidinediones, with rosiglitazone (Rosig) segregating with the non-
thiazolidinedione S26948 and pioglitazone, MCC 555, and troglitazone segregating 
together.  
All of these terminal subgroups fall within a larger module containing 26 
chemicals, highlighted by expression patterns consistent with increased adipogenic 
activity including up-regulation of genes significantly enriched in pathways involved in 
adipogenesis and lipid metabolism (Soukas et al. 2001). In addition, these chemicals also 
demonstrated consistent down-regulation of extracellular component genes.  Up-
regulation of extracellular matrix (ECM) genes are known to be associated with obesity 
(Huber et al. 2007), though to our knowledge down-regulation of extracellular matrix 
genes has not been reported as a direct result of exposure to PPARγ agonists in 
adipocytes. This effect was strongest in cells exposed to thiazolidinediones and flame 
retardants, two classes of chemicals well-described to be strong PPARγ agonists (Berger 
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et al. 1996; Fang et al. 2015; Riu et al. 2011). The subgroup of thiazolidinediones, which 
also includes S26948, is highlighted by up-regulation of genes involved in beta-
oxidation, the process by which fatty acids are metabolized.  This metabolic process has 
been previously observed with Rosig exposure (Benton et al. 2008). 
The gene expression profiles of the remaining 17 chemicals, including naïve 
controls, demonstrate markedly less up-regulation of genes regulated by PPARγ.  Of 
these 17 perturbations, a subgroup of 8 chemicals (BADGE, PrPar, 15dPGJ2, SR1664, 
METBP, DINP, BuPA, and fenthion) includes the reference vehicle signature.  Compared 
to the next closest subgroup, expression profiles of these compounds are characterized by 
up-regulation of adipogenesis related pathways indicative of modest PPARγ agonism. 
Additionally, a subgroup comprised of 9CRA, DBT, LG754, ATRA, and the naïve 
exposure signatures is characterized by down-regulation of genes involved in 
adipogenesis and lipid metabolism, indicating repression of PPARγ activity. 
Interestingly, both protectin D1 (Prote) and resolvin E1 (Resol) cluster closely in a 
subgroup with the CDK inhibitor, roscovitine (Rosco), which is known to induce insulin 
sensitivity and brite adipogenesis (Hong Wang et al. 2016). 
In summary, our top-down clustering approach elucidates subgroups of PPARγ 
activity modifying compounds, characterized by differential transcriptomic activity at 
each split. Annotation of these transcriptomic signatures reveals clear differences in the 
set and magnitude of perturbations to known adipocyte biological processes by subgroups 
of chemicals. Membership of these subgroups confirms many expectations, such as 
subgroups comprised of solely of phthalates, thiazolidinediones, or flame retardants. The 
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novel observation that the transcriptomic patterns induced by Resol and Prote segregate 
with the CDK5 inhibitor Rosco, suggests that Resol and Prote may modify PPARγ 
phosphorylation and activation distinctly from synthetic PPARγ ligands.  
 
Adipogen portal 
Given the breadth of results generated by this analysis, this description is far from 
exhaustive.   As such, we have created an interactive website 
(https://montilab.bu.edu/Adipogen/) to support the interactive exploration of these results 
at both the gene and pathway-level.  The portal is built around a point-and-click 
dendrogram of the clustering results as in Figure 3.3.  Selecting a node of this 
dendrogram will populate the rest of the portal with the chemical lists, differential 
analysis, and pathway level hyper-enrichment results for each subgroup defined by a 
split.  For instance, selecting node “H” will show the chemicals in each subgroup to the 
right (Group 1 = Honokiol, T007907; Group 2 = Prote, Resol, and Rosco), as well as the 
differential gene signature for each group below. Selecting Cidec, the top gene in the 
Group 2 signature, displays hyper-enrichment results for gene sets which include Cidec 
and have a nominal p-value < 0.50.  The hyper-enrichment results for all genes can be 
found below this table. Finally, selecting a gene set name will display the gene set 
members at the bottom frame of the portal, with gene hits in bold. All tables are 
queryable and downloadable.  
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Investigation of the white and brite adipocyte taxonomy  
We aimed to better assess how the distinction between gene expression patterns 
translated into functional differences in the induced adipocytes. Therefore, we selected 
chemicals from representative groups related to PPARγ modification for genotypic and 
phenotypic characterization. We compared a strong PPARγ therapeutic agonist that also 
modifies PPARγ phosphorylation (Rosig), a chemical that modifies only PPARγ 
phosphorylation (Rosco), a weak PPARγ agonist and endogenous molecule (15dPGJ2) 
and two known environmental PPARγ ligands (TBBPA and TPhP). 3T3-L1 cells were 
either maintained in an undifferentiated state (naive) or differentiated and treated with Vh 
(0.1% DMSO, final concentration), Rosig (1 μM), Rosco (4 μM), 15dPGJ2 (1 μM), 
TBBPA (20 μM) and TPhP (10 μM). Gene expression and phenotype were determined 
after 10 days. Analysis of mitochondrial membrane potential confirmed that the 
concentrations used were not toxic (Figure S3.3.a).  
The balance of white and brite adipogenesis is controlled by PPARγ and the 
balance is skewed toward brite adipogenesis by recruitment of specific coactivators to 
PPARγ (e.g., PGC1α and PRDM16) (Chrisman et al. 2018; Puigserver et al. 1998; Qiang 
et al. 2012; Seale et al. 2007). As expected, all of the PPARγ agonists (Rosig, 15dPGJ2, 
TBBPA, TPhP) significantly increased Pparg expression, while Rosco did not (Figure 
3.4.a). Similarly, the PPARγ agonists induced expression of adipocyte genes common to 
all adipocytes (Plin, Fabp4, Cidec), while roscovitine did not (Figure 3.4.b). In contrast, 
only the chemicals known to prevent phosphorylation of PPARγ at S273 (i.e., Rosig and 
Rosco) induced expression of Pgc1a (Figure 3.4.a) and induced expression of brite 
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adipocyte genes (Cidea, Elovl3) (Figure 3.4.c). Rosig, Rosco, and 15dPGJ2 induced the 
expression of Adipoq (Figure 3.4.c). In order for brite adipocytes to catabolize fatty acids 
and expend excess energy, they must upregulate expression of β-oxidation genes and 
mitochondrial biogenesis. In line with their browning capacity, Rosig and Rosco 
upregulated expression of Ppara and the mitochondrial marker gene Acaa2 (Figure 
3.4.d). Furthermore, only Rosig and Rosco strongly upregulated Ucp1, the protein 
product of which dissociates the H+ gradient the mitochondrial electron transport chain 
creates from ATP synthesis (Figure 3.4.d).  
Next, we determined if changes in gene expression correlated with changes in 
adipocyte function. Fatty acid uptake by adipocytes is necessary for lipid droplet 
formation and for removal of free fatty acids from circulation. Compared to vehicle-
treated cells, all of the adipogens significantly induced fatty acid uptake (Figure 3.5). In 
order to increase the utilization of fatty acids, mitochondrial number and/or function must 
increase. Only Rosig and Rosco significantly induced mitochondrial biogenesis, while 
15dPGJ2 and the environmental PPARγ agonists had no effect (Figure 3.6). Interestingly, 
Rosig significantly reduced the pH of the culture medium, suggesting that the 
rosiglitazone-induced adipocytes were highly energetic (Figure S3.4). 
Rosig and Rosco, therapeutic PPARγ ligand and PPARγ modifier, respectively, 
were able to induce gene expression and metabolic phenotypes related to upregulation of 
mitochondrial processes and energy expenditure. In comparison, environmental PPARγ 
ligands (TBBPA and TPhP) were not able to induce the gene and phenotypic markers of 
brite adipocytes. 
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Identification of novel adipogens that favor white adipogenesis 
Quinoxyfen (Quino) and tonalide (Tonal) were two of the environmental 
chemicals that received the highest PPARγ modifiers vote and segregated distinctly from 
the therapeutic ligands (Table 3.1). Thus, we tested the hypothesis that Quino and Tonal 
are adipogens that do not induce gene expression or metabolic phenotypes indicative of 
healthy energy expenditure or brite adipogenesis. We tested this hypothesis in the 3T3-L1 
model and primary human preadipocytes. In 3T3-L1 cells, Quino and Tonal significantly 
induced lipid accumulation (Figure 3.7.a). They significantly increased expression of the 
white adipocyte marker gene, Cidec. However, Quino failed to significantly increase 
expression of Cidea, the brite adipocyte marker gene, while Tonal significantly 
suppressed Cidea expression (Figure 3.7.b). Accordingly, Quino and Tonal increased 
fatty acid uptake (Figure 3.7.c) but not mitochondrial biogenesis (Figure 3.7.d). Quino 
increased maximal cellular respiration, but did not change spare capacity (Figure 3.7.e). 
Consistent with the 3T3-L1 results, in human preadipocytes Quino and Toanl 
significantly induced lipid accumulation (Figure 3.8.a) and expression of CIDEC (Figure 
3.8.b). Furthermore, Quino failed to induce CIDEA expression, while Tonal suppressed 
CIDEA expression (Figure 3.8.b). In contrast to 3T3-L1 cells, Quino and Tonal did not 
increase fatty acid uptake over that induced by the hormonal cocktail (Figure 3.8.c). 
However, the reduction in mitochondrial biogenesis (Figure 3.8.d) and cellular 
respiration (Figure 3.8.e) can still explain the ability of these chemicals to increase lipid 
accumulation.  
In summary, the combination of random forest classification voting and gene 
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expression clustering identified two environmental contaminants likely to favor the 
induction of white adipocytes. Hypothesis testing carried out with functional analyses 
confirmed that Quino and Tonal induce white, but not brite, adipogenesis in both mouse 
and human preadipocyte models. Importantly, hypothesis testing can be conducted with 
readily available cells lines and analytical reagents. 
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Discussion 
 
The chemical environment has changed dramatically in the past 40 years, and an 
epidemic increase in the prevalence of obesity has occurred over the same time period. 
Yet, it is still unclear how chemical exposures may be contributing to adverse metabolic 
health effects. New tools are needed not just to identify potential adipogens, but to 
provide information on the type of adipocyte that is formed. Here, we have both 
developed a new analytical framework for adipogen identification and characterization 
and tested its utility in hypothesis generation. We show that adipogens segregate based on 
distinct patterns of gene expression, which we used to identify two environmental 
contaminants for hypothesis testing. Our results support the conclusion that quinoxyfen 
and tonalide have a limited capacity to induce the health-promoting effects of 
mitochondrial biogenesis and brite adipocyte differentiation. 
 
Adipogen taxonomy identifies environmental chemicals that favor white 
adipogenesis 
Of the four compounds predicted with high confidence to modify PPARγ activity, 
quinoxyfen and tonalide are of particular public health concern. Quinoxyfen is among a 
panel of pesticides with different chemical structures and modes of action (i.e., zoxamide, 
spirodiclofen, fludioxonil, tebupirimfos, forchlorfenuron, flusilazole, acetamaprid, and 
pymetrozine) that induce adipogenesis and adipogenic gene expression in 3T3-L1 cells 
(Janesick et al. 2016). Quinoxyfen is a fungicide widely used to prevent the growth of 
powdery mildew on grapes (Duncan et al. 2018). We chose to test tonalide because it was 
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reported to strongly increase adipogenesis in 3T3-L1 cells, although it was concluded that 
this response was not due to direct PPARγ activation (Pereira-Fernandes et al. 2013). Our 
results differ in this regard. Tonalide bioaccumulates in adipose tissue of many organisms 
including humans, and exposure is widespread because of its common use in cosmetics 
and cleaning agents (Kannan et al. 2005). Combined, tonalide and galaxolide constitute 
95% of the polycyclic musks used in the EU market and 90% of that of the US market 
(HERA 2004).  
Our results support the conclusion that quinoxyfen and tonalide are adipogenic 
chemicals, likely to be acting through PPARγ. In clustering analysis, quinoxyfen and 
tonalide were among the largest subgroup of eight potential strong PPARγ agonists 
(Figure 3).  Notably, this cluster includes both synthetic/therapeutic (nTZDpa, 
tesaglitazar, telmisartan) and environmental compounds (allethrin, tributyl phosphate, 
and TPhP) and is characterized by general up-regulation of pathways of adipogenic 
activity. However, quinoxyfen and tonalide generate adipocytes that are phenotypically 
distinct from adipocytes induced by therapeutics such as rosigltiazone. Quinoxyfen and 
tonalide induced white adipocyte functions such as increased lipid accumulation, but in 
contrast to rosiglitazone, did not induce mitochondrial biogenesis, energy expenditure or 
brite adipocyte gene expression.   
We hypothesize that the differences in adipocyte phenotype that are induced by 
environmental PPARγ ligands (e.g. TBBPA, TPhP, quinoxyfen, tonalide) result from the 
conformation that PPARγ assumes when liganded with these chemicals rather than with 
therapeutic agents. These differences in conformation not only determine the efficacy to 
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which PPARγ is activated but also the transcriptional repertoire (Chrisman et al. 2018). 
Access to post-translational modification sites and coregulator binding surfaces depends 
upon the structure that PPARγ assumes. Furthermore, the white adipogenic, brite/brown 
adipogenic and insulin sensitizing activities of PPARγ are regulated separately through 
differential co-regulator recruitment (Villanueva et al. 2013) and post-translational 
modifications,(Choi et al. 2010; Choi et al. 2011) with ligands having distinct abilities to 
activate each of PPARγ’s functions. Suites of genes have been shown to be specifically 
regulated by the acetylation status of PPARγ (SirT1-mediated) (Qiang et al. 2012), by the 
phosphorylation status of PPARγ (ERK/MEK/CDK5-mediated) (Choi et al. 2010; Wang 
et al. 2016) and/or by the recruitment of Prdm16 to PPARγ (Seale et al. 2007). Future 
work will investigate the connections between the phosphorylation status of PPARγ 
liganded with environmental PPARγ ligands such as quinoxyfen and tonalide, the 
recruitment and release of coregulators, and the ability of PPARγ to recruit 
transcriptional machinery to specific DNA-binding sites.   
 
Analytical approaches for adipogen characterization 
In this study, we performed high-throughput, cost-effective transcriptomic 
screening to profile adipocytes formed from 3T3-L1 preadipocytes exposed to a panel of 
compounds of known and unknown adipogenic impact. Common to toxicogenomic 
projects, this panel-based study design allows for characterization of the extent to which 
each chemical modifies differentiation (in this case, adipogenesis as related to the change 
in lipid accumulation). It also supports the exploration of how subsets of chemicals 
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influence multiple biological processes that determine the functional status of a cell (in 
this case, processes that determine white vs. brite adipogenesis). Exploration of these 
biological processes allows for the prediction of the phenotypic impact of previously 
unclassified compounds, as well as for the characterization of the heterogeneity of the 
cellular activity of compounds with similar known phenotypic impact. Here we have 
performed both types of analyses: first through the implementation and application of 
random forest classification models to identify potential PPARγ activity-modifying 
compounds, and second via the recursive clustering of the data to identify and 
characterize taxonomic subgroup of known and predicted PPARγ activity modifying 
compounds.  
For both analyses, we introduced amendments to commonly used machine 
learning procedures, to improve accuracy and resolution of the acquired result. For the 
classification task, we amended the random forest algorithm to tailor it to study designs 
typically adopted in toxicogenomic projects (see Methods). With the addition of an extra 
step to average the expression across replicates of the bootstrapped samples, we observe 
consistently higher performance across conventional metrics than with the standard 
algorithm (Figure S1).  For the clustering task, we employ a procedure where we 
recursively divide sets of chemicals into two subgroups and assess the robustness of each 
division, as well as annotate transcriptional drivers of each division. As a result, we are 
not limited to interpreting the clustering results as mutually exclusive groups, but rather 
as a taxonomy of subgroups where sets of compounds share some transcriptional impact 
and differ in others, as is expected given the dynamic nature of the modifications by 
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which compounds directly and indirectly affect PPARγ activity. 
Future work will generalize random forest method to incorporate more complex 
study designs. To this end, the classification approach adopted in this project is being 
developed as a random forest software tool soon to be made available as an R package, 
allowing for the interchanging independent functions at different steps of the algorithm. 
The strength and utility of this approach extends beyond toxicogenomic studies, and can 
be used in a variety of applications of high-throughput screening, including drug 
discovery, such as the Connectivity Map (CMAP) (Subramanian et al. 2017), and 
longitudinal molecular epidemiology studies, such as the Framingham Heart Study 
(Mahmood et al. 2014). 
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Conclusions 
 
Emerging data implicate contributions of environmental metabolism-disrupting 
chemicals to perturbations of pathways related to metabolic disease pathogenesis, such as 
disruptions in insulin signaling and mitochondrial activity. There is still a gap in 
identifying and examining how environmental chemicals can act as obesity-inducing and 
metabolism-disrupting chemicals. Our implementation of novel strategies for 
classification and taxonomy development can help identify environmental chemicals that 
are acting on PPARγ. Further, our approach provides a basis from which to investigate 
effects of adipogens on not just the generation of adipocytes, but potentially pathological 
changes in their function. To this end, we have shown how two environmental 
contaminants, quinoxyfen and tonalide, are inducers of white adipogenesis. 
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Tables: 
 
Table 3.1. Amended random forest classification results for 17 compounds suspected 
to be PPARγ modifiers. 
 
CHEMICAL NAME KNOWN SOURCE/USE PPARҮ MODIFIER 
VOTE ± 95% CI 
CHEMICALS ABOVE THE HIGHEST F1-SCORE THRESHOLD 
D-CIS,TRANS-
ALLETHRIN  
Insecticide 0.91 ± 0.01 
TONALIDE Musk (fragrance) 0.90 ± 0.01 
QUINOXYFEN Fungicide 0.90 ± 0.01 
FENTHION  Insecticide 0.88 ± 0.01 
2,4,6-TRIS(TERT-
BUTYL)PHENOL 
Antioxidant (industrial) 0.80 ± 0.02 
PRALLETHRIN Insecticide 0.78 ± 0.02 
TEBUCONAZOLE Fungicide 0.78 ± 0.02 
FLUDIOXONIL Fungicide 0.77 ± 0.02 
TRIS(1,3-DICHLORO-2-
PROPYL) PHOSPHATE 
Flame retardant 0.76 ± 0.02 
CYAZOFAMID  Pesticide 0.72 ± 0.02 
PERFLUOROOCTANOI
C ACID 
Fluorosurfactant 0.59 ± 0.02 
TRIPHENYL 
PHOSPHITE 
Pesticide 0.57 ± 0.02 
TRIS(1-CHLORO-2-
PROPYL) PHOSPHATE 
Flame retardant 0.54 ± 0.02 
CHEMICALS BELOW THE HIGHEST F1-SCORE THRESHOLD 
TRIPHENYLPHOSPHI
NE OXIDE 
Crystallizing aid, 
byproduct 
0.49 ± 0.02 
DIPHENYL 
PHOSPHATE 
Metabolite of TPhP 0.47 ± 0.02 
DIOCTYL 
SULFOSUCCINATE 
SODIUM 
Surfactant 0.41 ± 0.02 
PERFLUOROOCTANE
SULFONIC ACID 
Fluorosurfactant 0.40 ± 0.02 
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Figures 
 
Figure 3.1. Lipid accumulation in differentiated and treated 3T3-L1 pre-adipocytes. 
3T3-L1 cells were cultured with adipocyte differentiation medium and treated with 
vehicle (Vh, 0.1% DMSO, final concentration) or test chemical (Table S3.1). On days 3, 
5, and 7 of differentiation, the medium was replaced and the cultures re-dosed. Following 
10 days of differentiation and dosing, cells were analyzed for lipid accumulation by Nile 
Red staining. Data are presented as mean ± SE (n=4). * Statistically different from Vh-
treated (highlighted in green) (p<0.05, ANOVA, Dunnett’s). 
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Figure 3.2. Amended random forest classification performance and gene importance 
of final classification model. (a) Performance of random forest classification procedure 
based on 10-fold cross validation. (b) Gini Importance versus ranking of genes used in 
the final random forest model. The names of the top 2 genes are highlighted.  Compound-
specific gene expression of Rpl13 and Cidec are shown in supplementary figure S3.2. 
(a)  (b) 
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Figure 3.3. Chemical taxonomy of PPARγ-modifying compounds based on K2 
clustering of the 3’DGE data. The dendrogram shows the taxonomy-driven hierarchical 
grouping of compounds and naive exposures of 3T3-L1 cells.  Each split is labeled with a 
letter, and the proportion of gene-level bootstraps which produced the resulting split is 
shown. Highlights of hyper-enrichment of gene ontology (GO) biological processes are 
shown. 
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Figure 3.4. White and brite gene expression in differentiated and treated 3T3-L1 
adipocytes. 3T3-L1 cells were cultured with adipocyte differentiation medium and dosed 
with Vh (0.1% DMSO, final concentration), rosiglitazone (Rosig, 1 μM), roscovitine 
(Rosco, 4 μM), 15dPGJ2 (1 μM), TBBPA (20 μM) and TPhP (10 μM). On days 3, 5, and 
7 of differentiation, the adipocyte maintenance medium was replaced and the cultures re-
dosed. Following 10 days of differentiation and dosing, cells were analyzed for gene 
expression by RT-qPCR. (a) PPARγ and coregulator expression. (b) Genes related to 
white adipogenesis. (c) Genes related to brite adipogenesis. (d) Genes related to 
mitochondrial biogenesis and energy expenditure. Data are presented as mean ± SE of 
n=4 independent experiments. Statistically different from Vh-treated (highlighted in 
green)(*p<0.05, **p<0.01, ANOVA, Dunnett’s). 
(a) 
(b) 
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(c) 
 
(d) 
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Figure 3.5. Fatty acid uptake in differentiated and treated 3T3-L1 adipocytes. 
Differentiation and dosing were carried out as described in Figure 3.4. Following 10 days 
of differentiation, fatty acid uptake was analyzed using a dodecanoic acid fluorescent 
fatty acid substrate. Data are presented as means ± SE (n=4). Statistically different from 
Vh-treated (highlighted in green) (*p<0.05, **p<0.01, ANOVA, Dunnett’s). 
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Figure 3.6. Mitochondrial biogenesis in differentiated and treated 3T3-L1 
adipocytes. Differentiation and dosing were carried out as described in Figure 3.4. 
Following 10 days of differentiation, mitochondrial biogenesis was analyzed by 
measuring mitochondria-specific proteins. Data are presented as means ± SE (n=4). * 
Statistically different from Vh-treated (highlighted in green) (p<0.05, ANOVA, 
Dunnett’s). 
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Figure 3.7. Tonalide and quinoxyfen induce white, but not brite, adipogenesis in 
3T3-L1 pre-adipocytes. 3T3-L1 cells were cultured with adipocyte differentiation 
medium and dosed with Vh (0.1% DMSO, final concentration), quinoxyfen (Quino, 10 
μM) or tonalide (Tonal, 4 μM). On days 3, 5, and 7 of differentiation, the adipocyte 
maintenance medium was replaced and the cultures re-dosed. Following 10 days of 
differentiation and dosing, cultures were analyzed for (a) adipocyte differentiation, (b) 
white (Cidec) and brite (Cidea) gene expression, (c) fatty acid uptake, (d) mitochondrial 
biogenesis and (e) cellular respiration using the Seahorse assay. Data are presented as 
means ± SE (n=4). *Statistically different from Vh-treated (highlighted in green) 
(p<0.05, ANOVA, Dunnett’s). 
(a) (b) 
       
(c)                                                  (d)        (e) 
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Figure 3.8. Tonalide and quinoxyfen induce white, but not brite, adipogenesis in 
primary human adipocytes. Primary human adipocytes were differentiation medium 
and dosed with Vh (0.1% DMSO, final concentration), quinoxyfen (Quino, 4 μM) or 
tonalide (Tonal, 4 μM).   On days 3, 5, 7, 10, and 12 of differentiation, the medium was 
replace and the cultures re-dosed. Following 14 days of differentiation and dosing, 
cultures were analyzed for (a) adipocyte differentiation, (b) white (Cidec) and brite 
(Cidea) gene expression, (c) fatty acid uptake, (d) mitochondrial biogenesis and (e) 
cellular respiration. Data are presented as mean ± SE (n=3, each n is from adipocytes 
from an individual). *Statistically different from Vh-treated (highlighted in green) 
(p<0.05, ANOVA, Dunnett’s). 
(a)                                                (b) 
   
(c)                                           (d)                                            (e) 
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Supplement material 
 
Table S3.1. Chemical information. 
Chemical Name Abbreviation CAS # Supplier Catalog # 
Final 
Concentration 
[M] 
PPARγ 
Activity 
Modifier 
15-deoxy-Δ12,14-prostaglandin J2 15dPGJ 
87893-55-
8 
Cayman 
Chemical 
18570 1*10-6 Yes 
2,2',4,4',5,5'-Hexachloro-1,1'-biphenyl PCB153 
35065-27-
1 
Ultra 
Scientific 
RPC-047 1*10-5 No 
2,2',5,5'-Tetrachloro-1,1'-biphenyl PCB52 
35693-99-
3 
Sigma 
Aldrich 
35599 1*10-5 No 
2,4,6-Tris(tert-butyl)phenol TTBP 732-26-3 
Sigma 
Aldrich 
T49409 2*10-5 Suspected 
2-ethylhexanol EtHex 104-76-7 
Sigma 
Aldrich 
W315109 1*10-5 No 
3,3',4,4',5-Pentachloro-1,1'-biphenyl PCB126 
57465-28-
8 
Ultra 
Scientific 
RPC-102 1*10-8 Suspected 
3,3',5,5'-Tetrabromobisphenol A TBBPA 79-94-7 
Sigma 
Aldrich 
330396 2*10-5 Yes 
4,4'-Dichlorodiphenyldichloroethylene DDE 72-55-9 
Sigma 
Aldrich 
48679 1*10-5 Suspected 
4,4'-Dichlorodiphenyltrichloroethane DDT 50-29-3 
Sigma 
Aldrich 
40124 1*10-5 Suspected 
4,5,6,7-Tetrabromobenzotriazole TBB Synthesized by Asis Chemical 1*10-5 No 
9-cis-retinoic acid 9cRA 5300-03-8 
Sigma 
Aldrich 
R4643 2*10-6 Yes 
All-trans retinoic acid ATRA 302-79-4 
Sigma 
Aldrich 
R2625 1*10-6 Yes 
Benzyl butyl phthalate BBzP 85-68-7 
Sigma 
Aldrich 
36927 1*10-5 Suspected 
  
 
1
0
0
 
Bisphenol A BPA 80-05-7 
Sigma 
Aldrich 
239658 1*10-5 Suspected 
Bisphenol A diglycidyl ether BADGE 1675-54-3 
Sigma 
Aldrich 
D3415 1*10-5 Suspected 
Bisphenol S BPS 80-09-1 
Sigma 
Aldrich 
43034 1*10-5 Suspected 
Candesartan Cande 
145040-
37-5 
Sigma 
Aldrich 
SML0245 4*10-6 Yes 
CL 316,243 CL316 
138908-
40-4 
Sigma 
Aldrich 
C5976 5*10-6 No 
Corticosterone Corti 50-22-6 
Sigma 
Aldrich 
27840 2*10-6 No 
Cyazofamid Cyazo 
120116-
88-3 
Sigma 
Aldrich 
33874 2*10-5 Suspected 
d-cis,trans-Allethrin Allet 548-79-2 
Sigma 
Aldrich 
33396 1*10-5 Suspected 
Dexamethasone Dex-SP 2392-39-4 
Sigma 
Aldrich 
D1159 2*10-7 No 
Di(2-ethylhexyl) phthalate DEHP 117-81-7 
Sigma 
Aldrich 
36735 1*10-5 Suspected 
Dibutyltin DBT 683-18-1 
Sigma 
Aldrich 
205494 2*10-7 Suspected 
Diisononyl phthalate DINP 
28553-12-
0 
Sigma 
Aldrich 
376663 1*10-5 Suspected 
Dioctyl sulfosuccinate sodium DOSS 577-11-7 
Sigma 
Aldrich 
323586 5*10-6 Suspected 
Diphenyl phosphate DiPhPho 838-85-7 
Sigma 
Aldrich 
850608 1*10-5 Suspected 
Ethylene brassylate EtBra 105-95-3 
Sigma 
Aldrich 
W354309 1*10-5 No 
Fenthion Fenth 55-38-9 
Sigma 
Aldrich 
36552 4*10-5 Suspected 
Firemaster 550 FM550 Gift from Heather Stapleton, Duke 10 ug/ml Yes 
  
 
1
0
1
 
Fludioxonil Fludi 
131341-
86-1 
Sigma 
Aldrich 
46102 2*10-6 Suspected 
Honokiol Honok 
35354-74-
6 
Sigma 
Aldrich 
H4914 4*10-6 Yes 
LG100268 LG268 
153559-
76-3 
Sigma 
Aldrich 
SML0279 1*10-7 Yes 
LG100754 LG754 
180713-
37-5 
Tocris 3831 2*10-7 Yes 
Magnolol Magno 528-43-8 
Sigma 
Aldrich 
M3445 2*10-5 Yes 
MCC-555 MCC555 
161600-
01-7 
Sigma 
Aldrich 
SML0896 5*10-6 Yes 
Melengestrol acetate Melen 2919-66-6 
Sigma 
Aldrich 
73248 2*10-5 No 
Mono-(2-ethyhexyl) 
tetrabromophthalate 
METBP Synthesized by Asis Chemical 1*10-5 Suspected 
Mono(2-ethylhexyl) phthalate MEHP 4376-20-9 
Sigma 
Aldrich 
CDS010608 1*10-5 Yes 
Monobenzyl phthalate MBzP 2528-16-7 
Sigma 
Aldrich 
89505 1*10-5 Suspected 
Mono-n-butyl phthalate MBuP 131-70-4 
Sigma 
Aldrich 
30751 2*10-5 Suspected 
n-Butylparaben BuPara 94-26-8 
Sigma 
Aldrich 
54680 2*10-5 Suspected 
N-nitro-2-imidazolidinimine Imida 
138261-
41-3 
Sigma 
Aldrich 
37894 1*10-5 Suspected 
nTZDpa nTZDpa 
118414-
59-8 
Sigma 
Aldrich 
SML0616 1*10-6 Yes 
Perfluorooctanesulfonic acid PFOS 2795-39-3 
Sigma 
Aldrich 
77282 1*10-5 Suspected 
Perfluorooctanoic acid PFOA 335-67-1 
Sigma 
Aldrich 
33824 1*10-5 Suspected 
Pioglitazone hydrochloride Piogl 
112529-
15-4 
Sigma 
Aldrich 
E6910 1*10-5 Yes 
  
 
1
0
2
 
Prallethrin Prall 
23031-36-
9 
Sigma 
Aldrich 
32917 1*10-5 Suspected 
Pregnenolone 16α-carbonitrile Pregn 1434-54-4 
Sigma 
Aldrich 
P0543 1*10-5 No 
Propylparaben ProPara 94-13-3 
Sigma 
Aldrich 
P53357 1*10-5 Suspected 
Protectin D1 Prote 
871826-
47-0 
Cayman 
Chemical 
10008128 2*10-6 Yes 
Quinoxyfen Quino 
124495-
18-7 
Sigma 
Aldrich 
46439 1*10-5 Suspected 
Resolvin-E1 Resol 
552830-
51-0 
Cayman 
Chemical 
10007848 2*10-6 Yes 
Roscovitine Rosco 
186692-
46-6 
Sigma 
Aldrich 
R7772 4*10-6 Yes 
Rosiglitazone Rosig 
122320-
73-4 
Cayman 
Chemical 
71740 1*10-6 Yes 
S26948 S26948 
353280-
43-0 
Sigma 
Aldrich 
SML0510 2*10-6 Yes 
Sodium arsenite Arsen 7784-46-5 
Sigma 
Aldrich 
S7400 4*10-7 Suspected 
Sodium tungstate Tungs 
10213-10-
2 
Sigma 
Aldrich 
14304 2*10-5 Suspected 
SR1664 SR1664 
1338259-
05-4 
Sigma 
Aldrich 
SML0636 1*10-6 Yes 
T0901317 T1317 
293754-
55-9 
Sigma 
Aldrich 
T2320 1.0E-06 No 
T0070907 T007 
313516-
66-4 
Sigma 
Aldrich 
T8703 8*10-6 Yes 
Tebuconazole Tebuc 
107534-
96-3 
Sigma 
Aldrich 
32013 2*10-5 Suspected 
Telmisartan Telmi 
144701-
48-4 
Sigma 
Aldrich 
T8949 2*10-5 Yes 
Tesaglitazar Tesag 
251565-
85-2 
Sigma 
Aldrich 
SML1369 5*10-6 Yes 
  
 
1
0
3
 
Tolylfluanid Tolyl 731-27-1 
Sigma 
Aldrich 
32060 2*10-7 No 
Tonalide Tonal 
21145-77-
7 
Sigma 
Aldrich 
W526401 4*10-6 Suspected 
Tributyl phosphate TBuP 126-73-8 
Sigma 
Aldrich 
240494 2*10-5 Suspected 
Tributyltin TBT 1461-22-9 
Sigma 
Aldrich 
T50202 8*10-8 Yes 
Triflumizole Trifl 
68694-11-
1 
Sigma 
Aldrich 
32611 2*10-5 Yes 
Triphenyl phosphate TPhP 115-86-6 
Sigma 
Aldrich 
241288 2*10-5 Yes 
Triphenyl phosphite TPhPhi 101-02-0 
Sigma 
Aldrich 
T84654 1*10-5 Suspected 
Triphenylphosphine oxide TPhPhoOx 791-28-6 
Sigma 
Aldrich 
T84603 1*10-5 Suspected 
Triphenyltin TPhT 639-58-7 
Sigma 
Aldrich 
245712 8*10-8 Yes 
Tris(1,3-dichloro-2-propyl) phosphate TDCPP 
13674-87-
8 
Sigma 
Aldrich 
32951 2*10-5 Suspected 
Tris(1-chloro-2-propyl) phosphate TCCP 
13674-87-
5 
Sigma 
Aldrich 
32952 1*10-5 Suspected 
Troglitazone Trogl 
97322-87-
7 
Sigma 
Aldrich 
T2573 5*10-6 Yes 
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Table S3.2. Mouse (M) and human (H) primer sequences for reverse transcriptase 
qPCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene 
Symbol FORWARD REVERSE 
Annealing 
Temp. C 
M-18sRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 55 
M-B2M CTGCTACGTAACACAGTTCCACCC CATGATGCTTGATCACATGTCTCG 55 
M-Cidec AGGCCCTGTCGTGTTAGCAC CATGATGCCTTTGCGAACCT 55 
M-Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 55 
M-Elovl3 TCCGCGTTCTCATGTAGGTCT GGACCTGATGCAACCCTATGA 55 
M-Fabp4 AGCCCAACATGATCATCAGC  TTTCCATCCCACTTCTGCAC  55 
M-Plin1 GGGACCTGTGAGTGCTTCC GTATTGAAGAGCCGGGATCTTTT 55 
M-Pgc1a AACAAGCACTTCGGTCATCCCTG TTACTGAAGTCGCCATCCCTTAG 55 
M-Pparg2 TGGGTGAAACTCTGGGAGATTC AATTTCTTGTGAAGTGCTCATAGGC 55 
M-Rip140 AGAACGCACATCAGGTGGCA GATGGCCAGACACCCCTTTG 55 
M-Adipoq GCACTGGCAAGTTCTACTGCAA GTAGGTGAAGAGAACGGCCTTGT 55 
M-Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG 55 
M-Acaa2 TAACGAGGCTGGCTACTTCAA AGGGGCGTGAAGTTATGTTTT 55 
H-RPL27 GTGAAAGTGTATAACTACAATCACC TCAAACTTGACCTTGGCCT 58 
H-B2M GCTATCCAGCGTACTCCAAAG CACACGGCAGGCATACTC 58 
H-CIDEC GGGATACAGTGTTCATGGTCCT TCAATCTTCTTGGCAGGCTTATG 55 
H-CIDEA GGCAGGTTCACGTGTGGATA GAAACACAGTGTTTGGCTCAAGA 60 
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(Attached Separately as Excel File) 
 
Table S3.3. Detailed annotation of clustering results for individual modules. 
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Figure S3.1. Performance comparison of random forest methods. The mean AUC, 
balanced accuracy, F1-score, precision, sensitivity, and specificity were compared across 
the different statistical methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1
0
7 
Figure S3.2. Classification results (distributions of individual genes). Compound specific normalized gene expression of all 
compounds for the top two genes (Cidec, Rpl13). Mean expression across all vehicle samples is shown as a horizontal line 
spanning the plot. Exposures which have statistically significant different means from vehicle (FDR Q-value < 0.05) are 
highlighted with an asterisk. 
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Figure S3.3. Mitochondrial membrane potential in the differentiated and treated 
3T3-L1s. 3T3-L1 cells were cultured with adipocyte differentiation medium and dosed 
with (a) Vh (0.1% DMSO, final concentration), rosiglitazone (1 μM), roscovitine (4 μM), 
15dPGJ2 (1 μM), TBBPA (20 μM) and TPhP (10 μM) or (b) Vh (0.1% DMSO, final 
concentration), quinoxyfen (10 μM) and tonalide (4 μM). On days 3, 5, and 7 of 
differentiation, the adipocyte maintenance medium was replaced and the cultures re-
dosed. Following 10 days of differentiation and dosing, cells were stained with 
MitoOrange and fluorescence intensity (λex= 485nm/λem= 530nm) was measured. Data 
are presented as means ± SE (n=4). Statistically different from Vh-treated (**p<0.01, 
ANOVA, Dunnett’s). 
(a)           (b) 
 
109 
 
 
Figure S3.4. Photograph of differentiated and treated 3T3-L1 cultures. 3T3-L1 cells 
were cultured with adipocyte differentiation medium and dosed with vehicle (0.1% 
DMSO), 15dPGJ2 (1 µM), Rosi (1 µM), Rosco (4 µM), TBBPA (20 µM), TPhP (20 
µM), and Quinoxyfen (10 µM). On days 3, 5, and 7 of differentiation, the adipocyte 
maintenance medium was replaced and the cultures re-dosed. Following 10 days of 
differentiation and dosing, cells were photographed. The medium contains Phenol Red, 
which turns from pink to yellow as the acidity increases. 
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Abstract 
 
Triphenyl phosphate (TPhP) is an environmental PPARγ ligand, and growing evidence 
suggests that it is a metabolic disruptor. We have shown previously that TPhP, along with 
several other environmental PPARγ ligands, does not induce brite adipocyte gene 
expression or mitochondrial biogenesis. First, we tested whether TPhP also fails to induce 
brite adipogenesis in vivo and in a human primary preadipocyte model. Second, we tested 
the hypothesis that TPhP is a selective PPARγ modulator that is unable to protect PPARγ 
from phosphorylation at serine 273. C57BL/6J male mice were fed either a low or very 
high fat diet for 13 weeks. From weeks 7–13, mice were injected intraperitoneally, daily, 
with vehicle, rosiglitazone (Rosi), or TPhP (10 mg/kg). Mature adipocytes were isolated 
from inguinal adipose tissue to assess adipocyte gene expression. Adipocyte genotype 
and phenotype were assessed in human primary preadipocytes differentiated in the 
presence of Rosi, or TPhP. Adipocyte gene and protein expression were determined in 
3T3 L1 cells differentiated in the presence of Rosi or TPhP. Swiss 3T3 cell lines 
expressing wild-type PPARγ2 or PPARγ2 with alanine substitute for serine at position 
273 were used to determine effects of PPARγ phosphorylation on Rosi- and TPhP-
induced gene expression. Compared to Rosi, TPhP did not induce browning of mature 
adipocytes. TPhP also did not induce expression of brite adipocyte genes, mitochondrial 
biogenesis or cellular respiration in primary human adipocytes. Rosi and TPhP induced 
distinct proteomic and phosphoproteomic profiles; Rosi enriched more regulatory 
pathways related to fatty acid oxidation and mitochondrial proteins. Furthermore, TPhP 
maintained phosphorylation of PPARγ at ser273. Upon inhibition of phosphorylation at 
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ser273, TPhP was able to induce brite adipocyte genes. Here, we show that TPhP acts via 
a novel mechanism of action. TPhP disrupts brite adipocyte differentiation by failing to 
protect PPARγ from phosphorylation at ser273, in contrast to the therapeutic PPARγ 
ligand Rosi.  
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Introduction 
 
The Endocrine Society’s latest scientific statement on the obesity pathogenesis 
states that obesity is a disorder of the energy homeostasis system, rather than just a 
passive accumulation of adipose, and that environmental factors, including chemicals, 
confer obesity risk (Schwartz et al. 2017). This coincides with the Metabolism Disrupting 
Chemical (MDC) hypothesis, which proposes that environmental chemicals “ promote 
metabolic changes that can result in obesity, type 2 diabetes or fatty liver in animals 
including humans; these metabolic alterations may play an important role in the global 
epidemics of obesity, type 2 diabetes and metabolic syndrome” (Heindel et al. 2017). 
This hypothesis is not without controversy, in part, because many MDCs are ligands for 
PPARγ, a therapeutic target for treatment of type 2 diabetes. 
One class of chemicals that are suspected MDCs are organophosphate esters 
(OPEs). These chemicals are extensively used as flame retardants and plasticizers in 
consumer products from furniture to nail polish (Mendelsohn et al. 2016; Wang et al. 
2019). An analysis of 2,666 urine samples from the 2013-14 National Health and 
Nutrition Examination Survey for biomarkers of organophosphate flame retardant 
exposure showed that exposure to triphenyl phosphate (TPhP) and tris(1,3-dichloro-2-
propyl) phosphate are nearly ubiquitous in Americans (92% detection frequency) (Ospina 
et al. 2018). OPEs and their metabolites are ligands for multiple human nuclear receptors 
(Kojima et al. 2013, 2016). There is strong evidence that TPhP is a peroxisome 
proliferator-activated receptor γ (PPARγ) ligand and being is adipogenic (Belcher et al. 
2014; Fang, Webster, and Stapleton 2015; Pillai et al. 2014; Tung, Ahmed, et al. 2017; 
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Tung, Peshdary, et al. 2017). TPhP induced lipid accumulation and perilipin (lipid droplet 
marker) protein expression in mouse BMS2 cells and increased adipocyte protein 2 (aP2) 
mRNA expression in mouse 3T3-L1 adipocytes (Pillai et al. 2014; Tung, Ahmed, et al. 
2017). TPhP induced lipid accumulation and increased FABP4 and LPL mRNA 
expression in human preadipocytes (Tung, Peshdary, et al. 2017).  
Several studies have evaluated the metabolic effects of early life exposures to 
TPhP in adults. Perinatal TPhP exposure increased body and fat mass in 3.5 month old 
male and female rats and increased fasting plasma non-esterified-fatty acids in the male 
rats (Green et al. 2016). Perinatal TPhP exposure in male mice resulted in increased body 
weight, liver weight, lipid-related metabolites, and fat mass and suppressed pyruvate 
metabolism and tricarboxylic acid cycles in adults (D. Wang et al. 2018). There is also 
evidence of impaired glucose homeostasis in adults following early life exposures to 
TPhP (Green et al. 2016; Patisaul et al. 2013; D. Wang et al. 2018). 
PPARγ is required for adipocyte differentiation, regulation of insulin sensitivity, 
and in regulating the molecular events that generate white, brown, and brite (brown-in-
white) adipocytes (Lefterova et al. 2014; Ma et al. 2018). White adipocytes are 
characterized by a single large lipid droplet and store excess energy in forms of 
triglycerides (Ma et al. 2018). Brown adipocytes contain multiple, small lipid droplets 
and have a high density of mitochondria. A high level of expression of Ucp1 in brown 
adipocytes uncouples the electron transport chain from synthesis of ATP resulting in heat 
production and high energy expenditure. Brown adipocytes play an important role in 
thermogenesis (Ma et al. 2018). The more recently discovered brite adipocytes are of 
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white adipocyte origin, but have smaller, multi-locular lipid droplets and a higher 
mitochondrial density than white adipocytes (Chen, Pan, and Pfeifer 2016; Ma et al. 
2018). The ability of PPARγ to induce the differentiation and control the function of both 
white and brown adipocytes results from a fine tuning of its transcriptional repertoire by 
post-translational modification and recruitment of coregulators (T.-H. Kim et al. 2013). 
Transcriptional activity of PPARγ can be regulated by post-translational 
modifications such as phosphorylation (Burns and Vanden Heuvel 2007). 
Phosphorylation of PPARγ on ser112 in the N-terminal A/B domain inhibits ligand 
binding, but reduced phosphorylation at ser112 is associated with increased adiposity 
(Rangwala et al. 2003; Shao et al. 1998). PPARγ also can be phosphorylated by cyclin-
dependent kinase 5 (Cdk5) on ser273 in the ligand-binding domain, which dysregulates 
the expression of genes involved in insulin-sensitization including adipsin and 
adiponectin (J. H. Choi et al. 2010). PPARγ ligands, such as rosiglitazone (an anti-
diabetic therapeutic), that are capable of inhibiting phosphorylation at ser273 improve 
glycemic control and insulin sensitivity (Banks et al. 2015; J. H. Choi et al. 2010; Ma et 
al. 2018). These healthful metabolic effects can be mimicked by a Cdk5 inhibitor, 
roscovitine (Hong Wang et al. 2016). Thus, it has been suggested that PPARγ agonism is 
not a prerequisite for the beneficial effects of inhibited phosphorylation at ser273 (J. H. 
Choi et al. 2011). Moreover, ser273 of PPARγ is in close proximity with the RXRα DNA 
binding domain, implicating protein-protein interactions and resulting dynamics as a 
target for phosphorylation that can ultimately regulate the recruitment of coregulators 
(Chandra et al. 2008; Lemkul et al. 2015). Indeed, selective PPARγ activation is a 
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strategy being used to design therapeutics that maximize insulin sensitization while 
minimizing adverse effects (Garcia-Vallvé et al. 2015).   
We have previously shown that tributyltin (TBT) and TPhP, along with other 
emerging MDCs of concern such as quinoxyfen and tonalide, act through PPARγ to 
enhance adipocyte differentiation but are not able to induce health-promoting activities of 
PPARγ such as mitochondrial biogenesis and cellular respiration (S. Kim et al. 2018, 
2019). Yet, it is unclear how environmental MDCs act disparately from therapeutic 
PPARγ ligands . Here, we investigate the hypothesis that TPhP is a selective PPARγ 
modulator that fails to protect PPARγ from phosphorylation at ser273. We began by 
extending our original observation of TPhP’s failure to induce brite adipogenesis in 3T3 
L1 cells to an in vivo model and human pre-adipocytes. Then, we used the 3T3 L1 model 
and 3T3 cells expressing wildtype and mutant PPARγ to investigate the role of PPARγ 
phosphorylation in the disparate effects of TPhP and rosiglitazone on adipocyte 
differentiation. Overall, the results support the conclusion that TPhP is a selective PPARγ 
modulator. 
117 
 
 
Methods 
 
Chemicals. DMSO was purchased from American Bioanalytical (Natick, MA). 
Cell culture chemicals were from Sigma-Aldrich (St. Louis, MO). Rosiglitazone (#71740, 
purity > 98%) was from Cayman Chemical (Ann Arbor, MI). Roscovitine (#R7772, 
purity > 98%) and triphenyl phosphate ((#241288, purity > 99%) were from Sigma-
Aldrich. All other reagents were from Thermo Fisher Scientific (Waltham, MA), unless 
noted. 
In-vivo experiments. Six-week-old, male C57BL/6J mice (DIO, Stock No: 
380050 and DIO Control, Stock No: 380056) were obtained from Jackson Laboratory 
(Bar Harbor, ME) and housed at 23°C in a 12 hr light/dark cycle. Experimental 
procedures were approved by the Boston University Institutional Animal Care and Use 
Committee and performed in an American Association for the Accreditation of 
Laboratory Animal Care accredited facility (Animal Welfare Assurance Number: A3316-
01). Water and food were provided ad libitum. Mice were fed either a diet with 60% 
kcal% fat (high fat diet, D12492, Research Diets, New Brunswick, NJ) or 10% kcal% fat 
(low fat diet, D12450B, Research Diets) for a total of 13 weeks. Seven weeks after 
initiation of the diet, mice were injected intraperitoneally (i.p.), daily for 6 weeks with 
vehicle (composition: 50% saline, 45% PG400, and 5% TWEEN 80; volume was 
calculated depending on the mouse weight), rosiglitazone (Rosi, 10 mg/kg), or triphenyl 
phosphate (TPhP, 10 mg/kg). Mice were weighed daily. Body composition was measured 
by noninvasive quantitative MRI (EchoMRI700) before euthanasia. To isolate stromal 
vascular fraction (SVF) and mature adipocytes (MA), inguinal (IWAT) and epididymal 
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(EWAT) white adipose tissue were minced, resuspended in 5 ml 1% collagenase type II 
in DMEM with 2.5% BSA and incubated, rocking for 40 min at 37°C. Samples were 
filtered through 100 and 40 μm strainers (BD Bioscience), and centrifuged for 10 min at 
500 × rpm (pellet fraction were mature adipocytes).  For immunohistochemistry, IWAT, 
EWAT, and liver were fixed in 4% formalin, paraffin-embedded, sectioned (5 μm) and 
stained with hematoxylin and eosin (Rabhi et al. 2018). Adipocyte size and number were 
measured using ImageJ software (Schneider, Rasband, and Eliceiri 2012).  
Cell Culture. NIH 3T3-L1 (ATCC: CL-173, RRID:CVCL_0123), 3T3-PPARγ 
WT and 3T3-PPARγ S273A cells (Qiang et al. 2012) were maintained in high-glucose 
DMEM with 10% calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml 
amphotericin B. Cells were plated in maintenance medium and incubated for 3 days. 
“Naïve” cells were cultured in maintenance medium for the duration of an experiment. 
On day 0, differentiation was induced by replacing the maintenance medium with 
DMEM containing 10%  fetal bovine serum (FBS, Sigma-Aldrich), 250 nM 
dexamethasone, 167 nM of 1 µg/ml human insulin, 0.5 mM IBMX, 100 U/ml penicillin, 
and 100 μg/ml streptomycin. On days 3 and 5 of differentiation, medium was replaced 
with adipocyte maintenance medium (DMEM, 10% FBS, 167 nM human insulin, 100 
U/ml penicillin, 100 μg/ml streptomycin), and the cultures were dosed with vehicle 
(DMSO, 0.1% final concentration), Rosi (20uM), or TPhP (20uM). On Day 7 of 
differentiation, medium was replaced with adipocyte medium (DMEM, 10% FBS, 100 
U/ml penicillin, 100 μg/ml streptomycin), and the cultures were re-dosed. For CDK5 
inhibition experiments, cells were treated with Vh or roscovitine (Rosco, 20 µM) at the 
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initiation of differentiation as well as on days 3, 5, and 7 of differentiation. On day 10, 
cytotoxicity was assessed by microscopic inspection. For PPARγ antagonist experiments, 
cells were treated with Vh or T0070907 (20 µM) at the initiation of differentiation as well 
as on days 3, 4, 5 and 6 of differentiation. On day 7, cytotoxicity was assessed. Healthy 
cells were harvested for gene expression, proteomic, lipid accumulation, mitochondrial 
biogenesis, and cellular respiration analyses. 
Primary, human, subcutaneous pre-adipocytes were obtained from the Boston 
Nutrition Obesity Research Center (Boston, MA). Pre-adipocytes were maintained in 
αMEM with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml 
amphotericin B. Pre-adipocytes were plated in maintenance medium and incubated for 3 
days. “Naïve” cells were cultured in maintenance medium for the duration of the 
experiment. On day 0, differentiation was induced by replacing the maintenance medium 
with DMEM/F12, 25 mM NaHCO3, 100 U/ml penicillin, 100 μg/ml streptomycin, 33 μM 
d-Biotin, 17 μM pantothenate, 100 nM dexamethasone, 100 nM human insulin, 0.5 mM 
IBMX, 2 nM T3, and 10 μg/ml transferrin. Experimental wells received induction 
medium and were treated with vehicle (DMSO, 0.1% final concentration), Rosi (4μM), or 
TPhP (4μM). On day 3 of differentiation, medium was replaced with induction medium, 
and the cultures were re-dosed. On days 5, 7, 10, and 12 of differentiation, the medium 
was replaced with adipocyte medium (DMEM/F12, 25 mM NaHCO3, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 33 μM d-Biotin, 17 μM pantothenate, 10 nM 
dexamethasone, 10 nM insulin, and 3% bovine calf serum) and the cultures were re-
dosed. On day 14, cytotoxicity was assessed by microscopic inspection. Healthy cells 
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were harvested for gene expression, lipid accumulation, fatty acid uptake, mitochondrial 
biogenesis, and cellular respiration analyses. 
Reverse Transcriptase (RT)-qPCR. Total RNA was extracted and genomic 
DNA was removed using the Direct-zol 96-well MagBead RNA Kit (Zymo Research, 
Orange, CA). cDNA was synthesized from total RNA using the iScript™ Reverse 
Transcription System (BioRad, Hercules, CA). All qPCR reactions were performed using 
PowerUp™ SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA). The 
qPCR reactions were performed using a 7500 Fast Real-Time PCR System (Applied 
Biosystems, Carlsbad, CA): UDG activation (50°C for 2 min), polymerase activation 
(95°C for 2 min), 40 cycles of denaturation (95°C for 15 sec) and annealing (various 
temperatures for 15 sec), extension (72°C for 60 sec). The primer sequences and 
annealing temperatures are provided in Table S4.1. Relative gene expression was 
determined using the Pfaffl method to account for differential primer efficiencies (Pfaffl 
2001), using the geometric mean of the Cq values for beta-2-microglobulin (B2m) and 
18s ribosomal RNA (Rn18s) for mouse gene normalization and of ribosomal protein L27 
(RPL27) and B2M for human gene normalization. The Cq value from naïve, 
undifferentiated cultures was used as the reference point. Data are reported as “Relative 
Expression” compared to vehicle (Vh, 0.1%DMSO) for in-vitro experiments and 
compared to vehicle of low-fat or high-fat diet group for in-vivo experiments. 
Lipid Accumulation. Cells were plated in 24-well plates at 50,000 cells per well 
in 0.5 ml maintenance medium at initiation of the experiment. Medium was removed 
from the differentiated cells, and they were rinsed with PBS. The cells were then 
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incubated with Nile Red (1 µg/ml in PBS) for 15 min in the dark. Fluorescence 
(excitation 485 nm, 20 nm bandwidth; emission 530 nm, 25 nm bandwidth) was 
measured using a Synergy2 plate reader (BioTek Inc., Winooski, VT). Fluorescence in 
experimental wells was normalized by subtracting the fluorescence measured in naïve 
cells and reported as relative fluorescence units (“RFUs”). Fluorescent microscopic 
images were taken using the Nikon Deconvolution Wide-Field Fluorescence System (20x 
Objective). 
Fatty Acid Uptake. Cells were plated in 96-well, black-sided plates at 10,000 
cells per well in 0.2 ml maintenance medium at initiation of the experiment. Fatty acid 
uptake was measured by treating differentiated cells with 100 μL of Fatty Acid Dye 
Loading Solution (#MAK156, Sigma-Aldrich).  Following a 1 hr incubation, 
fluorescence (excitation 485 nm, 20 nm bandwidth; emission 530 nm, 25 nm bandwidth) 
was measured using a Synergy2 plate reader. The fluorescence in experimental wells was 
normalized by subtracting the fluorescence measured in naïve cells and reported as 
“RFUs.”  
Mitochondrial Biogenesis. Cells were plated in 24-well plates at 50,000 cells per 
well in 0.5 ml maintenance medium at initiation of the experiment. Mitochondrial 
biogenesis was measured in differentiated cells with the MitoBiogenesis In-Cell Elisa 
Colorimetric Kit, using the manufacturer’s protocol (Abcam, Cambridge, UK). The 
expression of two mitochondrial proteins (COX1 and SDH) was measured 
simultaneously and normalized to the total protein content via JANUS staining. 
Absorbance (OD 600nm for COX1, OD 405nm for SDH, and OD 595nm for JANUS) 
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was measured using a BioTek Synergy2 plate reader. The absorbance ratios of 
COX/SDH in experimental wells were normalized to the naïve cells.  
Cellular Respiration. Cells were plated in Agilent Seahorse 96-well plates at a 
density of 50,000 cells per well in 0.5 ml maintenance medium at initiation of the 
experiment. Prior to all assays, cell media was changed to Seahorse XF Assay Medium (0 
mM glucose, 1mM sodium pyruvate, 1mM GlutaMax, pH 7.4), and cultures were 
incubated at 37°C in a non-CO2 incubator for 30 min. Mitochondrial respiration/activity 
was measured using an Agilent Seahorse XF96 Cell Mito Stress Test Analyzer, following 
the manufacturer’s standard protocol (Boston University Analytical Instrumentation 
Core). The concentration of compounds used to determine oxygen consumption rate 
(OCR) included 0.5 μM oligomycin, 1.0 μM carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), and 2 μM rotenone for the 3T3-L1s and 5 μM 
oligomycin, 2.5 μM FCCP, and 10 μM rotenone for the primary human adipocytes. 
Immunoblot Analyses. Cells were plated in 6-well plates at 200,000 cells per 
well in 2 ml maintenance medium at initiation of the experiment. Cells were lysed in 
RIPA Buffer with PMSF (Cell Signaling Technology, Danvers, MA). Proteins (50 ug) 
were fractionated using SDS-PAGE on 10% Mini-PROTEAN TGX protein gels (Bio-
Rad) and were transferred to nitrocellulose membranes (Bio-Rad). Following transfer, the 
membranes were blocked with 5% bovine serum albumin in phosphate-buffered saline-
0.1% Tween 20 and probed with rabbit anti-PPARγ antibody (#2443S, Cell Signaling 
Technology) and phospho-ser273 PPARγ (bs-4888R, Bioss, Woburn, MA). 
Immunoreactive bands were detected using HRP-conjugated secondary antibodies 
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(Biorad) followed by enhanced chemiluminescence.   
Proteomic Analyses. Cells were plated in T75 flasks at 1,000,000 cells per well 
in 10 ml maintenance medium at initiation of the experiment. Cells were re-suspended in 
8M Urea/50mM triethylammonium bicarbonate (TEAB), with phosphatase and protease 
inhibitors (Roche, Basel, CH) then sonicated (3x10 seconds) on ice. Samples were 
reduced for 30 minutes with 8 mM dithiothreitol and alkylated for 15 minutes with 
20mM iodoacetamide at 30°C. The 8M urea solution was diluted to 1M with 50 mM 
TEAB, and samples were digested overnight at 37°C with 20 μg sequencing grade trypsin 
(90057, Thermo Fisher Scientific). 
Prior to TMT (Tandem Mass Tag) labeling, peptides were extracted from each 
sample using c18 spin columns (Toptip, Glygen, Columbia, MD), and peptide 
concentrations were normalized to 100ug in 100ul of 100mM TEAB. Peptides were 
labelled with 0.8 mg of TMT label (TMT10plex™ Isobaric Label Reagent Set, Thermo 
Fisher Scientific). Labelled samples were pooled, and 95% was set aside for phospho-
peptide enrichment using TiO2 (Titansphere Phos-TiO Bulk 10 um, GL Sciences, Tokyo, 
JP) (Cantin et al. 2007). The remaining 5% of labelled peptides and the phospho-peptide 
enriched samples were analyzed separately by mass spectrometry. 
  Samples were analyzed by a Q Exactive HFX mass spectrometer connected to 
Easy nLC 1200 reverse-phase chromatography system (Thermo Fisher Scientific). 
Mobile phase A was 0.1% formic acid and 2% acetonitrile, mobile phase B was 0.1% 
formic acid and 80% acetonitrile. Peptides were resuspended in 0.1% formic acid for 
loading. The samples were loaded onto a nano-trap column with mobile phase A, (75μm 
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i.d. × 2 cm, Acclaim PepMap100 C18 3μm, 100Å, Thermo Fisher Scientific) and were 
separated over an EASY-Spray column, (50 cm × 75 μm ID, PepMap RSLC C18, 
Thermo Fisher Scientific) by an increasing mobile phase B gradient over 180 minutes at a 
flow rate of 250 nL/min. The mass spectrometer was operated in positive ion mode with a 
capillary temperature of 300°C, and with a potential of 2100V applied to the frit. All data 
was acquired with the mass spectrometer operating in automatic data dependent 
switching mode. A high resolution (60,000) MS scan (350-1500 m/z) was performed 
using the Q Exactive to select the 10 most intense ions prior to MS/MS analysis using 
HCD (NCE 33, 45,000 resolution). 
Resulting RAW files were searched using MaxQuant (version 1.6.0; 
www.coxdocs.org/doku.php?id=maxquant:start) under standard settings using the 
UniProt mouse database (downloaded October 2018, www.uniprot.org/taxonomy/10090) 
allowing for two missed trypsin cleavage sites and variable modifications of N-terminal 
acetylation and methionine oxidation (Tyanova, Temu, and Cox 2016). Additionally, 
protein phosphorylation at S, T, and Y residues were included as variable modifications 
in the phosphoproteomics data. Carbamidomethylation of cysteine residues was a fixed 
modification in the search. Candidate (phospho)peptides, proteins, and phosphorylation-
site identifications were filtered based on a 1% false discovery rate threshold based on 
searching the reverse sequence database. Data are deposited and publicly available at the 
PRIDE archive. All phosphopeptide identifications in the MaxQuant evidence file had to 
meet a 0.7 probability cutoff. 
The searched intensity data were filtered, normalized, and clustered using R 
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[https://www.R-project.org/]. Feature filtering was performed to remove any feature in 
less than 70 percent of samples with 1627 proteins and 1066 phospho-sites passing the 
filter in the proteomics and phosphoproteomic data sets, respectively.  The LIMMA R 
package was used for LOESS normalization and differential expression analysis (Ritchie 
et al. 2015). A combined ranked list for both sets was generated where duplicate gene 
entries were removed to keep the entry with the highest absolute rank value.   
Gene Set Enrichment Analysis (GSEA) software from the Broad Institute 
(software. broadinstitute.org/GSEA)(version 3.0) was used in rank mode along with gene 
sets downloaded from the Bader Lab 
(Mouse_GOBP_AllPathways_no_GO_iea_October_01_2018_symbol.gmt) from 
http://baderlab.org/GeneSets) (Merico et al. 2010; Subramanian et al. 2005). GSEA 
results were visualized using the Enrichment Map app (Version 3.1) in Cytoscape 
(Version 3.6.1) and highly related pathways were grouped into a theme and labeled by 
AutoAnnotate (version 1.2). For the merged gene set analyses, we applied an enrichment 
P < 0.01 and FDR ≤ 0.1 cutoff and calculated overlap between gene set annotations using 
a combination of Jaccard and overlap coefficients with a cutoff of 0.375.  
Statistical Analyses and Publicly Available Data. All statistical analyses were 
performed in R (v 3.5.0) and Prism 7 (GraphPad Software, Inc., La Jolla, CA). Data are 
presented as means + standard error (SE). For 3T3-L1 experiments the biological 
replicate is an independently plated experiment. For human primary preadipocyte 
experiments, the biological replicate is a single individual’s preadipocytes (3 individuals 
in all). The qPCR data were log-transformed before statistical analyses. One-factor 
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ANOVAs (Dunnett’s) were performed to analyze the qPCR and phenotypic data. The 
mass spectrometry proteomics and phosphoproteomics data are available from PRIDE 
(http://www.proteomexchange.org) under accession number PXD012337. 
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Results 
 
Effect of TPhP on adipocyte browning in vivo 
 
We examined in-vivo effects of Rosi and TPhP exposure in six-week-old 
C57BL/6J male mice that were also fed either low fat diet (LFD) or high fat diet (HFD). 
We chose male mice as C57BL/6 male mice are more likely to become obese than female 
mice, and it has been suggested that male mice are more vulnerable than the females to 
the impacts of HFD on weight gain and metabolic disruption (Hong et al. 2009; Hwang et 
al. 2010). Compared to Vh-treated mice on LFD, small but not significant increases in 
body weight were observed in mice that were exposed to Rosi or TPhP (Figure S4.1.a). 
Generally, the body weights of HFD mice were greater than LFD mice exposed to Vh. 
Body weights, as well as fat mass, in Rosi- and TPhP- treated mice on HFD were lower 
than that of Vh-treated mice on HFD (Figures S4.1.a-b). There were no significant 
differences in lean mass (Figure S4.1.b).  
In inguinal white adipose tissue (IWAT), white adipocytes can attain a brown-like 
phenotype and express thermogenic genes (Kalinovich et al. 2017; Paschos et al. 2018). 
Rosi and TPhP increased the number of adipocytes in IWAT of mice fed either a high or 
low fat diet and significantly decreased the size of these adipocytes in both diet groups 
(Figures 4.1a-b). We measured expression of white adipocyte genes (Fabp4, Plin1, 
Cidec, Retn, and Wdnm1) and brite adipocyte genes (Adipoq, Cidea, Elovl3, Ucp1, 
Acaa2, CoxIV) in mature adipocytes (MA) of the IWAT. Rosi and TPhP did not change 
the expression of Fabp4 but significantly induced expression of Plin1 and Cidec, proteins 
associated with lipid droplets, in both diet groups (Figure 4.1.c). TPhP increased Retn 
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expression in both diet groups, while Rosi increased its expression only in the HFD group 
(Figure 4.1.c). Rosi only significantly reduced Wdnm1 expression in the LFD group 
(Figure 4.1.c). In the LFD group, Rosi only significantly induced expression of known 
markers of brite adipocytes; while TPhP significantly reduced expression of Elovl3 
andUcp1 and also reduced Acaa2 expression (Figure 4.1.d). In the HFD group, Rosi 
significantly induced expression of Elovl3, Cidea, Acaa2, and CoxIV; while TPhP 
significantly increased only Acaa2 expression (Figure 4.1.e). Moreover, in the HFD 
group, TPhP significantly reduced expression of Elovl3 and Ucp1 (Figure 4.1.d). Hence, 
in-vivo TPhP exposure did not significantly induce browning of white adipose tissue. 
 
Effect of TPhP on metabolic health in vivo 
In the in-vivo exposure experiments, we also investigated diet (i.e. high fat diet, 
HFD vs. low fat diet, LFD) and chemical exposure effects on metabolic outcomes such as 
insulin and glucose tolerance. There were no differences in glucose tolerance of Rosi- 
and TPhP-treated mice fed on LFD compared to vehicle-treated mice, and Rosi- and 
TPhP-treated mice showed slightly less improved insulin tolerance over time compared 
to vehicle-treated mice (Figure S4.2.a). Interestingly, Rosi and TPhP groups on HFD 
exhibited improved glucose tolerance compared to vehicle group, but there were no 
major differences of insulin tolerance in TPhP group on HFD (Figure S4.2.b).   
Liver is an important organ involved in metabolic homeostasis. As indicated by 
H&E staining of the liver tissue and triglyverides (TAG) assay, there were only small 
increases of TAG accumulated in the liver by Rosi- and TPhP-LFD groups, but decreased 
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TAG accumulation in both treatment groups on HFD (Figure S4.3.a). Moreover, PPARγ 
is not highly expressed in the liver compared to PPARα, but there was increased Pparg 
expression in both chemical treatment groups on either diet (Figure S4.3.b). Compared to 
the vehicle-LFD group, Rosi and TPhP groups on either diet significantly induced 
expression of Ppara and its target genes such as Cpt1a, Acox, Pdk4, Acadm, and Fgf21 
(Figure S4.3.b). Thus, the increased expression of Pparg, Ppara, and its target genes in 
the liver of Rosi- and TPhP-HFD groups may lead to improved beta-oxidation and insulin 
signaling. 
 Epididymal white adipose tissue (EWAT) is a model for visceral adipose tissue. 
Compared to the EWAT of vehicle-treated mice fed a LFD, Rosi- and TPhP- treated mice 
had greater infiltration of mononuclear cells and more crown-like structures, indicative of 
inflammatory state and presence of macrophages (Matsumoto et al. 2017; Murano et al. 
2008) (Figure S4.4.a). In contrast, there were no signs of an inflammatory state in the 
EWAT of HFD mice in all exposure groups (Figure S4.4.a). We examined gene 
expression of white and inflammatory markers in the stromal vascular fraction (SVF) 
isolated from EWAT, as SVF contains various cells including cells of mesenchymal 
origin and macrophages (Han et al. 2015). Compared to Vh-LFD group, TPhP-LFD and 
TPhP-HFD groups significantly induced expression of Plin1 and modestly increased 
expression of other white adipocyte markers (Fabp4, Col1a1 and Col3a1) in the SVF 
from EWAT (Figure S4.4.b). TPhP also did not induce or reduce white adipokine 
markers, Retn and Wdnm1, respectively (Figure S4.4.b). The inflammation seen in the 
H&E stains of the EWAT in LFD group were confirmed with gene expressions of 
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inflammatory and macrophage markers in the SVF from EWAT. Rosi and TPhP 
significantly increased expressions of inflammatory markers such as Hif1a and Tnfa and 
of macrophage markers: iNOS, Il12p40, Usp18, Cd11c, and Adgre (Figure S4.4.c). 
Interestingly in the HFD groups, Rosi and TPhP did not induce expressions of Hif1a, 
iNOS, Usp18, and Adgre and significantly reduced expressions of Il-6 and Cc12 (Figure 
S4.4.c).  
 
Effect of TPhP on differentiation of human adipocytes 
Primary human adipocytes were differentiated using a standard hormone cocktail 
for a total of 14 days. During differentiation, cells were treated with vehicle (0.1% 
DMSO, final concentration), Rosi (4 μM), or TPhP (4 μM). Both Rosi and TPhP 
significantly induced lipid accumulation (Figure 4.2.a). However, only Rosi significantly 
induced fatty acid uptake, mitochondrial biogenesis, and cellular respiration in 
differentiated primary human adipocytes (Figures 4.2.b-d). Both Rosi and TPhP 
significantly increased expression of PPARG and expression of the white adipocyte 
genes, PLIN1, CIDEC, and FABP4 (Figure 4.2.e). While both Rosi and TPhP 
significantly induced the energy expenditure gene, ACAA2, only Rosi significantly 
increased expression of browning markers, ELOVL3, CIDEA and UCP1 (Figure 4.2.e). 
These observations in primary human adipocytes are consistent with the in-vivo findings 
that Rosi, but not TPhP, induces brite adipogenesis.  
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Analysis of the TPhP-induced proteome in 3T3 L1 adipocytes 
First, we validated the induction of adipogenesis by the two PPARγ ligands, Rosi 
and TPhP, in 3T3 L1 cells, a mouse-derived pre-adipocyte model. 3T3 L1 cells were 
differentiated using a standard hormone cocktail for 10 days. During differentiation, cells 
were treated with Vh (0.1% DMSO, final concentration), Rosi (20 μM), or TPhP (20 
μM). Rosi and TPhP significantly induced lipid accumulation (Figure 4.3.a). Rosi and 
TPhP induced Plin1 expression in a PPARγ-dependent manner (Figure 4.3.b). Rosi, but 
not TPhP, induced expression of the brite adipocyte genes Elovl3 and Ucp1 in 3T3 L1 
cells (S. Kim et al. 2019), and this induction also is PPARγ-dependent (Figure 4.3.b). As 
in primary human adipocytes, only Rosi significantly induced mitochondrial biogenesis 
and mitochondrial activity (Figures 4.3.c-d). Thus, we performed proteomic analyses 
with differentiated and treated 3T3-L1s. The heatmap in Figure 4.4.a shows that Rosi-
treated cells expresses a suite of protein that are distinct from Vh- and TPhP-treated cells. 
TPhP-treated samples cluster and have expression patterns more similar to Vh-treated 
cells (Figure 4.4.a). The list of significant differentially expressed proteins is presented in 
Table S4.2. Rosi highly upregulated CD36, FABP4, and GPD1 (Figure 4.4.b), which are 
involved in fatty acid and glycerol metabolism (Gökhan S. Hotamisligil and Bernlohr 
2015; Kiskinis et al. 2014). TPhP highly upregulated CNN2, VASP, and SEC13 (Figure 
4.4.b), which are involved in actin polymerization (Erasmus et al. 2016). 
Protein phosphorylation is one of the most common post-translational 
modifications through which protein function is regulated in response to extracellular 
stimuli (Ardito et al. 2017); therefore we also investigated the effects of Rosi and TPhP 
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on the phospho-proteome. Rosi differentially regulated phosphoproteins compared to Vh 
and TPhP (Figure 4.5.a). All significant differential phosphoproteins are listed in Table 
S4.3. Rosi highly upregulated the phosphoproteins, SDPR and GYS1 (Figure 4.5.b), 
which are involved in insulin signaling and glucose metabolism (Bugge et al. 2009; 
Hansson et al. 2017). TPhP highly upregulated the phosphoproteins STEAP3 and 
EPB41L3 (Figure 4.5.b), which are involved in iron metabolism and tumor suppression, 
respectively (Lambe et al. 2009; Zeng et al. 2018). 
We used the combined differential protein and phosphoprotein lists to perform 
network analyses in order to determine which pathways are enriched or shared by the two 
PPARγ ligands (Figure 4.6). All network pathways are listed in Table S4.4. Figure 4.6 
shows the top networks significantly enriched by Rosi (red colored nodes), significantly 
enriched by TPhP (purple colored nodes), or shared by both (nodes split with red and 
purple). In order to interrogate the role of PPARy in the pathway networks, nodes were 
highlighted green to indicate PPARγ is in the gene set, showing many pathway clusters 
relate to PPARy activity. Rosi regulated networks related to oxidation/metabolic 
processes, mitochondrial proteins, and tissue morphogenesis. TPhP regulated networks 
related to ubiquitination of proteasomes. Shared networks were related to 
oxidation/metabolic processes as well as regulation of lipid ketones. That Rosi regulated 
protein networks related to oxidation/metabolic and mitochondrial processes is consistent 
with the phenotypic differences in the adipocytes that Rosi and TPhP induce. 
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Effect of TPhP on PPARγ phosphorylation and its contribution to adipocyte 
differentiation 
The phosphoproteomic experiments did not detect PPARγ and its phosphorylation 
as it was an untargeted proteomic profiling and PPARγ is not a highly expressed protein. 
Therefore, we used immunoblotting and a mutant form of PPARγ to investigate how 
phosphorylation of PPARγ at ser273 differentiates the effects of Rosi and TPhP. 3T3 L1 
cells were differentiated using a standard hormone cocktail for 10 days. During 
differentiation, cells were treated with Vh (0.1% DMSO, final concentration), Rosi (20 
μM), or TPhP (20 μM).  Rosi significantly reduced phosphorylation of PPARγ at ser273 
(Figure 4.7.a), which also has been shown by others (Banks et al. 2015; J. H. Choi et al. 
2010). TPhP did not protect PPARγ from phosphorylation (Figure 4.7.a).  
CDK5 is known to phosphorylate PPARγ at ser273, therefore we also tested 
whether inhibition of CDK5 by roscovitine (Rosco) would allow TPhP to induce brite 
adipocyte gene expression. Treatment of 3T3 L1 cells with Rosco (20 μM), along with 
Rosi and TPhP, during differentiation modestly decreased lipid accumulation (Figure 
S4.5.a) and did not change white adipocyte gene expression (Figure 4.7.b, Figure S4.5.b). 
However, inhibition of Cdk5 by Rosco significantly increased the ability of TPhP to 
induce brite adipocyte gene expression (Figure 4.7.b, Figure S4.5.c).  
Using Swiss 3T3 cells expressing wild-type PPARγ (3T3-WT) or PPARγ with 
alanine substitute for serine at position273 (3T3-SA), we examined whether a 
constitutively dephosphorylated PPARγ would enable TPhP to induce brite adipocyte 
gene expression. Lipid accumulation was less in 3T3-SA cells than in 3T3-WT cells 
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treated with either Rosi or TPhP (Figure S4.6.a) and expression of white adipocyte genes 
was modestly but not significantly reduced (Figure 4.7.c, Figure S4.6.b). However, in 
3T3-SA cells, TPhP had greater efficacy in inducing brite adipocyte genes, Adipoq, Ucp1 
and Cidea, in particular (Figure 4.7.c, Figure S4.6.c). In summary, when liganded with 
TPhP, PPARγ remain phosphorylated at ser273, which limits PPARγ’s ability to induce 
brite adipogenesis.  
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Discussion 
 
The environmental metabolism disrupting chemical, TPhP, is a PPARγ ligand that 
can induce adipocyte differentiation (Cano-Sancho, Smith, and La Merrill 2017; S. Kim 
et al. 2019; Pillai et al. 2014; Tung, Ahmed, et al. 2017). Previous studies have shown 
using the well-studied and characterized preadipocyte model, 3T3-L1cells, that TPhP 
increased lipid accumulation and mRNA levels of adipocyte differentiation markers such 
as Plin1 (Cano-Sancho, Smith, and La Merrill 2017; Tung, Ahmed, et al. 2017). 
However, we determined that TPhP is able to induce white adipogenesis but not brite 
adipogenesis compared to an anti-diabetic therapeutic PPARγ ligand, Rosi (S. Kim et al. 
2019). Brite adipogenesis can impact the ratio of lipid-storing (typical of white 
adipocytes ) to lipid-burning adipocytes (Rosenwald and Wolfrum 2014). Thus, skewing 
of adipogensis toward white and away from brite adipogenesis could have consequences 
on healthful adipocyte function. Indeed, rodents that lack brite adipocytes develop 
obesity, with insulin resistance and hepatic steatosis (Cohen et al. 2014). Here, we 
examined the characteristics of TPhP-induced adipocytes in multiple models and 
examined the mechanism that differentiates TPhP-liganded-PPARγ from Rosi-liganded-
PPARγ. 
The dose we chose for in vivo TPhP exposure (10 mg/kg/day) was to match the 
dose for Rosi (10 mg/kg) that was previously used to evaluate browning potential of the 
adipose tissue (Hong Wang et al. 2016). Our in vivo dose is higher than the human 
average daily intake of triphenyl phosphate among 25-30 year old females (0.8 ng/kg-
body weight-per day) and same age group males (1.6 ng/kg-body weight-per day) of 8 
136 
 
 
population groups in the FDA's monitoring program for chemical contaminants in the 
U.S. food supply (Gunderson 1988). However, our implemented dose is lower than that 
of studies that used a dose (70mg/kg/day) from an old in vivo TPhP exposure study in 
male Holtzman rats (Sutton et al. 1960) to derive a non-regulatory reference dose for 
TPhP (Ali et al. 2012; J. Li et al. 2018). Our TPhP dose is also in the lower-middle range 
of recent in vivo exposure studies as one recent study exposed C57Bl/6 dams to 0, 5, 25, 
or 50 mg/kg TPhP via intraperitoneal injection (Philbrook et al. 2018), and National 
Toxicology Program (NTP) recently exposed male Harlan Sprague Dawley rats to 0, 55, 
110, 220, 441, and 881 mg/kg TPHP daily for 4 days by oral gavage (National 
Toxicology Program 2018).  
In vivo studies to date have only examined the effect of early life TPhP exposure 
on adipose and metabolic homeostasis in adulthood (Green et al. 2016; Patisaul et al. 
2013; D. Wang et al. 2018). Further, no other study has yet investigated the effects of 
TPhP exposure on the browning of white adipose tissue. Inguinal adipose tissue is the 
largest fat depot that can recruit brite adipocytes upon chronic cold exposure of mice, and 
mature adipocytes in this depot have the potential to transdifferentiate from cells with the 
typical characteristics of white adipocytes to characteristics of brown adipocytes 
(Rosenwald and Wolfrum 2014; Waldén et al. 2012). The reduction of adipocyte size but 
increase of adipocyte number in IWAT of TPhP-exposed mice suggests that TPhP 
induced adipocyte hyperplasia, rather than hypertrophy. However, TPhP failed to induce 
expression of Cidea and significantly reduced the expression of Elovl3 and Ucp1 in the 
mature adipocytes isolated from the IWAT. Thus, it appears that TPhP induces the 
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differentiation of new, white adipocytes in IWAT. Lineage-tracing studies are needed to 
confirm this hypothesis.  
Interestingly, in vivo TPhP exposure in HFD mice led to overall improved 
metabolic health. The question as to how a functional liver and/or suppression of 
inflammation in the adipose tissues may contribute to better metabolic health will need to 
be examined. Another important question is whether sex of the animal modifies the effect 
of TPhP exposure. A recent study reported that perinatal TPhP exposure increased body 
and fat mass in 3.5 months-old male and female rats, while TPhP exposure increased 
plasma non-esterified- fasting fatty acids and accelerated type 2 diabetes mellitus onset 
only in the males (Green et al. 2016). In future studies, we can further validate if we 
observe similar adipogenic and metabolic effects in female mice from same in-vivo 
exposure methods done in this study. 
Like in 3T3-L1 cells and in mice in vivo, TPhP fails to induce brite adipocyte 
differentiation in primary human preadipocytes. In accordance with a previous study 
(Tung, Peshdary, et al. 2017), TPhP induced lipid accumulation and expression of white 
adipocyte genes (i.e. Plin1 and Cidec). However, TPhP induced neither brite adipocyte 
genes such as Elovl3 and Ucp1 nor mitochondrial biogenesis or activity in the 
differentiated primary human adipocytes. Interesting, humans with a lower propensity to 
develop brite adipocytes are more likely to be obese/diabetic (Claussnitzer et al. 2015; 
Timmons and Pedersen 2009). Moreover, our combined proteomic and 
phosphoproteomic analyses reveal that the two PPARγ ligands, Rosi and TPhP, show 
distinct expression of proteins and enrichment of pathways. Compared to TPhP, Rosi 
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enriched more regulatory networks related to oxidation/metabolic processes and 
mitochondrial proteins. Our dataset also uncovered an array of phosphorylation changes 
on several key enzymes, such as SDPR and GYS1, involved in lipid and glucose 
homeostasis; and these key enzymes were only upregulated by the therapeutic PPARγ 
ligand, Rosi.  
Phosphorylation of PPARγ regulates the suite of genes it can transactivate. In 
obese mice, which have been fed a high-fat diet, Cdk5 becomes activated in adipose 
tissues and phosphorylates PPARγ at ser273 (J. H. Choi et al. 2010). This modification of 
PPARγ reduces expression of the insulin-sensitizing adipokine, adiponectin, and studies 
have suggested that Cdk5-mediated phosphorylation of PPARγ may be involved in the 
pathogenesis of insulin-resistance (Banks et al. 2015; J. H. Choi et al. 2010, 2011). The 
phosphorylation of PPARγ by Cdk5 is blocked by anti-diabetic PPARγ ligands, such as 
Rosi, and by PPARγ-modifying compounds like Rosco (Banks et al. 2015; Hong Wang et 
al. 2016). The inhibition of phosphorylation of PPARγ at ser273 improves insulin 
sensitivity and recently has been linked to browning of adipose (J. H. Choi et al. 2010, 
2011; Hong Wang et al. 2016). In our in-vitro studies with 3T3-L1 cells, we observed 
that in the presence of TPhP, PPARγ remains phosphorylated at ser273. Further, when 
PPARγ cannot be phosphorylated at ser273 (either by inhibition of CDK5 or mutation of 
ser273), TPhP was able to induce brite genes such as Pgc1a, Elovl3, and Ucp1. 
Interestingly, TPhP gained the ability to induce Adipoq expression in 3T3-SA cells; 
adiponectin is well known to increase   insulin sensitivity (Gao et al. 2009; Yadav et al. 
2013).  
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The likely link between the ligand-determined phosphorylation state of PPARγ 
and the resulting transcriptional repertoire is differential co-regulator recruitment. PPARγ 
ser273 phosphorylation is regulated by a complex of interacting cofactors and can have 
downstream effects on the diabetic gene program (Ma et al. 2018). For example, a 
PPARγ corepressor, NCoR (nuclear receptor corepressor 1), enhances Cdk5 activity on 
phosphorylating PPARγ ser273, and an in vivo study has found that compared to wild 
type mice fed a HFD, fat-specific NCoR-deficient mice on HFD were prone to obesity 
yet have enhanced insulin sensitivity (P. Li et al. 2011). Another study found that Thrap3 
(thyroid hormone receptor-associated protein 3) can preferentially interact with PPARγ 
when ser273 is phosphorylated, and knockdown of Thrap3 in mature adipocytes restored 
several genes (i.e. adiponectin) dysregulated by Cdk5-mediated PPARγ phosphorylation, 
without altering adipogenesis (J. H. Choi et al. 2014). Hence, in future studies, we can 
further validate the role of differential recruitment of coregulators upon ligand-activated 
PPARγ phosphorylation. 
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Conclusions 
 
Exposure to the environmental MDC, TPhP, skews adipogenesis toward white 
adipocytes and away from brite adipocytes. TPhP fails to upregulate expression of genes 
that contribute to mitochondrial biogenesis and energy expenditure. This is in contrast to 
the therapeutic PPARγ ligand, Rosi. The mechanism contributing to this discrepancy is 
likely related to the fact that while Rosi protects PPARγ from phosphorylation at ser273, 
TPhP fails to do so. Indeed, when PPARγ cannot be phosphorylated, TPhP can much 
more efficaciously upregulated expression of brite adipocyte genes. Thus, we propose the 
novel conclusion that TPhP is a selective PPARγ modulator and the basis of that selective 
modulation is the failure to protect PPARγ from phosphorylation. We hypothesize that 
this mechanism of selective modulation may explain why a number of other 
environmental PPARγ ligands (e.g. TBBPA, quinoxyfen, tonalide) also fail to induce 
brite adipogenesis (S. Kim et al. 2019). Critical questions remain to be answered, 
including how exposure to TPhP at environmentally relevant doses in a human-like 
dietary context influences metabolic homeostasis and how changes in coregulatory 
recruitment link environmental ligand-induced differences in PPARγ coregulatory 
recruitment with specific gene repertoires. 
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Figures 
 
Figure 4.1. IWAT histology and gene expression in Rosi- and TPhP-treated mice.   
Six-week-old C57BL/6J male mice were fed either a diet with 10% kcal% fat (LFD) or 
60% kcal% fat (HFD) for a total of 13 weeks. Seven weeks after initiation of the diet, 
mice were i.p., daily for 6 weeks with vehicle, rosiglitazone (10 mg/kg), or triphenyl 
phosphate (10 mg/kg). Inguinal white adipose tissue (IWAT) was stained with 
hematoxylin and eosin. (a) Representative micrograph.  (b) The number and size of 
adipocytes were measured using ImageJ. Mature adipocytes were isolated from IWAT by 
digestion, filtering and centrifugation. Adipocytes were analyzed for gene expression by 
RT-qPCR. (c) White adipocyte marker genes. (d) Brite adipocyte genes. Data are 
presented as mean + SE (n=5). Statistically different from LFD Vh-treated (*p<0.05) or 
HFD Vh-treated (ap<0.05, ANOVA, Dunnett’s). 
(a) 
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(b) 
 
(c)
 
 
(d) 
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Figure 4.2. Functions of and gene expression in human adipocytes differentiated 
with Rosi and TPhP. Primary human adipocytes were differentiated using a standard 
hormone cocktail for a total of 14 days. During differentiation, cells were treated with 
vehicle (0.1% DMSO, final concentration), Rosi (4 μM), or TPhP (4 μM). (a) Lipid 
accumulation was determined by Nile Red staining. (b) Fatty acid uptake was analyzed 
using a dodecanoic acid fluorescent fatty acid substrate. (c) Mitochondrial biogenesis was 
analyzed by measuring mitochondria-specific proteins. (d) Cellular respiration was 
measured using the Seahorse assay.  Gene expression was analyzed by RT-qPCR. (e) 
White adipocyte marker genes. (f) Brite adipocyte genes. Data are presented as mean + 
SE of adipocytes differentiated from 3 individuals. Statistically different from Vh-treated 
(*p<0.05 or **p<0.01, ANOVA, Dunnett’s). 
(a) 
 
(b)                                       (c)                              (d) 
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(e) 
 
(f) 
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Figure 4.3. Functions of and gene expression in 3T3 L1 adipocytes differentiated 
with Rosi and TPhP. 3T3 L1 cells were differentiated using a standard hormone cocktail 
for 10 days. During differentiation, cells were treated with Vh (0.1% DMSO, final 
concentration), Rosi (20 μM), or TPhP (20 μM) in the presence or absence of the PPARγ 
antagonist T0070907 (20 µM). (a) Lipid accumulation was determined by Nile Red 
staining. (b) Gene expression was analyzed by RT-qPCR. (c) Mitochondrial biogenesis 
was analyzed by measuring mitochondria-specific proteins. (d) Cellular respiration was 
measured using the Seahorse assay.  Data are presented as mean + SE (n=3-6). 
Statistically different from Vh-treated (*p<0.05 or **p<0.01, ANOVA, Dunnett’s).  
(a)        (b) 
             
(c)   (d) 
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Figure 4.4. Proteomes of 3T3 L1 adipocytes differentiated with Rosi and TPhP. 3T3 
L1 cells were differentiated as described in Figure 3. The proteome was analyzed by 
precision quantitative LC/MS. (a) Heatmap and (b) volcano plot of top differentially 
expressed proteins between Rosi and TPhP. 
(a) 
 
(b) 
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Figure 4.5. Phosphoproteomes of 3T3 L1 adipocytes differentiated with Rosi and 
TPhP. 3T3 L1 cells were differentiated as described in Figure 3. Phospho-peptides were 
enriched using TiO2 and then analyzed by precision quantitative LC/MS. (a) Heatmap 
and (b) volcano plot of top differentially expressed phospho-proteins between Rosi and 
TPhP. 
(a) 
 
(b) 
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Figure 4.6. Network analyses of Rosi and TPhP-induced proteomes. Pathway themes 
are displayed above highlighted clusters. Nodes in red indicates enriched pathways in 
Rosi, blue indicates enriched pathways by TPhP, red/blue indicates shared pathways 
between Rosi and TPhP. Nodes with green surrounding indicate the presence of PPARγ 
in the pathway set. 
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Figure 4.7. PPARγ phosphorylation and its effect on gene expression adipocytes 
differentiated with Rosi and TPhP. (a) 3T3 L1 cells were differentiated as described in 
Figure 3 and phosphorylation of PPARγ at ser273 was determined relative to total 
PPARγ by immunoblot. (b) 3T3 L1 cells were differentiated as described in Figure 3, in 
the presence or absence of roscovitine (Rosco, 20 μM). Gene expression was determined 
by RT-qPCR and presented as a heatmap of expression levels of white adipocyte markers 
(Plin1, Fabp4) and brite adipocyte markers (Ppara, Pgc1a, Elovl3, Cidea, Adipoq, Ucp1, 
Acaa2). (c) 3T3 cells expressing wildtype PPARγ (3T3-WT) or 3T3 cells expressing 
PPARγ with alanine substituted for serine 273 (3T3-SA) were differentiated as described 
for 3T3 L1 cells in Figure 3. Gene expression was determined by RT-qPCR and 
presented as a heatmap of expression levels of white and brite adipocyte markers. Data 
are presented as mean + SE (n>3). Statistically different from Vh-treated (*p<0.05 or 
**p<0.01, ANOVA, Dunnett’s). 
(a) 
 
 
 
 
 
 
150 
 
 
(b)            (c) 
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Supplement material 
 
Table S4.1. Mouse (M) and human (H) primer sequences for reverse transcriptase 
qPCR. 
 
 
 
 
 
 
Gene 
Symbol FORWARD REVERSE 
Annealing 
Temp. C 
M-Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 55 
M-B2M CTGCTACGTAACACAGTTCCACCC CATGATGCTTGATCACATGTCTCG 55 
M-Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 55 
M-Cidec AGGCCCTGTCGTGTTAGCAC CATGATGCCTTTGCGAACCT 55 
M-Elovl3 TCCGCGTTCTCATGTAGGTCT GGACCTGATGCAACCCTATGA 55 
M-CoxIV TCACTGCGCTCGTTCTGATT CAGCATTCGCTTGGTCTGC 55 
M-Fabp4 AGCCCAACATGATCATCAGC  TTTCCATCCCACTTCTGCAC  55 
M-Plin1 GGGACCTGTGAGTGCTTCC GTATTGAAGAGCCGGGATCTTTT 55 
M-Pgc1a AACAAGCACTTCGGTCATCCCTG TTACTGAAGTCGCCATCCCTTAG 55 
M-Ppara GCGTACGGCAATGGCTTTAT GAACGGCTTCCTCAGGTTCTT 55 
M-Pparg2 TGGGTGAAACTCTGGGAGATTC AATTTCTTGTGAAGTGCTCATAGGC 55 
M-Rip140 AGAACGCACATCAGGTGGCA GATGGCCAGACACCCCTTTG 55 
M-Adipoq GCACTGGCAAGTTCTACTGCAA GTAGGTGAAGAGAACGGCCTTGT 55 
M-Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG 55 
M-Acaa2 TAACGAGGCTGGCTACTTCAA AGGGGCGTGAAGTTATGTTTT 55 
M-Retn TCGTGGGACATTCGTGAAGA GGGCTGCTGTCCAGTCTATCC 55 
M-Wdnm1 TGTCTGTTTGGAGCTCTGTGACCA AACAACTCCTTGTCCCACTCCACT 55 
H-RPL27 GTGAAAGTGTATAACTACAATCACC TCAAACTTGACCTTGGCCT 58 
H-B2M GCTATCCAGCGTACTCCAAAG CACACGGCAGGCATACTC 58 
H-PPARG TCAGCTCCGTGGATCTCTCC ACCCTTGCATCCTTCACAAG 55 
H-CIDEA GGCAGGTTCACGTGTGGATA GAAACACAGTGTTTGGCTCAAGA 60 
H-PLIN1 ATTGCTCTGAGCTGAAGGACACCA AGCTCGAGTGTTGGCAGCAAATTC 60 
H-FABP4 GCTTTTGTAGGTACCTGGAAACTT ACACTGATGATCATGTTAGGTTTGG 55 
H-ACAA2 TGTGGTTCTGGTTTTCAGTCC GTGACTGCAGGGCATATTTGT 55 
H-UCP1 GGGCTTCAGCGGCAAATCAGCT CAATGAATACTGCCACTCCTC 55 
H-ELOVL3 ATGTAGTTCTGCCCCACAGC AAGGACATGAGGCCCTTTTT 55 
H-CIDEC GGGATACAGTGTTCATGGTCCT TCAATCTTCTTGGCAGGCTTATG 55 
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(Attached separately as an Excel file). 
 
Table S4.2. Detailed list of proteins differentially expressed between chemical 
groups. 
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(Attached separately as an Excel file). 
 
Table S4.3. Detailed list of phosphoproteins differentially expressed between 
chemical groups. 
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(Attached separately as an Excel file). 
 
Table S4.4. Detailed list of network pathways. 
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Figure S4.1. Weight gain and fat mass in mice treated with Rosi and TPhP.  
Six-week-old C57BL/6J male mice were either fed a diet with 10% kcal% fat (LFD) or 
60% kcal% fat (HFD) for a total of 13 weeks. Seven weeks after initiation of the diet, 
mice were i.p., daily for 6 weeks with vehicle, rosiglitazone (10 mg/kg), or triphenyl 
phosphate (10 mg/kg). (a) Weight gain. (b) Body composition at 6 weeks of treatment. 
Data are presented as mean + SE (n=5). Statistically different from LFD Vh-treated 
(*p<0.05) or HFD Vh-treated (ap<0.05, ANOVA, Dunnett’s). 
(a) 
 
(b) 
 
 
 
156 
 
 
Figure S4.2. Insulin and glucose measurements in Rosi- and TPhP-treated mice. Six-
week-old C57BL/6J male mice were fed either a diet with 10% kcal% fat (LFD) or 60% 
kcal% fat (HFD) for a total of 13 weeks. Seven weeks after initiation of the diet, mice 
were i.p., daily for 6 weeks with vehicle, rosiglitazone (10 mg/kg), or triphenyl phosphate 
(10 mg/kg). The mice were fasted and blood glucose was measured (Bayer Contour) for 
(a) glucose tolerance (GTT) and (b) serum insulin tests (ITT). 
(a) 
  
(b) 
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Figure S4.3. Liver histology and gene expression in Rosi- and TPhP-treated mice. 
Six-week-old C57BL/6J male mice were fed either a diet with 10% kcal% fat (LFD) or 
60% kcal% fat (HFD) for a total of 13 weeks. Seven weeks after initiation of the diet, 
mice were i.p., daily for 6 weeks with vehicle, rosiglitazone (10 mg/kg), or triphenyl 
phosphate (10 mg/kg). (a) For histology, liver tissues were excised, fixed in 4% 
paraformaldehyde, paraffin-embedded, and sectioned prior to conventional hematoxylin 
and eosin (H&E) staining, and the number of triglycerides in the liver were measured. (b) 
Gene expression of Pparg, Ppara and its target genes in the livers were measured. Data 
are presented as mean + SE (n=5). Statistically different from LFD Vh-treated (*p<0.05) 
or HFD Vh-treated (ap<0.05, ANOVA, Dunnett’s). 
(a)       
    
(b) 
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Figure S4.4. EWAT histology and gene expression in Rosi- and TPhP-treated mice. 
Six-week-old C57BL/6J male mice were fed either a diet with 10% kcal% fat (LFD) or 
60% kcal% fat (HFD) for a total of 13 weeks. Seven weeks after initiation of the diet, 
mice were i.p., daily for 6 weeks with vehicle, rosiglitazone (10 mg/kg), or triphenyl 
phosphate (10 mg/kg). (a) Epididymal white adipose tissue (EWAT) was stained with 
hematoxylin and eosin (H&E). Stromal vascular fraction (SVF) were isolated from 
IWAT by digestion, filtering and centrifugation and were analyzed for gene expression 
by RT-qPCR. Gene expression of (b) white adipocyte markers and (c) inflammatory 
markers. Data are presented as mean + SE (n=5). Statistically different from LFD Vh-
treated (*p<0.05) or HFD Vh-treated (ap<0.05, ANOVA, Dunnett’s). 
(a) 
 
(b) 
 
(c) 
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Figure S4.5. Adipocyte differentiation and gene expression in roscovitine-treated 
3T3 L1 cells.  3T3 L1 cells were differentiated using a standard hormone cocktail for 10 
days. During differentiation, cells were treated with Vh (0.1% DMSO, final 
concentration), Rosi (20 μM), or TPhP (20 μM) in the presence or absence of roscovitine 
(Rosco, 20 μM). (a) Lipid accumulation was measured by Nile Red staining. Gene 
expression was determined by RT-qPCR analysis of white adipocyte markers (b, Plin1, 
Fabp4) and brite adipocyte markers (c, Ppara, Pgc1a, Elovl3, Cidea, Adipoq, Ucp1, 
Acaa2). Data are presented as mean + SE (n=6). Statistically different from - Rosco 
(*p<0.05 or **p<0.01, 2-Factor ANOVA, Sidak’s). 
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Figure S4.6. Adipocyte differentiation and gene expression in 3T3-WT and 3T3-SA 
cells. 3T3 cells expressing WT PPARγ (3T3 WT) or PPARγ with alanine substituted for 
serine at position 273 (3T3-SA) were differentiated using a standard hormone cocktail for 
10 days. During differentiation, cells were treated with Vh (0.1% DMSO, final 
concentration), Rosi (20 μM), or TPhP (20 μM). (A) Lipid accumulation was measured 
by Nile Red staining. Gene expression was determined by RT-qPCR analysis of white 
adipocyte markers (B, Plin1, Fabp4) and brite adipocyte markers (C, Ppara, Pgc1a, 
Elovl3, Cidea, Adipoq, Ucp1, Acaa2). Data are presented as mean + SE (n=5-6). 
Statistically different from 3T3-WT (*p<0.05 or **p<0.01, 2-Factor ANOVA, Sidak’s). 
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CHAPTER 5: Conclusions 
 
 This dissertation research was designed to investigate the biological effects of 
toxicants on adipose homeostasis and to determine the mechanism by which toxicants 
disrupt adipose function. We performed mouse and human in-vitro experiments and used 
a mouse in-vivo model to identify important changes in gene expression and phenotypes 
resulting from exposure to environmental toxicants that are agonists for peroxisome 
proliferator activated receptor gamma (PPARγ). The first study characterized differential 
genes and pathways in differentiated mouse bone marrow-derived mesenchymal stromal 
cells with exposures to an environmental PPARγ/RXRα ligand, tributyltin (TBT), a 
synthetic RXR ligand, LG100268, and a therapeutic PPARγ ligand, rosiglitazone (Rosi). 
We found that only Rosi induced brown fat cell-like differentiation and mitochondrial 
processes (Chapter 2). In the second study, we generated the transcriptional profiles from 
3T3-L1 adipocytes differentiated in the presence of 76 different chemicals, including 
emerging environmental chemicals of concern, endogenous signaling molecules, and 
therapeutic ligands, and used these data to build a taxonomy to identify environmental 
chemicals as PPARγ-modifying chemicals distinct from known PPARγ-modifying 
therapeutics. We identified tonalide and quinoxyfen as novel selective PPARγ ligands 
and demonstrated that these chemicals enhance white adipogenesis without inducing 
health-promoting functions such as mitochondrial biogenesis and activity in 
differentiated 3T3-L1s and primary human adipocytes (Chapter 3). In the third study, we 
determined that the environmental PPARγ ligand, triphenyl phosphate (TPhP), did not 
induce brite adipogenesis in mature adipocytes isolated from inguinal white adipose 
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tissue of exposed adult, male C57BL/6J mice, in differentiated 3T3-L1 adipocytes and in 
differentiated primary human preadipocytes. Importantly, we demonstrated a novel 
mechanism of action of TPhP as it maintained phosphorylation of PPARγ at ser273, 
which has been linked to reduced browning of fat and insulin resistance (Chapter 4). 
 
Chapter 2: Tributyltin induces a transcriptional response without a brite adipocyte 
signature in adipocyte models 
PPARγ is a therapeutic target in the treatment of type II diabetes, but there is still 
a question as to how environmental PPARγ ligands can perturb adipose and metabolic 
homeostasis. To begin to address this question, we compared the transcriptional 
responses induced in the bone marrow mesenchymal stromal cells (BM-MSCs) by the 
environmental PPARγ toxicant (TBT) to those induced by a therapeutic PPARγ ligand 
(Rosi) and a synthetic RXR agonist (LG100268). This study also used 3T3 L1 cells to 
characterize molecular activities upon the chemical exposures. The main objectives of 
this study were to analyze differential gene expression in ligand-exposed BM-MSCs 
using microarrays and to perform in silico functional annotation with pathway 
enrichment analyses. As expected, we found pathways related to osteogenesis were 
downregulated by all three ligands, and pathways related to adipogenesis were 
upregulated by Rosi and TBT. Our previous study demonstrated that TBT is able not only 
to stimulate adipocyte differentiation in BM-MSCs, but also to divert osteogenic 
differentiation toward adipocyte differentiation (Baker et al. 2015). Interestingly, 
pathways related to mitochondrial processes and browning of fat were more significantly 
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upregulated in Rosi-treated than TBT-treated cells. Differential expression of genes 
involved in brite adipogenesis and energy dissipation (i.e. Elovl3, Cidea, Ucp1) were 
confirmed by independent qPCR validations in BM-MSCs undergoing adipocyte 
differentiation. Furthermore, Rosi, but not TBT, induced mitochondrial biogenesis and 
mitochondrial respiration in differentiated 3T3 L1 adipocytes. This study was the first to 
show that an environmental PPARγ ligand (TBT) has a limited capacity to induce health-
promoting activities of PPARγ. 
Although the in-vitro isolation of BM-MSCs was performed using a standardized 
protocol, the primary limitation to this study was the cellular heterogeneity that was not 
taken into account as the bone marrow is a complex and multi-cellular environment (i.e. 
hematopoietic cells, macrophages, fibroblasts, and more). In future experiments, we can 
get better isolation of BM-MSCs with less contamination of other cell types, as there 
have been MSC-specific markers identified to isolate these cells (positive for CD29, 
CD44, and Sca-1 and negative for CD11b, CD19, and CD45) (Y. Hu et al. 2018).  
 Moreover, TBT is a dual ligand of PPARγ and its heterodimerization partner, 
RXR. Its dual nature raises the question whether RXR could contribute to TBT-induced 
effects on adipocyte differentiation. A recent paper indicated that TBT exposure in BM-
MSCs prior to differentiation can promote adipose lineage commitment in an RXR-
dependent manner (Shoucri et al. 2017). The same group compared BM-MSC exposures 
to TBT and a pure RXR agonist IRX4204 (4204) and found that both exposures led to 
adipocytes that reduced glucose uptake and adiponectin secretion as well as limited 
cellular response to mitochondrial uncoupling (Shoucri et al. 2018). 
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TBT is also known to activate permissive RXR heterodimeric partners such as 
LXR (Grün et al. 2006). LXRs (α and β) are known to be involved in multiple metabolic 
pathways such as insulin sensitivity, glucose and lipid metabolism, and energy 
expenditure (Korach-André and Gustafsson 2015). One study showed that in-vivo knock-
out of both LXRs prevented male mice from high fat and cholesterol diet-induced obesity 
by increased energy dissipation from ectopic expression of uncoupling proteins in muscle 
and white adipose tissues (Kalaany et al. 2005). Another study has shown that LXRα is a 
direct transcriptional inhibitor of β-adrenergic receptor-mediated and cAMP-dependent 
Ucp1 gene expression as LXRα is capable of binding to the enhancer region of Ucp1 
promoter (Haibo Wang et al. 2008). This study further evaluated that the mechanism of 
Ucp1 inhibition involves the differential recruitment of the corepressor, RIP140, to an 
LXRα binding site that overlaps with the PPARγ/PGC1α response element, which leads 
to the dismissal of PPARγ (Haibo Wang et al. 2008). Thus, this mechanism may also 
explain TBT’s reduced effects on brite adipogenesis by potentially mediating through 
LXRα. 
 
Chapter 3: A data-driven transcriptional taxonomy of adipogenic chemicals to identify 
emerging metabolic health threats 
The U.S. EPA developed the Toxicity Forecaster (ToxCast™) program in 2007 in 
order to utilize high-throughput screening assays to prioritize chemicals and to inform 
regulatory decisions regarding thousands of environmental contaminants since few had 
been tested for endocrine-disrupting endpoints (Dix et al. 2007). PPARγ is an essential 
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regulator for adipocyte differentiation and lipid metabolism, and many have suggested 
various environmental obesogens as PPARγ agonists (Pereira-Fernandes et al. 2013; 
Taxvig et al. 2012; Y.-F. Wang et al. 2010). Several ToxCast™ assays measure the 
ability of chemicals to bind to or activate PPARγ as well as predict the adipogenic 
potential of chemicals (Amanda Shaine Janesick et al. 2016). These assays were used to 
generate a toxicological priority index (ToxPi) that were expected to predict the ability of 
chemicals to promote adipogenesis in cell culture models (Amanda Shaine Janesick et al. 
2016; Reif et al. 2010). Thus, these ToxCast™ assays and ToxPi were expected to be 
useful tools for identifying chemicals of adipogenic potential. However, the results of 
ToxCast™ PPARγ assays did not correlate well with activity measured in laboratory 
settings, and the designed ToxPi performed poorly in identifying potential adipogenic 
chemicals as there were many false positives (Amanda Shaine Janesick et al. 2016). 
 Therefore, our study has developed a new tool not only to identify potential 
adipogens, but also to provide information on the type of adipocyte that is formed (white 
vs. brite). In our study, we evaluated environmental chemicals in disparate structural 
classes that may activate specific PPARγ’s transcriptional programs to generate 
adipocytes with distinct phenotypes. We used murine 3T3-L1 cells as this cell model has 
been well-studied with environmental chemical exposures and has advanced our 
understanding of the molecular mechanisms regulating adipocyte differentiation (S. R. 
Farmer 2005; Pereira-Fernandes et al. 2014, 2013; Regnier and Sargis 2014). We 
differentiated 3T3-L1s in the presence of 76 chemicals, including synthetic nuclear 
receptor ligands known to influence adipogenesis and suspected environmental PPARγ 
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ligands. We measured differential gene expression using a highly multiplexed and 
modified RNA-Seq known as 3’ Digital Gene Expression and developed a novel 
classification model to identify groups of chemicals acting through PPARγ with known 
PPARγ-modifying ligands. We were able to identify a subset of environmental 
contaminants as strong PPARγ agonists (i.e. quinoxyfen and tonalide) that were able to 
induce white adipogenesis but not induce characteristics of brite adipocytes such as 
mitochondrial biogenesis and mitochondrial respiration. Thus, from this study we 
conclude that identifying environmental chemicals as PPARγ ligands that can induce 
adipogenesis is not sufficient to identify potential metabolism disrupting chemicals. The 
metabolic processes that determine the functional status of the formed adipocytes, 
specifically processes that determine white vs. brite adipogenesis, also must be 
determined.   
Our implementation of novel chemical classification method and high throughput 
in-vitro assays can help identify environmental chemicals that are acting on PPARγ. Yet, 
a limitation is that agonism of PPARγ is not the only mechanism by which an 
environmental chemical may disrupt adipose homeostasis. For instance, environmental 
chemicals that activate the glucocorticoid receptor act as metabolism disrupting 
chemicals (Sargis et al. 2010). Moreover, in order to fully understand how environmental 
PPARγ ligands can induce adipogenesis but not necessarily brite adipogenesis, there also 
needs further investigation of the role of PPARγ coregulators. PPARγ dissociates 
corepressors (i.e. NCoR, HDAC, SMRT) and binds with coactivators (i.e. CPB, p300, 
and PBP) to initiate adipocyte differentiation of white, brown, and brite adipocytes 
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(Lynes and Tseng 2018; Ma et al. 2018). In brite and brown adipocytes, PPARγ can 
complex with PRDM16/EBF2/EHMT1 to promote adaptive thermogenesis and also 
interact with PRDM16/PGC1α and other cofactors such as MED1 and SRC1/2/3 to 
induce browning and energy dissipation (Ma et al. 2018). Thus, understanding how 
PPARγ dynamically complexes with its cofactors to transactivate gene networks for the 
development and function of different adipocytes would advance our knowledge of how 
specific ligands favor the generation of white or brite adipocytes.  
 
Chapter 4: Triphenyl phosphate is a selective PPARγ modulator that does not induce brite 
adipogenesis in-vitro and in-vivo 
 Triphenyl phosphate (TPhP) is an organophosphate flame retardant and an 
environmental PPARγ ligand. In Chapter 3, we show that TPhP, along with several other 
environmental PPARγ ligands, does not induce brite adipocyte gene expression or 
mitochondrial biogenesis in 3T3 L1 adipocytes. This study further evaluated overall 
effects of TPhP exposure on adipocyte differentiation and function in-vivo with adult, 
male C57BL/6J mice as well as in-vitro with primary human adipocytes. Rosi and TPhP 
exposures differentiated the mouse and human adipocytes, but only Rosi induced brite 
adipocyte functions such as mitochondrial biogenesis and respiration. In-vitro and in-vivo 
exposures to TPhP did not induce gene expressions of brite adipocyte markers such as 
Elovl3 and Ucp1. Importantly, we also found that TPhP acts via a novel mechanism of 
action as TPhP disrupts brite adipocyte differentiation by failing to prevent PPARγ from 
phosphorylation at ser273, in contrast to the therapeutic PPARγ ligand, Rosi.  
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However, the in-vivo exposures to TPhP and HFD indicated that metabolic health 
improved (i.e. no increased fat mass and better glucose tolerance), possibly due to 
compensatory changes in the liver and suppression of inflammation in the EWAT. 
Chronic inflammation is a pathogenic factor in obesity complications, such as insulin 
resistance, and there has been a recognition of the underlying role of adipose tissue 
macrophages in obesity-induced inflammation (Shaul et al. 2010). PPARγ itself may play 
an important role in suppressing inflammation as several studies have shown that PPARγ 
activation blocked the production of pro-inflammatory mediators (Orasanu et al. 2008; 
Sánchez-Hidalgo et al. 2005; Tsuchida et al. 2005; Varga, Czimmerer, and Nagy 2011; 
Welch et al. 2003; Youssef and Badr 2004). For example, Rosi inhibits expression of 
IFN-γ target genes (i.e. iNOS, Usp18, and Il12p40) in a PPARγ-dependent manner in 
elicited peritoneal macrophages of mice (Welch et al. (2003)). We also observed lack of 
induction of iNOS, Usp18, and Adgre, as well as suppression of pro-inflammatory 
markers Hif1a and Il-6 in the EWAT of Rosi-and TPhP-HFD groups. The suppression of 
adipokines (Retn and Wdnm1) in the white adipose tissue by TPhP in the HFD group may 
also contribute to improved glucose tolerance as the perturbed activation of these and 
other cytokines can lead to insulin resistance (Ailhaud 2006; G. S. Hotamisligil et al. 
1995). Follow-up in-vivo investigations need to be done to understand how TPhP does 
not induce browning of white adipose tissue but can improve overall metabolic health 
and also examine sex differences in metabolic effects from TPhP exposure. 
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Public Health Implications: 
The global epidemic of obesity is a major public health concern. Obesity is often 
a risk factor for and associated with metabolic pathologies such as metabolic syndrome 
(insulin resistance, dyslipidemia, high blood pressure) and metabolic disease (type 2 
diabetes, non-alcoholic fatty liver disease, atherosclerosis) (Corrales, Vidal-Puig, and 
Medina-Gómez 2018). Excess calories are stored in the form of lipids in the adipose 
tissue; however, excessive amounts of fat may overwhelm the functional capacity of the 
organ by leading to hypoxia, fibrosis, or inflammation. Functional adipose tissue is 
absolutely necessary for metabolic health, as those individuals with lipodystrophy (a 
reduction or absence of adipose tissue) also have impaired glucose homeostasis (Savage 
2009). 
Understanding the myriad of factors contributing to obesity and diabetes is 
essential. It is estimated that 592 million individuals worldwide will develop diabetes by 
2035, and 77% of these individuals are currently living in middle- or low-income 
countries with significantly less developed health systems (Sargis 2015). In the past 
decade, evidence from epidemiology and basic science supports a role for environmental 
metabolism disrupting chemicals (MDCs) in the development of obesity and diabetes 
(Kuo et al. 2013; Sargis 2015; Thayer et al. 2012). These environmental MDCs include 
bisphenol A, persistent organic pollutants, phthalates, antifouling agents, flame 
retardants, and pesticides (Casals-Casas and Desvergne 2011; Heindel, Newbold, and 
Schug 2015; Heindel et al. 2017).  
Many of these MDCs are PPARγ ligands. But this presents a puzzle, as PPARγ is 
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also a target for therapeutic ligands. Thus, PPARγ is an important molecular target of 
endogenous and exogenous ligands and associated with metabolic processes that could 
either benefit metabolic health or contribute to obesity-induced metabolic dysfunctions 
(Evans, Barish, and Wang 2004). For example, thiazolidinediones (i.e. rosiglitazone) are 
PPARγ ligands to treat type 2 diabetes by improving insulin maintenance, but an 
environmental PPARγ ligand, TBT, can impair insulin sensitivity (Zuo et al. 2011). 
However, PPARγ is not the only molecular target as activation of its heterodimeric 
partner, RXR, or other nuclear receptors are emerging as important mechanisms of 
metabolic disruption.  There is still a critical gap whether environmental metabolic 
disruptors alter molecular signaling directly at the ligand binding site or by indirect 
mechanisms such as coregulator recruitment, allosteric effects, and post-translational 
modifications (Neel and Sargis 2011). More in-depth mechanisms of actions of 
environmental metabolic disruptors need to be examined in order to understand the 
ligand-dependent modulating effects on lipid and glucose homeostasis as well as other 
metabolic and inflammatory responses.  
We also need to consider that it is unlikely that the effects of a single chemical 
will be sufficient to explain the rapid increase in global obesity and diabetes rates. There 
are tens of thousands of synthetic chemicals to which humans are potentially exposed on 
a daily basis. Thus, the potential exposure to multiple environmental MDCs may affect 
molecular mechanisms at play and influence metabolic pathogenesis (Sargis 2014). The 
efficacies of environmental MDCs may also be enhanced by factors in specific 
individuals that predispose these individuals to environmental-mediated metabolic 
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disease. These factors include underlying genetics, diet, lifestyle, pre-existing 
comorbidities, medications, and states of fat distribution that can alter the individual’s 
baseline physiology that increase sensitivity to metabolic disruption (Sargis 2015). 
Hence, a comprehensive understanding of the interplay between these risk factors and 
environmental MDCs will be essential for determining the contribution of environmental 
pollutants to the current epidemic of obesity and increase in metabolic disease and for 
devising strategies to address the threat of environmental chemicals on human metabolic 
health. 
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